



HAL
open science

Nanomedicine-Based Approaches for mRNA Delivery

Satoshi Uchida, Federico Perche, Chantal Pichon, Horacio Cabral

► **To cite this version:**

Satoshi Uchida, Federico Perche, Chantal Pichon, Horacio Cabral. Nanomedicine-Based Approaches for mRNA Delivery. *Molecular Pharmaceutics*, 2020, 17 (10), pp.3654 - 3684. 10.1021/acs.molpharmaceut.0c00618 . hal-02995814

HAL Id: hal-02995814

<https://hal.science/hal-02995814v1>

Submitted on 9 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Nanomedicine-based approaches for mRNA delivery

Satoshi Uchida, Federico Perche, Chantal Pichon, and Horacio Cabral

Mol. Pharmaceutics, **Just Accepted Manuscript** • DOI: 10.1021/acs.molpharmaceut.0c00618 • Publication Date (Web): 26 Aug 2020

Downloaded from pubs.acs.org on September 2, 2020

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Nanomedicine-based approaches for mRNA delivery

Satoshi Uchida^{1,2}, Federico Perche³, Chantal Pichon^{3,4}, Horacio Cabral^{1,2*}

¹Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.

²Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion, 3-25-14, Tonomachi, Kawasaki-ku, Kawasaki 210-0821, Japan.

³Centre de Biophysique Moléculaire, UPR4301 CNRS Rue Charles Sadron Orléans, Orléans Cedex 02, France.

⁴University of Orleans, Faculty of Sciences and techniques, 45071 Orléans, France

*Corresponding author

Horacio Cabral, PhD

horacio@bmw.t.u-tokyo.ac.jp

Abstract

Messenger RNA (mRNA) has immense potential for developing a wide range of therapies, including immunotherapy and protein replacement. As mRNA presents no risk of integration into the host genome and does not require nuclear entry for transfection, which allows protein production even in non-dividing cells, mRNA-based approaches can be envisioned as safe and practical therapeutic strategies. Nevertheless, mRNA presents unfavorable characteristics, such as large size, immunogenicity, limited cellular uptake and sensitivity to enzymatic degradation, which hinder its use as therapeutic agent. While mRNA stability and immunogenicity have been ameliorated by direct modifications on the mRNA

1
2
3 1 structure, further improvements in mRNA delivery are still needed for promoting its activity in biological
4
5 2 settings. In this regard, nanomedicine has shown the ability for spatiotemporally controlling the function
6
7
8 3 of a myriad of bioactive agents *in vivo*. Direct engineering of nanomedicine structures for loading,
9
10 4 protecting and releasing mRNA, and navigating in biological environments, can then be applied for
11
12 5 promoting mRNA translation toward the development of effective treatments. Here, we review recent
13
14 6 approaches aimed at enhancing mRNA function and its delivery through nanomedicines, with particular
15
16
17 7 emphasis on their applications and eventual clinical translation.
18
19 8

9 **Keywords**


10 mRNA delivery; mRNA engineering; Nanomedicine; mRNA therapeutics; Clinical translation
11
12

12 **1. Introduction**

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Messenger RNA (mRNA) mediates the translation of genetic information from genes into proteins. Delivering exogenous mRNA into cells allows to transiently produce proteins in a precise manner. Such mRNA-mediated transfection offers an attractive alternative to plasmid DNA (pDNA)-based gene therapy by expressing proteins even in non-dividing and hard to transfect cells without the risks of genomic integration.¹ Moreover, while pDNA needs to be delivered inside the nucleus of targeted cells, the access of mRNA to the cytosol and the subsequent engagement with the translation machinery of the cells are sufficient to obtain the proteins of interest. The mRNA delivered inside the cells can also last for several days, which is convenient for developing efficient therapeutic strategies, as well as commercially viable approaches. On the other hand, mRNA presents inherent limitations for being used as a stand-alone drug, including fast degradation by nucleases, limited cellular uptake, and immunogenicity.² While the immunogenic signals triggered by mRNA could be exploited for vaccination or immunotherapy applications,³ major efforts have been dedicated to reduce mRNA immunogenicity

1 and improve the stability of the molecule by either chemical modification or by RNA architectonics,
 2 aiming at increasing the significance of mRNA as a therapeutic agent. Nevertheless, mRNA is still
 3 susceptible to degradation and the cellular uptake of naked mRNA should be improve for eliciting
 4 adequate amounts of proteins. Thus, the development of safe carrier systems capable of intracellular
 5 delivery of intact mRNA molecules is fundamental for progressing into effective treatments.



7
 8 **Figure 1. Nanomedicine approaches for mRNA delivery.** Various platforms are under intense research
 9 and development for the delivery of mRNA based on their unique ability to promote navigation in
 10 biological environments, intracellular delivery and engagement with the translation machinery of cells.

1
2
3 1
4
5 2 A wide range of nano-scaled carriers are under intense investigation for developing mRNA
6
7 delivery systems.¹ Viral vectors, which have been extremely useful for delivering other nucleic acids,
8 3
9 have been among the first carriers to be considered for developing mRNA delivery systems.⁴
10 4
11 Nevertheless, viral carriers present intrinsic limitations, such as small packing size, immunogenicity,
12 5
13 cytotoxicity and complex production processes,⁵ which have spurred the development of safe and
14 6
15 effective non-viral vehicles.^{6, 7} These non-viral vehicles can benefit from a myriad of biocompatible
16 7
17 synthetic and natural materials for attaining specific physicochemical and functional features directed to
18 8
19 develop mRNA-loaded nanomedicines with improved mRNA bioavailability, targeting to specific
20 9
21 tissues and cells, and enhanced cellular uptake and intracellular release of mRNA molecules (**Figure 1**).
22 10
23 Thus, various non-viral strategies have achieved major breakthroughs in the *in vivo* delivery of mRNA,
24 11
25 as well as in the clinical translation of mRNA-based therapies.^{1, 6, 7}
26 12
27
28
29

30 13 Here, we present the recent progress in mRNA-loaded nanomedicine toward innovating
31 14
32 vaccination, immunotherapy, treatment of genetic disorders and protein replacement approaches. We
33 15
34 have focused on the different non-viral strategies with emphasis on the employed materials and the
35 16
36 advantages offered by each approach. Moreover, the mRNA modification methods are also reviewed,
37 17
38 highlighting opportunities for synergistically enhancing nanomedicine efficiency. Finally, the trends in
39 18
40 the application of mRNA-loaded nanomedicines and their future perspectives are discussed.
41 19
42
43
44

45 19

46 20 **2. Engineering mRNA for enhanced function**

47 21

48

49 21 mRNA modification by approaches that enhance the stability and promote its function have
50 22
51 been considered for improving mRNA biological activity, as well as reducing immunogenicity issues.
52 23
53 Notably, these modification methods do not affect the main structural features of mRNA, *i.e.* being a
54 24
55 negatively-charged macromolecule, which provides opportunities for developing orthogonal cooperative
56 25
57
58
59
60

1
2
3 1 approaches in combination with nanomedicine with potential for synergistic enhancement of mRNA
4
5 2 function. We have categorized these methods as chemical modifications of mRNA, introduction of self-
6
7 3 replication functions to mRNA sequences, stabilization through RNA architectonics and circularization
8
9 of RNA. In the following sections, we review each of these approaches.
10
11
12 5

14 6 **2.1. Chemical modifications of mRNA**

16
17 7 Chemical modification of mRNA structure is an effective way for promoting mRNAs that are
18
19 8 more resistant to enzymatic degradation than their native counterparts, as well as mRNAs with decreased
20
21 9 immunogenicity. Major strategies have focused on the introduction of a m7G 5'-Cap structure^{8, 9},
22
23 10 modifications through poly(A) tails^{10, 11}, incorporation of untranslated regions (UTRs)^{12, 13}, and insertion
24
25 of modified nucleotides¹¹ to the structure of mRNA (**Figure 1**). In the following sections, we summarize
26
27 11 the advantages provided by these features.
28
29 12

31 13 32 33 14 **2.1.1. 5'-Cap structure**

34
35 15 During maturation of primary transcripts, a cap is added at the 5' extremity of pre-mRNA.¹⁴
36
37 16 This step occurs very early, before the addition of the first 30 nucleotides. The 5'-cap consists of an
38
39 17 inverted 7-methylguanosine connected to the rest of the eukaryotic mRNA via a 5'-5' triphosphate bridge
40
41 18 (m7GpppN, Cap 0). Besides Cap 0, the cap can be further modified by methylation at the 2'-O position
42
43 19 of the +1 ribonucleotide (m7GpppNm, Cap 1) or the +2 ribonucleotide (m7GpppNmNm, Cap 2),
44
45 20 respectively.¹⁵ This methylation is necessary to distinguish self from viral RNA.¹⁶ The presence of the
46
47 21 cap is first required for RNA export from the nucleus after binding to the cap binding complex.¹⁷ Once
48
49 22 in the cytoplasm, the cap is required for initiation of translation and protection against nuclease
50
51 23 degradation.^{18, 19} Accordingly, cap analogs are incorporated in synthetic mRNA by 2 strategies: post-
52
53 24 transcriptional capping or co-transcriptional capping.¹⁷ In post-transcriptional capping, capping enzymes
54
55
56
57
58
59
60

1
2
3 1 from RNA viruses (mostly *Vaccinia*) are used to produce cap1-capped mRNA using GMP. Although
4
5 2 very effective, this strategy requires the expensive production and purification of capping enzymes and
6
7
8 3 is limited to existing natural cap structures.^{17, 20}
9

10 4 In co-transcriptional capping, chemical cap analogs are incorporated during transcription. This
11
12 5 allows optimization of chemical analogs, a work well covered by Jemielity's group, as reviewed
13
14 6 elsewhere.⁸ During transcription, the m7G cap analog can be incorporated either in correct orientation
15
16 7 with the methylated guanosine in 5' (m⁷GpppGpN) or inverted orientation (Gpppm⁷GpN), with a sharp
17
18 8 decrease in translation efficiency of mRNA with inverted cap.²¹
19
20

21 9 The ARCA (Anti Reverse Cap Analog) has been developed for obliged incorporation in the
22
23 10 correct orientation.²² In this analog, the hydroxyls of the ribose have been substituted by OCH₃, this stops
24
25 11 elongation in the incorrect orientation as it prevents bonds between nucleotides. ARCA-capped mRNAs
26
27 12 have 1.8-fold higher translation efficiency over uncapped- or m7G-capped mRNAs.²³
28
29

30 13 Chemical cap analogs aimed at decreasing cleavage by Dcp1/2 decapping enzymes which
31
32 14 cleave the triphosphate bond. Analogues with the second phosphate replaced by an heteroatom have been
33
34 15 developed: either carbon²⁴ or nitrogen²⁵. Bridging oxygens have also been substituted with
35
36 16 dihalogenmethylenbisphosphonate, and were superior to phosphate substitution both in terms of
37
38 17 resistance towards hydrolysis and translation.²⁶
39
40

41 18 Analogues combining ARCA and phosphorothioated riboses have also been developed (β -S-
42
43 19 ARCA analogs).^{9, 27} Such analogues allowed 3-fold higher expression *in vivo* in mice over ARCA-capped
44
45 20 mRNA resulting in superior immune response induction.²⁸ Increased translation of β -S-ARCA-capped
46
47 21 mRNA was related to increased affinity for the cap-binding translation initiation factor eIF4E and
48
49 22 increased resistance to Dcp2 or Dcps degradation over ARCA or m7G caps.^{9, 27, 29}
50
51

52 23 A further refinement in cap design has been to optimize the first transcribed nucleotide. Indeed,
53
54 24 mammalian mRNA can be capped with cap1/cap2 with different first nucleotide (A,G,C,U).³⁰ Sirkoski
55
56
57

1
2
3 1 *et al.* compared the translation efficiency of in vitro transcribed and HPLC-purified mRNA harboring
4
5 2 caps with different first nucleotides.³¹ They synthesized trinucleotides cap analogs m7GpppNpG where
6
7 N is the unmethylated or methylated nucleotide and, used them for co-transcriptional capping. They
8 3
9
10 4 reported that guanine as the first transcribed nucleotide led to the lowest expression in JAWSII murine
11
12 5 dendritic cells: 20-fold lower expression of m7GpppGpG cap compared to m7GpppApG cap. This was
13
14 6 not due to increased affinity for eIF4E nor increased resistance to decapping enzymes and is in agreement
15
16 7 with the abundance of adenosine as first nucleotide in human cell lines.³⁰
17
18

19 8 One of the drawbacks of co-transcriptional capping is that, due to competition with GTP, not
20
21 9 all cap analogs are incorporated alongside transcription and, the efficiency of capping is around 80-
22
23 90 %.³² To limit antiviral responses, uncapped mRNA is usually removed by Xrn1.^{14, 31, 33}
24 10
25
26 11

27 28 12 2.1.2 Poly(A) tail

29
30
31 13 Another step of pre-mRNA maturation occurs after release from the RNA polymerase II.¹⁴ At
32
33 14 the 3' extremity, pre-mRNA is cleaved at 20 nucleotides after a consensus polyadenylation sequence
34
35 15 (AAUAAA).³⁴ After cleavage, the polyA polymerase binds to the pre-mRNA and adds a 100 to 250
36
37 16 adenosines polyA tail. The presence of the poly(A) tail is required for translation and for protection
38
39 17 against degradation.¹
40
41

42 18 Polyadenylation of synthetic mRNA can be achieved either by enzymatic polyadenylation of
43
44 19 capped mRNA or by cloning a poly(T) sequence in the plasmid template.³⁵ However, enzymatic
45
46 20 polyadenylation yields mRNAs with profound differences in poly(A) lengths resulting in a mixture of
47
48 21 mRNAs critically affecting reproducibility and purity of mRNA.^{35, 36}
49
50

51 22 Electroporation of dendritic cells and cancer cells with mRNAs of different poly(A) lengths
52
53 23 (0, 16, 42, 51 or 120A) demonstrated the requirement of a poly(A) tail for *in cellulo* translation and a
54
55 24 critical impact of poly(A) length on translation efficiency.³⁵ GFP-120A mRNA resulted in a 4-fold higher
56
57
58
59
60

1
2
3 1 transcript level over 51A or 42A mRNA 24 h after electroporation. Increased transcript levels were
4
5 2 correlated with higher GFP protein levels. On the contrary, transcript and protein levels were negligible
6
7 3 after electroporation of untailed mRNA or mRNA with 16A. Following studies confirmed that the
8
9 4 optimal length of the tail is between 120A and 150A, and that is should not be masked by additional
10
11 5 bases.³⁷⁻⁴¹
12
13
14
15 6
16

17 7 *2.1.3. Untranslated regions*

18
19 8 5' and 3' UTRs regulate both translation and stability of mRNA.¹⁴ Therefore a strategy to
20
21 9 increase translation efficiency and half-life of synthetic mRNA is to include UTRs sequences from stable
22
23 10 and highly translated mRNA such as beta-globin, albumin, complement factor 3 (C3) and cytochrome
24
25 11 p4502E1 (CYP2E1).^{12, 13} The 5' UTR plays a critical role in the initiation of translation as it controls both
26
27 12 mRNA scanning and the selection of the initiation codon.⁴² Because of this role, highly structured 5'
28
29 13 UTR regions are avoided and more research has been focused on 3' UTRs. 3' UTRs derived from α - or
30
31 14 β -globin, which have long half-lives in erythrocytes (enucleated cells) are the most frequently used for
32
33 15 mRNA,^{10, 43} particularly when two 2 sequential β -globin 3' UTRs are fused head to tail.³⁵ Since
34
35 16 homologous double UTR (dUTRs) are unstable and prone to recombination, heterologous dUTRs are
36
37 17 preferred.^{44, 45} Sahin's group used a SELEX (Systematic Evolution of Ligands by Exponential
38
39 18 enrichment) to identify best dUTRs for vaccination and cell reprogramming.⁴⁵ They tested 64
40
41 19 combinations of dUTRs. The two best dUTRs identified were mtRNR1 (mitochondrially encoded 12S
42
43 20 rRNA) / β -globin and mtRNR1/ AES (Amino Enhancer of Split) with both 1.89-fold mRNA half-life
44
45 21 over double β -globin UTR in human dendritic cells (hDCs). Superior half-life was mirrored with
46
47 22 decreased miRNA binding. mtRNR1/AES dUTR also improved mRNA translation in hDCs by 1.6-fold
48
49 23 over double β -globin UTR. The intravenous injection of luciferase mRNA lipoplexes in mice revealed a
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 3-fold higher expression of mtRNR1/AES dUTR over double β -globin UTR, which resulted in superior
4
5 2 induction of antigen-specific T cells. For the reprogramming of human foreskin fibroblasts, the
6
7 3 AES/mtRNR1 dUTR was the best demonstrating a cell type specificity for optimal dUTR. Recently,
8
9 4 Asrani *et al.* evaluated a library of 10 variants of 5' and 3' UTRs in their ability to improve arginase 1
10
11 5 mRNA expression.¹² They reported higher dependence of mRNA translation on 5' UTR sequence relative
12
13 6 to 3' UTR variants. Moreover, improved protein production was associated with increased protein
14
15 7 translation efficiency, and not to an improved mRNA stability. UTR sequences from C3 and CYP2E1
16
17 8 were found to be the most efficient.
18
19
20
21

22 9 Besides optimization of 5' UTR and 3' UTR regions, sequence engineering of the coding
23
24 10 sequence is also required for maximal expression.⁴⁶ Whereas AU-rich motifs are prone to exosome-
25
26 11 mediated degradation of mRNA, GC-rich mRNAs have increased expression.⁴⁷⁻⁴⁹ Accordingly, mRNA
27
28 12 sequences have been optimized to be GC-rich.⁵⁰⁻⁵²
29
30
31
32

33 14 2.1.4 Modified nucleotides

34
35 15 The first generation of synthetic mRNA lacked the diversity of natural nucleotides present in
36
37 16 mammalian mRNA with natural modified nucleotides such as pseudouridine (Ψ), 5-methylcytidine
38
39 17 (5meC), N6-Methyladenosine (m6A), 5-methyluridine (m5U), or 2-thiouridine (S²U).^{11, 53} This led to
40
41 18 recognition of mRNA as foreign mRNA by intracellular sensors, such as Toll Like Receptors (TLRs) 7
42
43 19 and 8, resulting in the induction of type I interferon (INF α/β) expression and associated anti-viral
44
45 20 responses. These signals resulted in mRNA translation suppression and degradation, and even host cell
46
47 21 apoptosis.^{54, 55}
48
49
50
51

52 22 Incorporation of Ψ is the most frequent modification of synthetic mRNA.⁵⁶ Ψ -modified mRNA
53
54 23 resists RNase degradation⁵⁷ and lacks TLR activation⁵⁴ resulting in improved translation in cell lysates
55
56 24 and cultured cells.^{58, 59} Then, combination of modifications have been preferred to mirror the diversity
57
58
59
60

1
2
3 1 of natural mRNA. Andries *et al.* reported that mRNA harboring both N methyl Ψ (m1 Ψ) and m5C
4
5 2 outperformed mRNA with single Ψ modification or m5C and Ψ modifications in several cell lines and
6
7
8 3 *in vivo*.⁶⁰ Notably, they showed that after intramuscular or intradermal injection of luciferase mRNA
9
10 4 lipoplexes, m1 Ψ -mRNA yielded 13-fold higher expression over Ψ -mRNA and 4-fold higher expression
11
12
13 5 over m5C/ Ψ - or m5C/m1 Ψ -modified mRNA suggesting m1 Ψ as a new standard for chemically
14
15 6 modified mRNA.

16
17 7 Importantly, the incorporation of modified nucleotides is cell-type and mRNA sequence-
18
19 8 dependent, requesting application-based screening of modifications.⁶¹⁻⁶³ For instance, Li *et al.*, re-ported
20
21
22 9 that, in THP-1 macrophages, 5meC/ Ψ modified Fluc mRNA resulted in significantly higher Fluc
23
24
25 10 expression, while 5meC/ Ψ modified eGFP mRNA resulted in a decreased GFP expression; m1 Ψ
26
27 11 modified Fluc in THP-1 cells generated 8-fold more Fluc than that in hepatocellular carcinoma Hep 3B
28
29 12 cells.⁶²

30 31 32 13 33 34 14 **2.2. Self-amplifying RNA**

35
36 15 Another approach to increase the activity of mRNA comes from mimicry of RNA viruses.
37
38 16 Indeed, RNA viruses need to replicate their genome in the host cell for virion production.⁶⁴ Accordingly,
39
40
41 17 researchers have used strategies derived from RNA viruses for vaccination as early as 1999.⁶⁵ These
42
43 18 RNA with self-amplification capacity are called self-amplifying RNA (saRNA) or replicons.^{64, 66, 67} In
44
45 19 most studies, saRNA are derived from alphaviruses.^{39, 65, 66, 68-72} In alphaviruses, on part of the genome
46
47
48 20 codes for non-structural proteins which assemble to form the RNA-dependent RNA polymerase
49
50 21 (replicase), the other part for structural proteins (capsid and envelope proteins).⁷³ After infection,
51
52 22 replicase is expressed from the positive strand RNA genome to synthesize the minus RNA strand, which
53
54
55 23 serves as template to amplify the genomic RNA and, for subgenomic RNA synthesis (**Figure 2**). It is

important to notice that saRNA is amplified after a first round of translation to assemble the replicase, highlighting similar bottlenecks for the early steps of mRNA and saRNA transfection.^{74, 75}





Figure 2. Replication and translation of saRNA. Early after infection the non-structural proteins (NS) are translated and self-assemble to form the replicase. The replicase both amplifies the genome and synthesizes the minus strand RNA. Finally, the replicase translated subgenomic RNA which contains virulence genes allowing production of virions. In synthetic saRNA virulence genes (e.g. capsid) are replaced by the gene of interest. The figure is based on information from a reference⁷³.

2.3. Circular RNA

Another solution to face the degradation of RNA by exonucleases is the circularization of RNA.⁷⁶⁻⁷⁹ This strategy was inspired by the endogenous circular RNA with covalently linked ends found in viruses⁸⁰, archaea⁸¹, all eukaryotes⁸² among which humans.⁸³ CircRNA is formed by the pre-mRNA splicing machinery from introns^{84, 85} or from exons^{71, 86} and its biogenesis is regulated by several factors⁸⁷. circRNA is generated by back-splicing to join a splice donor to an upstream splice acceptor (**Figure**

1 3).⁸⁷

2



3

Figure 3. Canonical splicing, back-splicing and self-splicing. **A.** For pre-mRNA, the spliceosome binds to 5' and 3' splice sites (5'ss and 3'ss). The then 2'OH of a 3'ss branchpoint nucleotide performs a nucleophilic attack on the first nucleotide of the 5'ss. This results in the formation of an exon1-3'OH and a lariat intermediate-exon2. Finally, 5'ss-OH attack of exon 2 3'ss joins exons and releases a lariat. **B.** In back-splicing, 5'ss and 3'ss are in reverse orientation. As back-splicing is not sterically favorable, it is supported by complementary base pairing of flanking exons which juxtaposes 5'ss and 3'ss. Then 3'ss attack of the 5'ss splice acceptor joins the two introns and releases circRNA. **C.** An exogenous guanosine (G) attacks the 5'ss separating exon1 5'ss-OH from G-intron 3'ss-exon2. The, 5'ss attack of the 3'ss results in exon joining and release of a linear intron. Group I introns possess a 3' terminal G and this 3'G-OH performs a self-catalyzed nucleophilic attack close to the exogenous G resulting in the formation of circRNA. The figures are based on information from references ⁸⁷⁻⁹¹.

15

For pre-mRNA canonical splicing, the spliceosome recognizes consensus intron/exon boundary sites: 5' splice site (5'ss) and 3' splice site (3'ss) to remove introns in two steps: 1) formation

17

1
2
3 1 of a free hydroxyl at the 5'ss, 2) attack of the 3'ss by the 5'ss-OH resulting in exon joining and an excised
4
5 2 lariat (**Figure 3A**).⁸⁹

6
7
8 3 Endogenous circRNA is generated when splicing occurs not between 5'ss of exon 1 and 3'ss
9
10 4 of exon 2 but between 3'ss of exon 2 and 5'ss of exon 2 that is, back-splicing (**Figure 3B**).^{90, 92} circRNA
11
12 5 formation is not frequent due to the low efficiency of the process as upstream 5'ss-3'ss ligation by the
13
14 6 spliceosome is sterically unfavorable.⁹³ Thus, circRNA formation is reinforced by repetitive flanking
15
16
17 7 sequences, particularly Alu repetitive sequences in an inverted orientation.^{87, 94}

18
19 8 The most frequent method used for *in vitro* production of synthetic circRNA derives from group from
20
21 9 *Tetrahymena* or *Anabena* containing end-to-end fused exons that interrupt half intron sequences.⁹⁰ As
22
23
24 10 the exon sequences do not participate in the back-splicing they can be replaced by a sequence of interest.^{90,}
25
26 11 ⁹⁵

27
28 12 Group I introns self-splice by recruiting a guanosine (G) which, in the presence of Mg²⁺,
29
30
31 13 performs a nucleophilic attack on the 5'ss phosphate resulting in covalent linkage of G to the end of the
32
33 14 intron and generation of a reactive OH on the 5'ss.^{88, 90} The site of G attack is defined by an internal guide
34
35 15 sequence present in a duplex formed between the last nt of the 5'ss and the first nt of the intron. The
36
37
38 16 second step involves attack of the 3'ss by the 5'ss-OH. This ligates the 5' and 3' exons and releases a
39
40 17 linear intron. Finally, the linear intron undergoes a self-catalyzed intramolecular cyclization reaction
41
42 18 (**Figure 3C**).⁹⁶

43
44 19 CircRNA is resistant to exonucleases and highly stable with a median half-life of 24h.⁹⁷ Due
45
46
47 20 to the low efficiency of back-splicing⁹³, most circRNA have been categorized as side products of pre-
48
49 21 mRNA splicing ⁹⁸ or miRNA sponges.⁹⁵ Only few circRNA have been proven to bind and regulate
50
51 22 specific miRNA ^{95, 99, 100} or express proteins.^{101, 102}

52
53
54 23 Progression of RNA therapeutics in preclinical and clinical studies ^{103, 104} supported the demand
55
56 24 for circRNA to benefit from its enhanced stability.^{76-79, 105} Synthetic circRNA is prepared by

1 intramolecular ligation of a linear precursor followed by elimination of linear RNA using RNase R
2 (RNA circularization strategies reviewed in ^{90, 92}). Use of exogenous circRNA for protein expression in
3 mammalian cells is recent (2018).⁷⁸ Authors used a permuted intron-exon method for RNA
4 circularization. This strategy had been applied in 1994 for circRNA production in yeast and bacteria
5 using group I intron of phage T4.¹⁰⁶ Wesselhoeft et al used the group I intron in the thymidylate synthase
6 gene of the T4 phage.⁷⁸ They took advantage of exon-joining by Group I introns and inserted a cassette
7 between 5'ss and 3'ss. Their construct contains 5' and 3' introns. They permuted 5'ss and 3'ss on both
8 sides of the cassette to circularize the insert between splicing sites by group I intron mediated exon
9 joining. The cassette contains an EMCV IRES (encephalomyocarditis virus internal ribosomal entry site)
10 for cap-independent translation followed by Gaussia luciferase with a 3'ss in 5' and a 5'ss in 3' (**Figure 4**).
11 Contrary to group I introns where intron is between two exons, in their construct the 5'ss and 3'ss are
12 separated by the inserted cassette, a distance unfavorable to group I intron self-splicing. Accordingly,
13 authors added homology arms (in green in **Figure 4**) in 5' and 3' to bring introns closer to 5'ss and 3'ss.
14 Using this strategy, they reported circularization of RNA up to 5, 000 nt with close to 100 %
15 circularization efficiency.

Group I intron and base-pairing inspired production of synthetic circRNA




Figure 4. Production of exogenous circRNA by a Group I intron-based strategy. The I intron-based strategy, the 3'ss and 5'ss are too far from each other to allow splicing. Thus, homology arms are added on both sides to bring the two splicing sites closer. Exogenous G attack of the 5'ss releases the 5' intron-homology arm and produces an exon1-OH. This is followed by 5'ss-OH attack of the 3'ss to form a circRNA and release the 3' intron-homology arm. The figures are based on information from a reference⁷⁸.

Transfection of human cancer cells (HEK293) with circRNA complexed with Lipofectamine Messenger Max (Invitrogen) resulted in 8-fold more luciferase expression over unmodified luciferase mRNA and 50 % more than nucleoside-modified mRNA. This was accompanied with a doubling of luciferase production half-life reaching 80 h compared to 40 h for linear mRNA. Two critical improvements of linear mRNA: HPLC purification and incorporation of modified nucleotides¹⁰⁷ have

1
2
3 1 also been applied to circRNA and further enhanced its translation and decreased its immunogenicity.⁷⁶
4
5 2 ⁷⁸ Circularization of RNA followed by HPLC purification reduces TLR and RIG-1 sensing.⁷⁸ Concerning
6
7 3 incorporation of modified nucleotides it appears that the circRNA production method needs to be adapted
8
9 4 as replacement of uridine by methyl pseudo uridine or replacement of adenosine by N-methyl adenosine
10
11 5 greatly decreased splicing efficiency.⁷⁹
12
13

14 6 Along with the stabilization against exonuclease, RNA circularization strategy has a potential
15
16 7 to improve the efficiency of protein production. Among the three protein translational processes,
17
18 8 initiation, elongation and termination, initiation is the rate-limiting phase. In circular RNA without stop
19
20 9 codon, ribosomes continue translation with low frequency of detachment from RNA, thereby skipping
21
22 10 rate-limiting re-initiation step. Indeed, circular RNA without stop codon improved the efficiency of
23
24 11 protein production compared to linear mRNA and circular RNA with stop codon in cell-free translational
25
26 12 system from *E. Coli*, and also in human cells.^{108, 109} For application of this strategy to mRNA therapeutics,
27
28 13 additional mechanism is needed to post-translationally cleave large protein translated from circular RNA
29
30 14 without stop codon for obtaining intended protein.
31
32
33
34
35
36
37

38 16 ***2.4. mRNA engineering with RNA architectonics***

39
40 17 While chemical methods have provided improved translational activity and decreased mRNA
41
42 18 immunogenicity,^{54, 58, 60, 110} only a few types of modified nucleosides allow to preserve mRNA
43
44 19 translational activity, and even widely used modified nucleoside species induce negative effect on
45
46 20 translational processes, depending on their introduction ratio and target cell types (see *Section 2.1.4* for
47
48 21 detail).^{61, 62} Thus, other approaches are needed to expand the options of mRNA engineering.
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. mRNA engineering with RNA architectonics. A, B. Introduction of (A) cholesterol moieties,¹¹¹ and (B) PEG.¹¹² C. mRNA nanoassemblies.¹¹³ D. mRNA hybridized with poly U for mRNA vaccination.¹¹⁴

We proposed an original approach of mRNA architectonics for introducing various functional moieties to mRNA, through hybridization of mRNA with functionalized RNA oligonucleotides (OligoRNAs) (Figure 5). Although formation of double stranded RNA structure resulting from OligoRNA hybridization may impair mRNA translational processes and increase mRNA immunogenicity, these unfavorable outcomes were successfully avoided by limiting OligoRNA hybridization length to 17 nt.¹¹¹ This finding motivated us to functionalize mRNA carriers, such as polymeric micelles (PMs) and lipid nanoparticles (LNPs), using OligoRNAs introduced with functional moieties. For structural stabilization of PMs, OligoRNAs introduced with hydrophobic cholesterol (Chol) moiety (Chol-OligoRNAs) was hybridized to mRNA (Figure 5A), and then resulting mRNA was mixed with ω -cholesteryl poly(ethylene glycol) (PEG)-polycation block copolymers to prepare PMs (see Section 3.5 for detail about PMs). Hybridization of just one or a few Chol-OligoRNAs provided drastic

1
2
3 1 effect on tightening mRNA structure in PM core, presumably through stacking between Chol moieties
4
5 2 on mRNA and those on the block copolymers. As a result, PMs became stabilized against nuclease
6
7 3 attacks and polyion exchange reaction. Eventually, the stabilized PMs showed efficient mRNA
8
9 4 introduction in mouse lung with minimal toxicological responses, after intratracheal administration,
10
11 5 demonstrating *in vivo* utility of Chol-OligoRNA hybridization strategy.
12
13

14 6 The hybridization-based mRNA engineering approach is versatile to improve bioavailability
15
16 7 of other types of carriers, such as LNPs (see *Section 3.1* for detail about PMs). Although mRNA LNPs
17
18 8 have demonstrated their high potential especially in delivery to the liver and the spleen,¹¹⁵⁻¹¹⁷ arduous
19
20 9 processes, including the use of microfluidics, are needed for mRNA preparation, especially for
21
22 10 preventing LNP aggregation after the mixture of cationic lipids with mRNA.¹¹⁸ To tackle this issue, we
23
24 11 developed a simple and robust strategy through hybridization of mRNA with PEGylated OligoRNAs
25
26 12 (**Figure 5B**).¹¹⁹ This strategy allowed to prevent aggregation after mixing mRNA with commonly used
27
28 13 LNPs, including lipofectamine LTX and DOTAP/Chol liposomes, with minimal influence on mRNA
29
30 14 translational activity. The PEGylated LNPs thus prepared exhibited high structural stability even in
31
32 15 physiological environment, without forming aggregates in mouse blood circulation, while unPEGylated
33
34 16 LNPs formed several micrometer-sized aggregates in blood, and caused lung embolism.
35
36
37
38
39

40 17 Other applications of OligoRNA hybridization strategy include mRNA structuring to improve
41
42 18 its nuclease stability. Growing field of RNA nanotechnology revealed that nuclease attack to RNA is
43
44 19 weakened by structuring RNA, presumably through steric hindrance, and this strategy was applied to
45
46 20 siRNA delivery.^{120, 121} Meanwhile, precise sequence designing is needed to obtain intended base-pairing
47
48 21 for structuring RNA. This issue hampers direct application of this technology to the delivery of mRNA,
49
50 22 which possesses limited sequence flexibility with fixed structure containing a 5'-cap, 5'- and 3'-
51
52 23 untranslated regions, a coding region, and a poly-A tail. To prepare structured mRNA possessing all of
53
54 24 these endogenous mRNA components without sequence optimization, we crosslinked mRNA strands
55
56
57
58
59
60

1
2
3 1 using linker OligoRNAs, which possess two complementary arms for hybridization (**Figure 5C**).¹²² Each
4
5 2 mRNA nanoassembly thus prepared was comprised of 7.7 strands of mRNA on average, with average
6
7 3 size below 100 nm, and the nanoassemblies exhibited around 100-fold increase in nuclease stability
8
9 4 compared to naïve mRNA, with preserved translational activity. Intriguingly, this result suggests that
10
11 5 nanoassemblies remained accessible to translational factors, although the recognition by nucleases is
12
13 6 effectively weakened presumably through steric hinderance. In mechanistic analysis, nanoassemblies
14
15 7 from mRNA with 5' cap were selectively dissociated in the environment mimicking intracellular space,
16
17 8 while those from mRNA without 5' cap failed to dissociate. This result suggests that translational factors
18
19 9 recognize 5' cap in nanoassemblies to trigger translation, and then nanoassemblies dissociate through
20
21 10 endogenous mRNA unwinding mechanism of translational complexes, which facilitates further
22
23 11 translation. Similar unwinding mechanism might contribute to protein translation from mRNA
24
25 12 hybridized with Chol-OligoRNAs or PEG-OligoRNAs. Nanoassemblies exhibited efficient mRNA
26
27 13 introduction to mouse brain, demonstrating their *in vivo* utility. Rolling circle transcription of plasmid
28
29 14 DNA, a widely-used method, can also provide structured RNA with protein expressing capability, and
30
31 15 this approach resulted in improvement of RNA nuclease stability,¹²³ which is consistent with our finding
32
33 16 of mRNA nanoassemblies. However, protein translation from RNA prepared by rolling circle methods
34
35 17 relies on an internal ribosomal entry site, which tends to yield a much lower level of translational
36
37 18 efficiency compared to cap-dependent translation.¹²⁴ Other strategies to improve mRNA nuclease
38
39 19 stability includes the preparation of long double stranded structure in mRNA by hybridizing long
40
41 20 antisense strand.¹²⁵ Although this strategy was effective in facilitating mRNA delivery to the liver after
42
43 21 hydrodynamic injection, its versatility is unclear, because long RNA hybridization to mRNA resulted in
44
45 22 impaired translational activity and enhanced mRNA immunogenicity.^{111, 114}
46
47
48
49
50
51
52

53
54 23 Interestingly, in RNA hybridization to poly A region, even 120 nt poly U RNA attachment
55
56 24 resulted in only modest decrease in translational activity,¹¹⁴ whereas hybridization of 23 nt or longer
57
58
59
60

1
2
3 1 OligoRNA to protein coding region led to the decrease in translational activity.¹¹¹ Meanwhile, mRNA
4
5 2 hybridized with 120 nt poly U (mRNA:pU) induced strong innate immune responses, especially when
6
7 3 the poly U strand possesses triphosphate structure at its 5' end, which is a substrate of an innate immune
8
9 4 receptor, retinoic acid-inducible gene (RIG)-I.^{126, 127} We utilized these unique properties of mRNA:pU,
10
11 5 preserved translational activity and enhanced immunogenicity, for mRNA vaccine, to obtain antigen
12
13 6 expression and immunostimulatory adjuvant function simultaneously (**Figure 5D**). After introduction to
14
15 7 cultured mouse and human dendritic cells, mRNA:pU induced enhanced expression of dendritic
16
17 8 activation markers, CD86 and CD40, compared to naïve mRNA. Mechanistic analyses indicate the
18
19 9 involvement of RIG-I and Toll-like receptor (TLR)-3 for the immunostimulation by mRNA:pU.
20
21 10 Eventually, in mouse vaccination experiment using a model antigen, ovalbumin (OVA), mRNA:pU
22
23 11 formulation induced cellular and humoral immunity against OVA more efficiently compared to naïve
24
25 12 mRNA. Together, mRNA engineering approach based on OligoRNA hybridization is versatile to
26
27 13 improve bioavailability of naked mRNA and various types of mRNA carriers, and also enhance the
28
29 14 activity of mRNA vaccine, opening up broad opportunities for expanding the potential of mRNA
30
31 15 therapeutics.
32
33
34
35
36
37
38
39

40 17 **3. Nanomedicine-approaches for mRNA delivery**

41
42 18 The application of nano-scaled carriers is necessary for allowing mRNA molecules to endure
43
44 19 in the harsh *in vivo* environments, as well as promote the intracellular delivery of mRNA. Various
45
46 20 materials have been employed for constructing such mRNA-loaded nanomedicines, allowing
47
48 21 physicochemical and functional control. By engineering the interaction with mRNA and the carrier
49
50 22 components, it is then possible to obtain nanomedicines capable of maximizing the stability of mRNA
51
52 23 in biological settings, obtaining optimal translation in targeted cells for therapeutic purposes, and reduce
53
54 24 the side effects from mRNA molecules or off-target translation. The choice of the carrier components
55
56
57
58
59
60

will depend on the eventual route of administration and therapeutic purpose of the nanomedicines. In the following sections, we review major nanomedicine approaches for mRNA delivery categorized by the materials used to make the carriers. The delivery systems highlighted in this section are summarized in

Table 1.

Table 1 Nanomedicine-approaches for mRNA delivery

Category	Key component(s)	Core technologies	Size (nm)	Delivery route(s)	Gene(s)	Ref
Lipid-based nanoparticles	DLin-MC3-DMA ^{a)}	Clinically approved ionizable lipid	75-85	i.v., i.c.v. (mouse)	Luc, frataxin	133
	Lipid 5	Optimized ionizable lipids	86	in vitro, i.v. (mouse, rat, NHP)	Luc, EPO, IgG	135
	TT3 ^{a)}	Orthogonal array optimization	110	in vitro, i.v. (mouse)	Luc, hFIX	136
	A18-Iso5-2DC18 ^{a)}	cyclic head group in ionizable lipid for STING activation	96	in vitro, s.c.	Luc, Cre, OVA, tumor antigens	137
	C12-200 ^{a)}	A large scale <i>in vivo</i> screening of mixture ratio	152	i.v. (mouse)	Luc, EPO	139
	SORT lipid (DLin-MC3-DMA ^{a)} , C12-200 ^{a)} , 5A2-SC8 ^{a)} , DOTAP ^{a)} , 18PA ^{a)} , etc.)	Addition of cationic, anionic and ionizable lipid to change tissue tropism	70-200	i.v. (mouse)	Cre, EPO, IL-10, Cas9	141
	C-24 alkyl phytosterols ^{a)}	Optimized cholesterol	102	in vitro	Luc, GFP, Cas9	143
5A2-SC8 ^{a)}	Dendrimer LNP	100	in vitro, i.v. (mouse)	Luc, FAH	147	
Polyplexes	PEtOx-PEI	Optimization of Mw and charge density	80-450	in vitro	Luc	152
	hyperbranched PBAE	Hyperbranched polycation for nebulization.	150	inhalation (mouse)	Luc, GFP, Cre	153
	Dimannose-PGA/PBAE	Macrophage targeting	100	in vitro, i.p., i.v. (mouse)	IRF5, IKK β	154
	PAsp(EDA), PAsp(TET)	Polyplex stabilization	82, 93	in vitro	Luc	155
	PAsp(TET), PAsp(TEP)	Efficient translation	62, 51	in vitro	Luc	156
	PAsp(DPT), PAsp(TET)	Pre-complexation with eIF4E to facilitate translation	100	in vitro, i.v. (mouse)	Luc	157
Lipopolyplexes	HpK-PEG + HDHE/chol	Protonable histidylated lipids	100	i.v. (mouse)	MART1	38
	PEI + Chol/DOPA/DOPE/DSPE-PEG/Man-lip	Neutral and mannosylated LPP	160-190	i.m., i.v. (mouse)	Luc, HA	39
	HpK-PEG + KLN25/MM27	Mannosylated and histidylated lipids	100-140	i.v. (mouse)	MART1	158
	HpK-PEG +	Histidylated lipids and a tri-	100-	i.v. (mouse)	E7	164

	KLN25/MM27/TriMan-lip	mannosylated diether lipid	150			
	PBAE + EDOPC/DOPE/DSPE-PEG	Biodegradable polymer	n.d.	s.c. (mouse)	OVA	167
	PBAE + PEGylated DD90- C12-122	Alkyl chain installation to PBAE for anchoring PEG-lipid	190	i.v. (mouse)	Luc	168
	TT3 ^{a)} , PLGA	Optimal PLGA formulation for potentiate TT3LNP	100- 250	in vitro	Luc, GFP	169
Polymeric micelles	PEG-PAsp(DET)	Alleviation of mRNA immunogenicity	50	in vitro, i.c., i.n., HTVi (mouse, rat)	Luc, GFP, BDNF, Bcl-2, EPO	40, 175, 176
	PEG-PAsp(TET)-Chol	Micelle stabilization using cholesterol	56	in vitro, i.v. (mouse)	Luc, sFlt-1	41
	PEG-PAsp(DET)-Chol/Chol- mRNA	Introduction of cholesterol to mRNA for stabilization	60	in vitro, i.t. (mouse)	Luc	111
	cRGD-PEG/PNIPAM- PLys(SH)	Tumor targeting; hydrophobic layer and disulfide crosslinking for stabilization	59	in vitro, i.v. (mouse)	Luc, GFP	173
	PEG-PLys(AMP)	Disulfide crosslinking and polycation optimization for stabilization	53	in vitro	Luc	178
	PEG-PGBA	Flexible polycation for stabilization	56	in vitro, i.t., i.v. (mouse)	Luc	181
Exosomes	HEK293T-derived exosome	miRNA-responsive translation system	70- 220	i.v. (mouse)	Luc, PGC1 α	189
	Exosome possessing glioma- targeting peptides	microfluidic cellular nanoporation biochip with electrical pulses to increase exosome production and DNA transfection	30- 170	i.v. (mouse)	PTEN	192

^{a)} See **Figure 6** for chemical structure

Lipid5, ; Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate PEtOx, poly(2-ethyl-2-oxazoline); PEI, poly(ethylene imine); PBAE, poly(beta amino esters); PGA, poly(glutamic acid); PAsp(EDA), poly[N-(2-aminoethyl)aspartamide]; PAsp(TET), poly(N-{N'-[N''-(2-aminoethyl)-2-aminoethyl]-2-aminoethyl}aspartamide); PAsp(TEP), poly-[N-(N'-{N''-[N'''-(2-aminoethyl)-2-aminoethyl]-2-aminoethyl]-2-aminoethyl)aspartamide]; PAsp(DPT), poly{N'-[N-(3-aminopropyl)-3-aminopropyl]aspartamide}; HpK, Histidylated polylysine; HDHE, L-Histidine-(N,N-di-n-hexadecylamine)ethylamide; Chol, Cholesterol; DOPA, 1,2-dioleoyl-sn-glycero-3-phosphate; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphatidyl-ethanolamine; DSPE, 1,2-distearoyl-sn-glycero-3-hosphoethanolamine; Man-lip, 16:0 1,2-dipalmitoyl-sn-glycero-3-phospho((ethyl-1',20,30-triazole)triethyleneglycolmannose; TriMan-lip, trimannosylated archeal diether lipid; EDOPC, 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine; PLGA, poly(lactic-co-glycolic acid); n.d., not determined; i.v., intravenous injection; i.c.v., intra-cerebroventricular injection; s.c.; subcutaneous injection; i.c., intracisternal injection; i.n., intranasal delivery; HTVi, hydrodynamic tail-vein injection; i.t., intratracheal delivery; NHP, non-human primate; Luc, luciferase; EPO, erythropoietin; OVA, ovalbumin; IL-10, interleukin 10; FAH, fumarylacetoacetate hydrolase; hFIX, human factor IX, IRF5, interferon regulatory factor 5; IKK β inhibitor of nuclear factor kappa- β kinase subunit β ; MART-1, Melanoma antigen recognized by T cells 1; E7, human papillomavirus 16 oncoprotein E7; HA, Hemagglutinin; eIF4E, eukaryotic translation initiation factor 4E; BDNF, brain-derived neurotrophic factor; Bcl-2, B-cell lymphoma-2; sFlt-1, soluble fms-like tyrosine kinase-1; PGC1 α , proximosome proliferator- activated receptor γ coactivator 1 α ; PTEN: phosphatase and tensin homolog.


3.1. Lipid-based nanoparticles

1
2
3 1 LNP are one of the most advanced mRNA delivery systems (reviewed in ^{46, 103}). LNP are
4
5 2 prepared by microfluidic mixing of lipids in ethanol and mRNA in acidic buffer (pH 3.0-4.0).¹²⁸ Lipids
6
7 3 include an ionizable lipid (pKa < 7) that will be protonated at acidic pH to condense mRNA and release
8
9 4 it inside the cells, cholesterol for stabilization, an helper lipid for endosomal escape (usually DOPE,
10
11 **Figure 6**) and a PEGylated lipid to prevent aggregation of LNPs.¹²⁹ Using an ionizable cationic lipid for
12
13 5 mRNA complexation instead of a permanently charged one limits toxicity *in vivo* and increases half-life
14
15 6 of the mRNA.¹³⁰ The rapid mixing leads to the formation of an electron dense core surrounded by a lipid
16
17 7 monolayer.¹³¹ Mixing is followed by dialysis against a neutral buffer to remove ethanol.

18
19 8
20
21 9 LNP were first developed for siRNA delivery, mostly to the liver. The system has produced
22
23 10 an FDA-approved siRNA LNP called Onpattro, which includes the DLin-MC3-DMA (MC3, **Figure 6**)
24
25 11 ionizable lipid.¹³² Accordingly, earlier studies on mRNA LNPs used ionizable lipids with a structure
26
27 12 similar to DLin-MC3-DMA.^{46, 133} LNPs are internalized by clathrin-mediated endocytosis, resulting in
28
29 13 their accumulation in endosomes and possible clearance by exocytosis.^{134, 135} Protonation of the ionizable
30
31 14 lipid at endosomal pH (5.5-6.5) and presence of fusogenic lipids such as DOPE disrupts the endosomal
32
33 15 membrane allowing intracellular delivery of mRNA and its translation.^{46, 135}

34
35 16 Biodegradability is an important parameter for the clinical translation of mRNA LNPs. Sabnis
36
37 17 *et al.* screened a library of different amino lipid-based LNPs and compared their safety and expression
38
39 18 levels in rodents and non-human primates to MC3-LNPs.¹³⁵ They identified ethanolamine as the best
40
41 19 headgroup and their library included ethanolamine with different lipid tails. Intravenous administration
42
43 20 of all the variants led to expression in the liver of mice. By measuring lipid levels in the liver along time,
44
45 21 they reported that ester linkages accelerated liver clearance. Whereas primary esters increased pKa and
46
47 22 decreased mRNA expression, secondary esters improved mRNA expression. The best lipid, lipid 5
48
49 23 (Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate), contains one lipid
50
51 24 chain with a primary ester and one lipid chain with a secondary ester and provided 3-fold higher
52
53
54
55
56
57
58
59
60

1 expression over MC3-LNP. Higher expression was correlated with enhanced endosomal escape with 6-
 2 fold more cytosolic mRNA after transfection of HeLa cells with lipid 5-LNPs over MC3-LNPs. Lipid 5-
 3 LNPs were more rapidly cleared from liver, spleen and plasma than MC3-LNPs and, contrary to MC3-
 4 LNPs did not accumulate in the heart, arguing for better biosafety. Evaluation of the LNPs then moved
 5 to Cynomolgus monkeys. Intravenous injection of 0.01 mg/kg of mRNA encoding either human
 6 erythropoietin or anti-human IgG influenza antibody resulted in 5-fold higher protein levels of lipid 5-
 7 LNPs over MC3-LNPs, with minimal activation of immune markers.



10 **Figure 6. Common lipid and small surfactant structures for preparing LNPs.**

12 Dong *et al.* introduced LNPs where the ionizable lipid is based on TT (N^1, N^3, N^5 -tris(2-
 13 aminoethyl)benzene-1,3,5-tricarboxamide, **Figure 6**), a group consisting of a phenyl ring, three amide
 14 linkers and three amino lipid chains.¹³⁶ LNPs were prepared with TT3 (T3, DOPE, Cholesterol, DMG-

1
2
3 1 PEG2000 at molar ratios of 20/30/40/0.75). Intravenous injection of TT3-LNPs resulted in 6-fold higher
4
5 2 bioluminescence in mice spleen over C12-200 LNPs (**Figure 6**). They also prepared LNPs using mRNA
6
7 3 coding human factor IX (hFIX), a blood clotting factor deficient in hemophilia. Intravenous injection of
8
9 4 hFIX mRNA TT3-LNPs at a dose of 1.1 mg/kg was able to restore FIX levels to normal physiological
10
11 5 values in FIX knockout mice, suggesting a broad potential for protein replacement therapies.
12
13

14 6 A further improvement over MC3-LNPs was to use a cyclic lipid headgroup instead of a linear
15
16 7 one.¹³⁷ The Anderson group screened a library of LNPs formed with headgroups containing linear or
17
18 8 heterocyclic amines (dimethylamino, dimethylaminopropyl, dibutylaminopropyl, dipropylaminopropyl)
19
20 9 which were benchmarked against MC3-LNPs. Irrespective of the number of carbon bonds, subcutaneous
21
22 10 injection of OVA mRNA LNPs with heterocyclic polar heads showed superior activation of murine
23
24 11 splenocytes compared to linear polar heads. Piperazin and azepanyl polar heads induced the highest
25
26 12 levels of specific lymphocytes. LNPs with the A18 polar head increased IFN- γ secretion by 10-fold over
27
28 13 MC3-LNPs and 75-fold over LNPs with a linear tertiary amine polar head (**Figure 6**). This was explained
29
30 14 by enhanced affinity of cyclic lipids towards the binding pocket of the STING protein, resulting in
31
32 15 superior expression of the dendritic cell activation markers CD40, CD86 and HLA-DR (Human
33
34 16 Leukocyte Antigen DR isotype). A18-LNPs achieved superior protection against tumor growth and
35
36 17 extended survival over MC3-LNPs in two murine cancer models.
37
38
39
40
41

42 18 Helper lipids such as DOPE and cholesterol are critical components of LNPs (**Figure 6**).^{46, 103}
43
44 19 DOPE is preferred to DSPC as helper lipid as presence of DSPC leads to the formation of protrusions on
45
46 20 the surface of LNPs and mRNA LNPs enriched in DSPC have low transfection efficiency *in cellulo* and
47
48 21 lower expression *in vivo*.^{131, 137-139} mRNA LNPs containing DSPC were also reported to induce
49
50 22 inflammation at the injection site.¹⁴⁰
51
52

53 23 All mRNA LNPs to date include cholesterol as a stabilizer and to promote membrane fusion.^{135,}
54
55 24 ^{137, 139-144} Substitution of cholesterol by natural analogues has been proposed to increase the potency of
56
57
58
59
60

1
2
3 1 mRNA LNPs.¹⁴³ Authors prepared LNPs with MC3:sterol:DSPC:DMG-PEG at 50:38.5:10:1.5 molar
4
5 2 ratios using three groups of cholesterol analogs. Group I included Vitamin D analogs (e.g. Vitamin D3),
6
7 3 group II analogs included phytosterols (e.g. β -Sitosterol, **Figure 6**), group III included pentacyclic
8
9 4 terpenoids (e.g. botulin). LNPs containing group I analogs had similar size and mRNA encapsulation
10
11 5 efficiency as cholesterol LNPs but low transfection efficiency. Inclusion of group III analogs decreased
12
13 6 encapsulation efficiency by ≥ 50 % and increased the size of LNPs resulting in poor transfection
14
15 7 efficiency. The group II analog β -Sitosterol did not alter LNPs size nor encapsulation efficiency but
16
17 8 improved translation efficiency by 48-fold in cancer cells. This enhancement in transfection efficiency
18
19 9 was even observed in primary cells, with a 14-fold enhancement in *ex vivo* transfected human peripheral
20
21 10 blood macrophages over MC3-LNPs. Improved transfection was due to differences in both
22
23 11 microstructure of LNPs and intracellular trafficking. Whereas cholesterol-LNPs presented a smooth
24
25 12 surface, β -Sitosterol-LNPs' surface was highly faceted suggesting phase separation of lipid domains¹⁴⁵,
26
27 13 packing defects suggested to improve fusion with membranes and thus intracellular delivery.¹⁴⁶ Confocal
28
29 14 microscopy imaging of transfected cells highlighted a higher rate of cellular uptake and retention of β -
30
31 15 Sitosterol-LNPs, with a no significant enhancement in endosomal escape but higher cytoplasmic mobility
32
33 16 of β -Sitosterol-LNPs.

34
35
36
37
38
39
40 17 Cheng *et al.* developed LNPs for mRNA delivery and gene editing in lungs, spleen or liver
41
42 18 after intravenous injection.¹⁴¹ The tissue tropism of these particles is based on modulation of the internal
43
44 19 charge of the LNPs by addition of an additional sorting lipid. LNPs consisted of ionizable lipid (11.9-
45
46 20 50%), DOPE as co-lipid (5-23.8 %), cholesterol (19.3-47.6 %), DMG-PEG (1,2-dimyristoyl-rac-
47
48 21 glycerol-methoxy(poly(ethylene glycol, 0.8-4.8 %) (**Figure 6**) and an increasing percentage of sorting
49
50 22 lipid (0-50%). They compared three different ionizable lipids: the 5A2-SC8 dendrimer (**Figure 6**) which
51
52 23 allowed FAH (fumarylacetoacetate hydrolase) mRNA delivery in the hepatocytes of FAH knockout mice
53
54 24 and extended their survival¹⁴⁷, the MC3 lipid and the same lipid composition as the FDA-approved
55
56
57
58
59
60

1
2
3 1 siRNA LNP Onpattro¹³², the C12-200 lipid (**Figure 6**) which allowed mRNA delivery in the liver.¹³⁹ For
4
5 2 LNPs prepared with these 3 different ionizable lipids, expression of mRNA in organs was controlled by
6
7 3 the content of DOTAP (1,2-dioleoyl-3-trimethylammonium-propane, **Figure 6**) permanently charged
8
9 4 cationic lipid. LNPs without DOTAP were expressed in the liver, LNPs with intermediate DOTAP
10
11 5 content (10-15%) were expressed in the spleen and LNPs with 50 % DOTAP were expressed in the lungs.
12
13 6 Measurements of surface charge showed that DOTAP is in the core of LNPs together with the mRNA as
14
15 7 zeta potentials were close to 0. Interestingly, the type of lipid dictated organ specificity. Using an
16
17 8 ionizable lipid as sorting lipid reinforced the liver tropism of LNPs. Adding an extra 20 % of 5A2-SC8
18
19 9 increased mRNA expression in the liver by 3-fold. Using a zwitterionic sorting lipid favored spleen
20
21 10 targeting with exclusive distribution to the spleen of LNPs containing 80% DSPC (1,2-distearoyl-sn-
22
23 11 glycerol-3-phosphocholine) or 50% DOPC (2-((2,3-bis(oleoyloxy)propyl)dimethylammonio)ethyl ethyl
24
25 12 phosphate). Negatively charged sorting lipids also favored spleen targeting with exclusive expression in
26
27 13 the spleen of LNPs with 10-40% 18PA (1,2-dioleoyl-sn-glycerol-3-phosphate) (**Figure 6**). Selective
28
29 14 organ targeting (SORT) LNPs achieved high expression of erythropoietin and interleukin 10 after
30
31 15 intravenous injection and nearly 100 % gene editing in murine hepatocytes after a single intravenous
32
33 16 injection of 0.3 mg/kg of mRNA.
34
35
36
37
38
39
40
41

42 18 **3.2. Polyplexes**

43
44 19 Polymer-mRNA complexes (polyplexes), particularly using PEI (polyethylenimine) is one of
45
46 20 the earliest strategies used for nucleic acid delivery.¹⁴⁸ Whereas the high cationic density of PEI allows
47
48 21 RNA complexation and endosomal escape by “proton-sponge” effect,¹⁴⁹ this also induces cytotoxicity¹⁵⁰
49
50 22 and alters cellular homeostasis.¹⁵¹ Formation of conjugates of low molecular weight PEI with lipids
51
52 23 decreases the cytotoxicity while preserving transfection efficiency.¹⁴⁹ Using a library of poly(2-ethyl-2-
53
54 24 oxazoline) with varying molar mass and charge densities identified the optimal M_w of PEI for pDNA or
55
56
57
58
59
60

1
2
3 1 mRNA delivery, the EI content being controlled by hydrolysis kinetics.¹⁵² Whereas large and densely
4
5 2 charged polymer (83 kDa and 100 % hydrolysis) was optimal for pDNA transfection of HEK 293T cells,
6
7 3 the optimal polymer for mRNA was smaller and with lower charge density (45 kDa and 80 % hydrolysis).
8
9
10 4 This polymer has not been used *in vivo* yet.

11
12 5 Poly(β -amino) esters (PBAEs) are biodegradable polymers that are less toxic than PEI and
13
14 6 showed efficient mRNA delivery *in vivo*.^{153, 154} An hyperbranched PBAEs (hPBAEs) formulation has
15
16 7 been designed for nebulized mRNA delivery to the lungs.¹⁵³ To evaluate the influence of PBAEs
17
18 8 structure on mRNA inhalation, Authors compared linear PBAEs (lPBAEs) and hPBAEs. Whereas
19
20 9 lPBAEs and hPBAEs showed similar transfection of A549 lung cells in culture, only hPBAEs were suited
21
22 10 for nebulization. Indeed, size of lPBAEs increased from 150- to 1200-nm after nebulization with high
23
24 11 polydispersity. Oppositely, hPBAEs size remained stable under 200 nm with low polydispersity.
25
26 12 Nebulization of luciferase mRNA polyplexes prepared with hPBAEs resulted in 16-fold higher luciferase
27
28 13 protein levels in mice lungs compared to 25 kDa branched PEI polyplexes. Notably, hPBAEs allowed
29
30 14 mRNA delivery to all lung lobes and the transfection of 24.6 % of lung epithelial cells with no
31
32 15 transfection of lung immune cells nor alveolar damage. This technology holds potential for future clinical
33
34 16 application of mRNA polyplexes.
35
36
37
38
39

40 17 The control of the structure of the polycations may also provide opportunity for intracellular
41
42 18 navigation. For example, polyplexes made from *N*-substituted polyaspartamides having odd number of
43
44 19 repeats, *i.e.* polyaspartamides modified with ethylene diamine (P(Asp(EDA))) or triethylamine
45
46 20 (P(Asp(TET))), showed higher and prolonged expression *in vitro* compared to polyaspartamides having
47
48 21 even number of repeats, *i.e.* polyaspartamides modified with diethylenetriamine P(Asp(DET)) or
49
50 22 tetraethylenepentamine (P(Asp(TEP))).¹⁵⁵ This effect was associated with the protonation behaviors of
51
52 23 the aminoethylene groups in response to changes in pH during endosomal uptake, which direct the
53
54 24 endosomal escape and the stability of the polyplexes. Thus, despite the polyaspartamides with even
55
56
57
58
59
60

1
2
3 1 number of repeats promoted endosomal escape, they showed lower stability of mRNA in the cytosol of
4
5 2 cells, which may lead to mRNA degradation and less protein translation. On the other hand,
6
7
8 3 polyaspartamides having odd number of repeats facilitated a rapid escape from endosomes, though their
9
10 4 higher stability in the cytosol resulted in prolonged protein translation. Thus, the stability of these
11
12 5 polyplexes in the cytosol appears to correlate with the protonation of the primary amino groups at the
13
14 6 side chains. These primary amines are almost fully protonated for polyaspartamides having odd number
15
16
17 7 of repeats, while for polyaspartamides having even number of repeats, the protonation is lower.
18

19 8 The polycation structure may also affect the initiation of mRNA translation. For example, by
20
21 9 evaluating the translation of polyplexes from a series of polyaspartamides in cell free conditions, it was
22
23
24 10 found that the translation efficiency of polyplexes formed from polymers having higher number of
25
26 11 aminoethylene repeating units, *i.e.* (P(Asp(TET))) and (P(Asp(TEP))), was comparable to that of naked
27
28 12 mRNA. On the other hand, the efficiency of polyplexes from polyaspartamides having less repeating
29
30
31 13 units, *i.e.* P(Asp(EDA)) and P(Asp(DET)) was significantly decreased.¹⁵⁶ This behavior was explained
32
33 14 by the high negative charge of the triphosphate of the m⁷G group in the cap of mRNA. Thus,
34
35 15 polyaspartamides presenting higher number of aminoethylene repeating units may bind to the
36
37
38 16 triphosphates in the caps more strongly, and promote binding to eIF4E. Such binding profile was
39
40 17 confirmed in a separate study by using FRET imaging studies of Cy5-mRNA/Cy3-eIF4E complexes
41
42 18 electrostatically stabilized by polyaspartamides,¹⁵⁷ showing that P(Asp(DPT)) and P(Asp(TET)) keep the
43
44
45 19 co-localization of mRNA and eIF4E inside cells. These findings indicate the relevance of the polycations
46
47 20 design for regulating intracellular delivery and targeting to the translational machinery of cells.
48

49 21 50 51 22 **3.3. Lipopolyplexes**

52
53
54 23 Lipopolyplexes (LPP) are ternary Lipid-Polycation-nucleic acid complexes.^{39, 158, 159} These
55
56 24 ternary complexes were introduced by Leaf's group by complexation of DNA by protamine or polylysine
57

1
2
3 1 into polyplexes before interaction with DOTAP cationic liposomes.^{160, 161} Lipopolyplexes allowed a
4
5 2 better protection against DNAses and a superior gene expression *in vivo* over DOTAP liposomes / DNA
6
7 3 lipoplexes. This technology was later applied to RNA delivery by Pichon's group.¹⁶²
8
9

10 4 We used LPP where mRNA is first complexed with PEGylated and histidylated polylysine
11
12 5 (PEGHpK) before interaction with cationic liposomes made of cholesterol/HDHE (L-Histidine-(N,N-di-
13
14 6 nhexadecylamine)ethylamide).³⁸ The interesting feature of this formulation is the spleen targeting
15
16 7 obtained following intravenous administration. Vaccination of mice with LPP prepared with mRNA
17
18 8 (termed LPR) coding a melanoma antigen resulted in superior inhibition of melanoma tumor growth
19
20 9 compared to mRNA polyplexes or mRNA lipoplexes. To better target dendritic cells harboring mannose
21
22 10 receptors on their surface, liposomes harboring mannose moieties have been synthesized. In this second
23
24 11 set of study, liposomes were made with bio-inspired lipids: N-methyl imidazolium lipophosphoramidate
25
26 12 (cationic lipid, KLN25) and histamine lipophosphoramidate (protonable lipid, MM27), and a
27
28 13 mannosylated lipid. These cationic lipopolyplexes made of PEGHpK polymer and KLN25/MM27
29
30 14 mannosylated liposomes were designated LPR. Following IV injection, they allowed a better *in vivo*
31
32 15 transfection of DCs over unmannosylated LPR resulting in superior tumor growth inhibition and
33
34 16 extended survival of mice bearing B16F10 melanoma.¹⁵⁸ To further increase the transfection of DCs *in*
35
36 17 *vivo*, a second generation of mannosylated LPR were also formed with the PEG-HpK polymer and
37
38 18 KLN25/MM27 liposomes but included a glycolipid containing a tri-antenna of α -D-mannopyranoside
39
40 19 instead of a monovalent mannose for improved endocytosis by DCs.¹⁶³ LPR prepared with the tri-antenna
41
42 20 targeting motif allowed better transfection of DCs *in vitro* and a stronger tumor growth inhibition in mice
43
44 21 compared to untargeted LPRs or LPRs with a mannosylated lipid harboring only one mannose.^{164, 165}
45
46 22 Indeed, knowing the structure of oligosaccharides on the ligands recognized by mannose receptors on
47
48 23 dendritic cells, having more than one moiety leads to an increase of the receptor avidity and an improved
49
50 24 targeting.¹⁶⁶ One of the interesting feature of this formulation is the fact that mRNA lipopolyplexes e did
51
52
53
54
55
56
57
58
59
60

not rely on type I IFN for effective T-cell immunity by contrast to lipoplexes (**Figure 7A**). This property led to a similar protection against melanoma growth after vaccination with unmodified or m1 Ψ -modified mRNA encoding a tumor antigen (**Figure 7B**)




Figure 7. Cationic and trimannosylated lipopolyplexes induce protection against melanoma. A.

Preparation procedure of hybrid lipid-shell polymer core mRNA nanoparticles (LPR). **B.** Percent of target cell lysis as measurement of cytolytic T cell response following a single intravenous immunization with LPR containing Trimix RNA in wild-type mice and *Ifnar*^{-/-} mice. **C.** Tumor growth curves of mice vaccinated with unmodified or modified OVA mRNA trimannosylated LPR bearing B16-OVA melanoma. Adapted with permission from reference ¹⁶⁴. Copyright 2018 American Chemical Society.

LPP have also been prepared using other polymers such as PBAE and PEI.^{39, 167} 4 kDa PBAE/mRNA polyplexes were encapsulated in (1,2-dioleoyl-sn-glycero-3-ethylphosphocholine/1,2-dioleoyl-sn-glycero-3-phosphatidyl-ethanolamine/1,2-distearoyl-sn-glycero-3-hosphoethanolamine-N-[amino(polyethyleneglycol)-2000, EDOPC/DOPE/DSPE-PEG) liposomes.¹⁶⁷ Subcutaneous injection of these LPP resulted in stronger stimulation of DCs and better antigen presentation over lipoplexes or polyplexes confirming the superiority of the ternary platform. Importantly, LPP formulation has a potential to improve the functionalities of existing polyplexes and LNPs. For example, PBAE-based polymer was installed with alkyl tail to anchor PEG-lipids, which allowed efficient mRNA introduction to the lung after systemic delivery.¹⁶⁸ Incorporation of poly(lactic-co-glycolic acid) (PLGA) to TT3-

1
2
3 1 based LNP (**Figure 6**) was effective in increasing mRNA introduction efficiency to several human cell
4
5 2 lines.¹⁶⁹
6
7
8 3
9

10 4 **3.5. Polymeric Micelles**

11
12 5 Polymeric micelles (PMs) based on polyion complexation have also shown high potential for
13
14 6 delivering mRNA.^{170, 171} The PMs are self-assembled in aqueous conditions by ionic and hydrogen
15
16 7 bonding between the negatively charged mRNA and block cationomers, having a neutral segment and
17
18 8 polycation block. Thus, PMs form a nano-compartmentalized structure with a hydrophilic protective
19
20 9 shell surrounding the mRNA payload in the polyion complex core.¹⁷² The mRNA inside the PMs is
21
22 10 packaged in globular shape,^{40, 173} probably due to the flexibility of single stranded mRNA. The cationomers
23
24 11 can then be engineered to elicit effective protection of the loaded mRNA against enzymatic degradation,
25
26 12 as well as promote the cellular uptake by endocytosis and the eventual endosomal escape and access to
27
28 13 the cytosol. PMs also allowed to suppress immune responses of mRNA, probably by inhibiting the
29
30 14 interaction of mRNA with TLRs and/or hindering TLR mediated signals by endosomal disruption.^{40, 174}
31
32 15 These features indicate PMs as promising carriers for dealing with major challenges of mRNA therapy,
33
34 16 *i.e.* instability, immunogenicity and translation efficiency.
35
36
37
38
39

40 17 The potential of PMs for effective mRNA delivery has been demonstrated *in vivo* after local
41
42 18 or systemic administration. mRNA-loaded micelles based on the block cationomer poly(ethylene glycol)-
43
44 19 *b*-poly{N'-[N-(2-aminoethyl)-2-aminoethyl]aspartamide} (PEG-P(Asp(DET))) showed successful
45
46 20 transfection in the nasal epithelium,¹⁷⁵ the central nervous system,⁴⁰ and the liver.¹⁷⁶ The PEG-
47
48 21 P(Asp(DET)) block copolymer was designed to protect mRNA from rapid degradation and improve the
49
50 22 intracellular delivery of mRNA by polyion complexation and shielding with the PEG blocks. Moreover,
51
52 23 the polyaspartamide block, *i.e.* P(Asp(DET)), presents 2 pKas, *i.e.* 6.2 and 8.9, which allow for effective
53
54 24 polyion complexation at pH 7.4 and enhance endosomal escape after protonation at endosomal pH (pH
55
56
57
58
59
60


1
2
3 1 5-6.5).¹⁷¹
4

5 2 While mRNA-loaded PMs are stable under physiological salt conditions, polyelectrolytes in
6
7 3 biological environments can disrupt them by interfering with the polyion complex between polymers and
8
9 4 mRNA.¹⁷⁷ Thus, efforts directed to stabilize mRNA-loaded PMs have focused on maintaining the micelle
10
11 5 structure by cross-linking the core with stimuli-sensitive covalent bonds,¹⁷⁸ or by introducing
12
13 6 hydrophobic moieties in polycation segments or nucleic acids.^{41, 111} For example, PMs prepared by block
14
15 7 copolymers having cholesteryl group at the end (**Figure 8A**), as well as a relatively large PEG segment
16
17 8 of 23 kDa and polycation blocks for endosomal escape, showed improved blood circulation upon
18
19 9 intravenous injections, achieving 3-orders of magnitude higher concentration in blood compared to naked
20
21 10 mRNA. The high stability and extended bioavailability of these micelles promoted their tumor targeting,
22
23 11 which resulted in high translation of a mRNA encoding luciferase (**Figure 8B**). The ability of these
24
25 12 micelles to elicit antitumor effects was tested by using mRNAs producing the anti-angiogenic sFlt-1 in
26
27 13 a model of pancreatic cancer. The enhanced delivery by the cholesterol modified micelles significantly
28
29 14 improved the efficacy compared to the micelles without cholesterol (**Figure 8C**).⁴¹ PMs having their core
30
31 15 crosslinked *via* reduction-sensitive disulfide bonds by using cyclic-RGD peptide-modified PEG-poly(L-
32
33 16 Lysine-thiol) copolymers (cRGD-PEG-P(Lys(SH))) showed improved stability compared to PMs
34
35 17 prepared from PEG-P(Lys) block copolymers. Moreover, by adding a hydrophobic layer of
36
37 18 thermoresponsive blocks into these micelles just by mixing with poly(N-isopropylacrylamide)-
38
39 19 poly(lysine-thiol) (PNIPAM-P(Lys(SH))) copolymers at a temperature below the lower critical solution
40
41 20 temperature (LCST) of PNIPAM and then incubating the micelles at physiological temperature, it was
42
43 21 possible to further improve the bioavailability of polyion complex micelles 3-orders of magnitude higher
44
45 22 compared to PMs prepared from PEG-P(Lys) block copolymers.¹⁷⁹ The enhanced stability of the PMs
46
47 23 from cRGD-PEG-P(Lys(SH))/PNIPAM-P(Lys(SH)), as well as the tumor targeting by the cRGD ligand
48
49 24 on the surface of the PMs improved the mRNA accumulation in a mouse model of glioblastoma.¹⁷³
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 Besides crosslinking and increasing the hydrophobicity of the core, the stability of PMs could
4
5 2 be enhanced by improving the affinity of the polymers to the mRNA. In this regard, controlling the
6
7 3 rigidity of the main chain of the cationomers could provide a straightforward approach for promoting the
8
9 4 stability of mRNA-loaded PMs. In fact, molecular dynamics simulations have shown that polycations
10
11 5 with higher flexibility may have stronger binding to DNA and double stranded RNAs (dsRNAs) by
12
13 6 increasing the entropic gain through water release.¹⁸⁰ We have recently demonstrated this possibility by
14
15 7 using 2 cationomers having similar structure, except for their polycation backbone, *i.e.* the standard PEG-
16
17 8 P(Lys) bearing a relatively rigid polycation backbone composed of peptide bonds and PEG-poly(glycidyl
18
19 9 butylamine) (PEG-PGBA) block copolymer, which has a relatively flexible polycation block comprised
20
21 10 of a polyether backbone (**Figure 8D**).¹⁸¹ While both copolymers spontaneously formed PMs after mixing
22
23 11 with mRNA in aqueous conditions, PMs made from PEG-PGBA required less polymers to stabilize the
24
25 12 micelle structure. By isothermal titration calorimetry measurements (**Figure 8D**), PEG-PGBA was found
26
27 13 to have 50-fold higher binding to mRNA than PEG-P(Lys) due to the decreased in the binding enthalpy
28
29 14 and the increase in the binding entropy, which leads to lower Gibbs free energy and enhanced the binding
30
31 15 affinity to mRNA (**Figure 8D**). The stronger binding of PEG-PGBA resulted in PMs with significantly
32
33 16 enhanced the protection against enzymatic attack and disassembly by polyanions. The PMs from PEG-
34
35 17 PGBA showed higher intracellular delivery of mRNA, resulting in higher protein translation *in vitro* and
36
37 18 *in vivo*. When systemically injected, the PMs from PEG-PGBA were able to circulate in the bloodstream
38
39 19 longer time than the PMs from PEG-P(Lys).

40
41
42 20 These observations indicate the possibility to construct stable and functional mRNA-loaded
43
44 21 PMs for systemic applications through precise control of the chemical structure of the cationomers. Such
45
46 22 nanomedicine platforms could allow guiding mRNA molecules into hard to reach tissues and cells for
47
48 23 eliciting unprecedented therapies. The development of such advanced PM formulations will be associated
49
50 24 with systems capable of enduring harsh *in vivo* settings, promoting extravasation in through the blood
51
52
53
54
55
56
57
58
59
60

vessels of the target organ and effectively engaging with the targeted cells for efficient protein translation.



2

3 **Figure 8. Control of the cationer structure enhance mRNA-loaded micelles performance. A. Self-**

1
2
3 1 assembly of mRNA-loaded micelles by PEG-P(Asp(TEP)) or cholesterol-conjugated PEG-P(Asp(TEP))
4
5 2 (PEG-P(Asp(TEP))-Chol). The block copolymers contain TEP units for endosomal escape and
6
7 3 cholesterol for hydrophobic stabilization. **B.** Expression of luciferase in pancreatic BxPC3 tumors after
8
9 4 systemic mRNA delivery by PEG-P(Asp(TEP))-Chol or PEG-P(Asp(TEP)) based micelles. Data
10
11 5 expressed as the mean \pm S.E.M (n = 4). Statistical significance determined by one-way analysis of
12
13 6 variance (ANOVA) followed by Tukey's multiple comparison test. **C.** Efficacy of systemically injected
14
15 7 micelles loading sFlt-1-encoding mRNA against BxPC3. Data presented as the mean \pm S.E.M. (n = 8).
16
17 8 Statistical significance determined by ANOVA followed by Tukey's multiple comparison test. Arrows
18
19 9 indicate injection points. Reprinted in part with permission from reference ⁴¹. Copyright 2016 Elsevier.
20
21
22
23
24 10 **D.** The flexibility of the polycation segment affect the binding affinity to mRNA. Structures of PEG-
25
26 11 P(Lys) bearing a relatively rigid polycation backbone composed of peptide bonds and PEG-poly(glycidyl
27
28 12 butylamine) (PEG-PGBA) copolymer with a backbone having flexible ether bonds (left panel).
29
30
31 13 Isothermal titration calorimetry curves of the formation of mRNA-loaded micelles from PEG-P(Lys) or
32
33 14 PEG-PGBA (right panel). Adapted with permission from reference ¹⁸¹. Copyright 2020 John Wiley and
34
35 15 Sons.

36 37 38 39 40 17 **3.6. Exosomes**

41
42 18 In the search for biocompatible mRNA delivery systems, exosomes secreted by almost cell types have
43
44 19 been proposed as biological nanocarriers (Reviewed in ^{182, 183}). Exosomes are 50-150 nm vesicles
45
46 20 originating from the fusion of multivesicular bodies with the plasma membrane.¹⁸⁴ These vesicles are a
47
48 21 means of exchanging proteins, lipids and nucleic acids between producing and receiving cell types¹⁸²
49
50 22 with as much as 1, 300 different mRNAs in mast cell-derived exosomes.¹⁸⁵ Thanks to their cellular origin,
51
52 23 the surface of exosomes presents membrane proteins, transmembrane proteins and immunoglobulins
53
54 24 which are “don't eat me” signals decreasing their clearance from the circulation.^{186, 187} In addition, these

1
2
3 1 endogenous membrane proteins promote their fusion with cells allowing intracellular delivery of
4
5 2 cargo.^{182, 188} Nucleic acids can be loaded in exosomes either indirectly or directly. For indirect loading,
6
7 3 cells are transfected with nucleic acids before isolation of exosomes: transfection using pDNA to obtain
8
9 4 mRNA-loaded exosomes. For direct loading, purified exosomes in suspension are electroporated with
10
11 5 nucleic acids, this method is called bulk electroporation (BEP). Cell-derived exosomes are isolated and
12
13 6 purified from conditioned media of cells transfected with pDNA coding the desired mRNA or from
14
15 7 biological (e.g. blood) by ultracentrifugation or sucrose gradient ultracentrifugation and then stored at -
16
17 8 80 °C until use.¹⁸²

19
20
21 9 To decrease the expression of delivered mRNA in undesired tissues, Sun *et al.* applied tissue-
22
23 10 specific miRNA-controlled mRNA expression to exosome borne mRNA as an alternative to tissue
24
25 11 targeting.¹⁸⁹ In their system, the mRNA IRES contains two specific miRNA binding sites and binding of
26
27 12 the miRNA induces a conformational change resolving tertiary structures inhibiting translation. Using
28
29 13 luciferase mRNA harboring miR-21 binding sites they reported a 6-fold increase in luciferase expression
30
31 14 in the presence of miR-21. They later moved to adipocyte-targeted expression. They produced exosomes
32
33 15 by transfection of HEK293T packaging cells with a plasmid coding PGC1 α (Peroxisome proliferator-
34
35 16 activated receptor Gamma Coactivator 1 α) harboring two miR-148 binding sites. PGC1 α is an essential
36
37 17 transcription factor for fat browning¹⁹⁰ and miR-148 an adipose tissue specific miRNA.¹⁹¹ Exosomes
38
39 18 isolated from cell culture media contained 50-70 mRNA copies per 100 exosomes. Exosomes were
40
41 19 intravenously injected to fat diet-induced obesity mice and they proved that PGC1 α expression was
42
43 20 increased in adipose tissue but not in liver and lungs, common off-target accumulation organs of
44
45 21 exosomes after intravenous injection. Moreover, overexpression of PGC1 α in adipocytes promoted fat
46
47 22 browning suggesting promising applications for obesity therapy.

48
49 23 Using microfluidics and multiple transfections, Yang *et al.* were able increase the production
50
51 24 of mRNA-loaded exosomes and decorate them with a targeting peptide for anti-glioma therapy.¹⁹² They

1
2
3 1 developed a microfluidic cellular nanoporation biochip (CNP) where pDNA enters cells through 500 nm
4
5 2 channels at the bottom and secreted exosomes are collected from the top, followed by isolation using
6
7 3 sequential ultracentrifugation. As secretion of exosomes is a stress response, they compared exosome
8
9 4 production after stress by starvation, hypoxia, heat or electrical pulses. Electrical pulses generated 10-
10
11 5 fold more exosomes than all the other stress signals with a maximal secretion of 150 exosomes per 10⁴
12
13 6 mouse embryonic fibroblasts (MEFs) at 200V. Using a plasmid coding the tumor suppressor PTEN
14
15 7 (Phosphatase and TENsin homolog) and RT-qPCR quantitation, they demonstrated that exosomes
16
17 8 produced by CNP and electrical pulses stimulation contained 1,000-fold more intact mRNA over BEP
18
19 9 cells or Lipofectamine 2000[®]-transfected cells. To target glioma cells, they used a CDX-CD47 plasmid
20
21 10 coding the glioma targeting peptide CDX¹⁹³ fused to the N terminus of the exosome-enriched
22
23 11 transmembrane protein CD47 to produce targeted exosomes (Exo-T). Adding the CDX-CD47 plasmid
24
25 12 resulted in the production of PTEN mRNA-loaded Exo-T harboring the CDX peptide on their external
26
27 13 surface. Presence of the targeting peptide increased cellular uptake and PTEN expression in murine U87
28
29 14 glioma cells over untargeted exosomes. Finally, intravenously injected Exo-T were able to cross the
30
31 15 blood-brain barrier and accumulate in mice brain leading to superior tumor growth inhibition and
32
33 16 extended survival of mice bearing orthotopic gliomas compared to untargeted exosomes. As CNP
34
35 17 improve the yield of mRNA loading in exosomes using a microfluidic platform and versatile targeting
36
37 18 can be implemented using a CD47 fusion plasmid, this technology shows high translational potential for
38
39 19 exosomal mRNA targeted delivery.
40
41
42
43
44
45
46
47
48

49 21 **4. Applications**

50 22 **4.1. Vaccination**

51 23 Early applications of mRNA have been focused to the development of vaccines. This is because mRNA
52
53 24 presents several advantages for eliciting potent immunization, as well as the potential to fast and cheap
54
55
56
57
58
59
60

1
2
3 1 processing and easy handling.³ Moreover, as variety of antigens can be encoded in the mRNA sequence,
4
5 2 it is possible to utilize the same carrier platform for eliciting effective immunization against a wide-range
6
7
8 3 of diseases. The carriers used for mRNA vaccination are designed to deliver the antigen-encoding mRNA
9
10 4 molecules to antigen presenting cells (APCs). Inside the APCs the mRNA molecules produce proteins
11
12 5 that are processed into peptide epitopes for presentation through the major histocompatibility complex
13
14
15 6 (MHC) class I. The efficiency of the immunization will depend on several aspects, including the route
16
17 7 of vaccination, the cellular targeting, and the translation efficiency and the toxicity of the carrier.
18
19
20
21
22

23 9 **4.1.1. Carrier development for mRNA vaccines**

24 10 Among various mRNA carriers for mRNA vaccines, LNPs are most vigorously studied. In the
25
26 11 researches introduced in *Section 3.1*, LNP development was mainly directed to maximizing its protein
27
28 12 expression potential. Meanwhile, some researches optimized LNP formulations based on its vaccination
29
30
31 13 capability. Oberli *et al.* ranked LNPs on their ability to induce ovalbumin (OVA)-specific T cells 7 days
32
33 14 after subcutaneous injection.¹⁴⁰ They compared several ionizable lipids (C12-200, cKK-E12 and
34
35 15 503O13) and positively charged lipids combined with a lipid-anchored PEG, cholesterol and a helper
36
37 16 lipid (DSPC or DOPE). The best formulation, B11, was composed of cKK-E12/DOPE/Chol/C14-
38
39
40 17 PEG2000 (10/15/26/40.5/2.5 mol %) and induced 4.2 % OVA-specific T cells. Therapeutic vaccination
41
42 18 of mice harboring established B16-F10 melanoma with B11 LNPs prepared with TRP2 (Tyrosinase
43
44 19 Related Protein 2) and gp100 (glycoprotein of 100 kDa) tumor antigen mRNAs extended their survival
45
46
47 20 compared to LNPs prepared with irrelevant mRNAs.
48

49 21 Lutz *et al.* compared the vaccinal potency of LNPs to licensed influenza vaccines in non-human
50
51 22 primates.¹⁹⁴ They prepared LNPs using the ionizable lipid L319, DSPC, cholesterol and PEG-DMG at a
52
53
54 23 molar ratio of 555:10:32.5:2.5. They showed that intramuscular vaccination of cynomolgus monkeys
55
56 24 with LNPs formed with mRNA encoding the hemagglutinin antigen from the pandemic influenza strain
57
58
59
60

1
2
3 1 H1N1pdm09 induced functional antibody titers above protective levels for 5 months after vaccination.
4
5 2 Antibody titers were comparable to those obtained after vaccination of monkeys with the licensed Flud
6
7 vaccine. In addition, the LNP vaccine induced antigen-specific CD4 and CD8 T cells which were absent
8
9 in the Flud[®] group.
10
11

12 5 To advance the application of mRNA-LNP vaccines, the Coalition for Epidemic Preparedness
13
14 innovations initiated a partnership agreement worth up to US\$ 34 million with the German mRNA
15
16 vaccine company Curevac to develop a downscaled and transportable facility called RNA Printer for the
17
18 production of several grams of mRNA LNPs in a few weeks. Altogether, these data show that the LNP
19
20 technology is a powerful and biocompatible mRNA delivery platform and warrants clinical trials in the
21
22 near future. As of now few mRNA LNPs are under phase 1 clinical trial for several applications: SARS-
23
24
25 CoV-2 Infection (NCT04283461 in USA and BNT162 in Europe), a phase 1 melanoma trial (mRNA-
26
27 4157) and a phase 1 trial in several cancers (NCI-4650), phase 1 against cystic fibrosis (NCT03375047).
28
29

30
31 13 Besides LNPs, mRNA complexation with protamine, a small arginine-rich protein, provides a
32
33 promising platform.¹⁹⁵ Protamine/mRNA complex functions as an immunostimulatory adjuvant, by
34
35 stimulating TLR7 signaling. While tight complexation with protamine resulted in drastic reduction of
36
37 protein translational capability of mRNA, translational efficiency was recovered by decreasing
38
39 protamine/mRNA ratio to prepare mixture of naked mRNA and protamine/mRNA complexes.¹⁹⁶ The
40
41 optimal formulation that balanced the properties of immunostimulation and protein translation was used
42
43 in clinical trials of vaccination against infectious diseases (NCT02241135),¹⁹⁷ and cancer
44
45 (NCT01915524).¹⁹⁸ While carriers were used in most researches of mRNA vaccine, even naked mRNA
46
47
48 provided vaccination effects as described in the next section.
49
50

51 52 53 54 23 **4.1.2. Route of vaccination**

55
56 24 mRNA-based vaccines are usually administered through local or systemic injection depending
57

1
2
3 1 on the antigen expression localization requirements. Direct subcutaneous, intramuscular, or intradermal
4
5 2 injection of mRNA have been the main routes for vaccines directed to infectious diseases, while
6
7 3 intravenous injections are used when the systemic expression of antigens is required.
8
9

10 4 11 12 5 *Intradermal*

13
14 6 After intradermal delivery, mRNA-transfected resident DC need to migrate to lymph nodes to
15
16 7 present antigens to T cells and induce an adaptive immune response.¹⁹⁹ Intradermal injection of naked
17
18 8 mRNA resulted in the transfection of dermal DC with subsequent priming of antigen-specific CD8⁺ T
19
20 9 cells.²⁰⁰ Using fluorescently-labeled mRNA, authors could show mRNA expression occurred in the
21
22 10 dermis not the epidermis and, that dermal DCs and dermal macrophages internalized the mRNA.
23
24 11 Although mRNA was delivered to dermal DCs and macrophages to the same extent (5% mRNA positive
25
26 12 cells for both), using transgenic mice expressing the DC-specific integrin cD11c fused to the diphtheria
27
28 13 toxin receptor they could demonstrate that dermal DCs are the main contributor to mRNA expression in
29
30 14 the dermis. Internalization occurred *via* macropinocytosis as pre-conditioning the injection site with the
31
32 15 micropinocytosis inhibitor rottlerin dramatically decreased the expression of luciferase mRNA in the
33
34 16 dermis. Finally, T cell priming was reduced in rottlerin-treated animals confirming that intradermal
35
36 17 mRNA vaccination proceeds by macropinocytosis in dermal DCs. Feasibility of this administration route
37
38 18 for mRNA vaccine has already been demonstrated even in large animals, with mRNA LNP inducing the
39
40 19 production of antibodies against human immunodeficiency virus type 1 (HIV-1) in rhesus macaques.²⁰¹
41
42
43
44
45
46
47
48

49 21 *Intranodal*

50
51 22 Because ultimately, the naked mRNA requires to reach a lymph node, some groups directly
52
53 23 inject the mRNA in the lymph nodes: by intranodal injection.⁴⁶ As the lymph nodes are rich in immune
54
55 24 cells, intranodal injection results in mRNA accumulation in both macrophages and dendritic cells,
56
57
58
59
60

1
2
3 1 antigen-presenting cells capable of inducing an adaptive immune response.²⁰² However, in injections
4
5 2 need to be performed by highly-trained personnel: by surgically exposing the inguinal lymph node
6
7
8 3 followed by injection and wound closure in mice,²⁰³ by a radiologist guided by echography in inguinal
9
10 4 lymph nodes in humans.²⁰⁴

11
12 5 Kreiter et al. compared the vaccine activity of naked mRNA administered by intranodal,
13
14 6 subcutaneous or intradermal routes in mice.²⁰⁵ Using luciferase mRNA they showed highest
15
16
17 7 bioluminescence after intranodal injection, 3-fold higher than intradermal injection at 16h whereas no
18
19 8 signal was detected after subcutaneous injection. By injecting mRNA coding the influenza antigen
20
21 9 hemagglutinin they reported that only intranodal injection led to the expansion of antigen-specific T cells
22
23
24 10 both in lymph node, blood and spleen. Therapeutic evaluation as a preventive cancer vaccine
25
26 11 demonstrated superior survival of intranodally vaccinated mice over s.c. or i.d. vaccinated mice with s.c.
27
28 12 route offering no protection at all.

29
30
31 13 The same authors then evidenced that naked mRNA selectively accumulated in lymph node
32
33 14 DCs after intranodal injection *via* macropinocytosis highlighting the importance of this endocytic
34
35 15 pathway for naked mRNA vaccination both by intradermal and intranodal routes.²⁰²

36
37
38 16 Joe et al. compared intranodal mRNA vaccination to intramuscular pDNA vaccination against
39
40 17 influenza.²⁰³ Intramuscular pDNA vaccination was used as a benchmark. mRNA vaccination induced
41
42 18 more antigen-specific cytotoxic T lymphocytes both in the lymph nodes and the spleen over pDNA.
43
44 19 Intranodal mRNA also partially protected mice from viral challenge.

45
46
47 20 Intranodal mRNA vaccination recently reached Phase 1 clinical trial in HIV patients.²⁰⁴ HIV
48
49 21 patients received three intranodal doses of mRNA coding HIV immunogen sequences. This vaccine was
50
51 22 well tolerated in patients and induced a moderate HIV-specific T cell response supporting the ongoing
52
53
54 23 Phase 2 clinical trial.

1 *Intravenous*

2
3
4
5 2 Successful outcomes obtained by intranodal administration provided proof of concept to the
6
7
8 3 strategy of targeting lymphoid organs for effective vaccination. Intravenous administration allows for
9
10 4 targeting multiple lymphoid organs throughout the body, with an easier and less invasive procedure,
11
12 5 compared to intranodal administration. While uptake of mRNA carriers by reticuloendothelial system
13
14 6 typically induced negative influence on their application to disease treatment, this process provides
15
16 7 beneficial outcomes in mRNA vaccine. After intravenous administration of cationic mRNA LNPs based
17
18 8 on DOTAP, efficient protein expression was obtained in CD11⁺ antigen presenting cell in the spleen.²⁰⁶
19
20 9 In addition, this formulation activated APCs in several organs, including the spleen, liver, bone marrow
21
22 10 and lymph nodes. As a result, intravenous administration of the LNPs loading model antigen mRNA
23
24 11 induced enhanced cellular immunity compared to their intradermal and subcutaneous administration.
25
26 12 Another group also demonstrated the advantage of intravenous administration over intramuscular and
27
28 13 subcutaneous administration, using negatively charged mRNA LNPs based on lipofectamine RNAi
29
30 14 Max.²⁰⁷ Several reports attempted to improve the efficacy of intravenous mRNA vaccination by
31
32 15 introducing (tri-)mannose ligands to LNPs for targeting dendritic cell,^{208, 209} or by incorporating lipid-
33
34 16 based immunostimulatory adjuvant to LNPs.²¹⁰ In another report, α -galactosylceramide was co-
35
36 17 encapsulated to LNPs with mRNA encoding tumor antigens to activate natural killer T cells, leading to
37
38 18 improved efficiency of cancer vaccines.²¹¹
39

40 19 Intravenous mRNA vaccination was tested also in patients with advanced malignant melanoma,
41
42 20 in a phase I clinical trial. In the study, LNPs with various surface charges were prepared by tuning
43
44 21 LNP/mRNA mixture ratio, for optimization in animal experiments. As a result, LNPs with slightly
45
46 22 negative charge induced efficient protein expression from mRNA in the spleen, bone marrow and lymph
47
48 23 nodes, with histological observation showing efficient protein expression in dendritic cells. This
49
50 24 formulation showed efficient anti-tumor activity in several mouse models, and successfully induced
51
52
53
54
55
56
57
58
59
60

1
2
3 1 antigen-specific T cell responses in a clinical trial.¹¹⁶ A subsequent study indicated successful immune
4
5 2 activation in the spleen of patients, using [¹⁸F]Fluoro-2-deoxy-2-D-glucose positron emission
6
7 3 tomography (FDG-PET).²¹² The same group recently used this LNP formulation to potentiate chimeric
8
9 4 antigen receptor (CAR)-T cell therapy against solid tumor in an animal study.²¹³ In many cases of CAR-T
10
11 5 cell therapy against solid tumors, CAR-T cells are inactivated rapidly after transplantation due to low
12
13 6 accessibility to target cells, leading to reduced proliferative signal in CAR T cells. To solve this problem,
14
15 7 mRNA expressing cancer antigen that CAR-T cells target was administered using LNPs to obtain its
16
17 8 expression in APCs throughout lymphoid tissues in the body. Through interaction with APCs expressing
18
19 9 the cancer antigen, CAR-T cells proliferated with preserved activity, thereby inducing efficient anti-
20
21
22
23
24 10 cancer effect in mouse models.
25
26
27
28
29

30 12 **4.1.3. saRNA vaccines**

31 13 saRNA vaccines were first used in the form of Virus RNA Particles (VRPs).^{214, 215} In VRPs the
32
33 14 structural proteins have been replaced by the antigen, they are provided *in trans* in packaging cells to
34
35 15 produce replication-defective VRPs.^{215, 216} As reviewed previously,²¹⁶ alphavirus-based VRPs showed
36
37 16 promising results, among which protection against Meta pneumonia virus, respiratory syncytial virus and
38
39 17 dengue in primates.^{217, 218} However, VRPs face the same biosafety and production limits as viral
40
41
42 18 vectors.²¹⁹
43
44

45 19 Synthetic saRNA has been developed as an alternative to VRPs and, since synthetic saRNA do
46
47 20 not use packaging cells delivery systems are required. Delivery of saRNA faces the size challenge of
48
49 21 saRNA: as saRNA code for the replicase and the antigen(s) they are longer than mRNA: 10, 000 nt vs
50
51 22 1,000 nt for mRNA. Despite this increased length saRNA are produced by *in vitro* transcription from a
52
53
54 23 DNA template with yields similar to mRNA.³⁹
55

56 24 Because synthetic saRNA are more recent than mRNA, fewer formulations have been
57
58
59
60


1
2
3 1 developed for their delivery.^{56, 104, 220} saRNA has been used for vaccination both by intradermal injection
4
5 2 of naked or complexed saRNA followed by electroporation⁷⁴, as intramuscular injection of saRNA
6
7 3 lipopolyplexes³⁹, intramuscular injection of saRNA complexes with dendrimers.⁶⁹ In these studies,
8
9 4 saRNA demonstrated higher expression and extended duration of expression over mRNA.^{66, 67, 71} A few
10
11 5 examples will be detailed.

12
13
14 6 Vogel et al. used PEI polyplexes to deliver saRNA coding an influenza antigen.⁶⁶ Using
15
16 7 luciferase reporter gene they evidenced extended saRNA expression after intramuscular injection of
17
18 8 polyplexes over mRNA polyplexes with an expression delay of saRNA attributable to the necessary
19
20 9 production of replicase, minus strand RNA and translation of minus strand RNA. saRNA gave equivalent
21
22 10 protection as mRNA at 64-fold lower dose. Moreover, combining saRNA coding hemagglutinin from
23
24 11 three strains of influenza protected against sequential viral challenges. They later reported the induction
25
26 12 of CD4 and CD8 specific T cells against conserved HIV-1 regions after vaccination with saRNA
27
28 13 polyplexes.²²¹ These results validate the versatility and therapeutic potential of saRNA polyplexes.

29
30
31
32
33 14 A dendrimer platform has been used for multipurpose intramuscular saRNA vaccination.^{69, 222}
34
35 15 VEEV-derived saRNA was complexed using Modified Dendrimer Nanoparticles (MDNPs) into c.a. 100
36
37 16 nm stable in human serum. Intramuscular injection of MDNPs resulted in the induction of antigen-
38
39 17 specific T cells *in vivo*. Interestingly, when authors injected MDNPs prepared with luciferase saRNA,
40
41 18 they reported an increase in luciferase activity between 36 h and 60 h post injection suggesting *in situ*
42
43 19 replication of the saRNA. MDNPs formed with antigen-coding saRNA protected against lethal influenza
44
45 20 challenge, ebola virus, Zika virus and *Toxoplasma gondii*.^{69, 222}

46
47
48
49 21 We introduced neutral targeted lipopolyplexes (LPP) for the delivery of VEEV-derived saRNA
50
51 22 to dendritic cells.³⁹ Here, saRNA was first complexed in positively-charged polyplexes using PEI
52
53 23 (polyethylenimine) before interaction with anionic PEGylated liposomes to form neutral LPP (**Figure**
54
55 24 **9A**). A mannosylated lipid (16:0 PA-PEG3-mannose 1,2-dipalmitoyl-sn-glycero-3-phospho((ethyl-

1 1',2',3'-triazole)triethyleneglycolmannose) was included in liposomes to engage the mannose receptor on
 2 dendritic cells.^{158, 159} LPP were capable of transfecting a murine dendritic cell line *in vitro*. Intramuscular
 3 injection of LPP prepared with luciferase saRNA resulted in durable expression in the quadriceps (**Figure**
 4 **9B**). Vaccination with LPP formed with saRNA coding influenza antigens led to the induction of antigen-
 5 specific CD4 and CD8 T cells (**Figure 9C**). Another benefit of using saRNA, particularly saRNA derived
 6 from Venezuelan equine encephalitis virus has another advantage as the non-structural proteins also
 7 inhibit type I IFN signaling.^{74, 223}



9 **Figure 9. Formation of LPP-saRNA and activity *in vivo*.** **A.** To form neutral Lipopolyplexes, saRNA
 10 is first complexed with branched PEI to form positively charged polyplexes. Then, positively charged
 11 polyplexes are mixed with anionic liposomes resulting in the formation of neutral LPP. **B.** Intramuscular
 12 injection of LPP- luciferase saRNA complexes allowed sustained expression *in vivo*. **C.** Vaccination of
 13 mice by intramuscular injection of LPP- hemagglutinin saRNA induced antigen-specific IFN- γ secreting
 14 cells with superior immunogenicity over naked RNA or unvaccinated mice. Adapted with permission
 15 from reference ³⁹. Copyright 2019 Elsevier.

1 2 3 1 **4.2 Protein replacement therapy**


4
5 2 Alongside with vaccine, mRNA delivery was widely used for supplying therapeutic peptides
6
7
8 3 or proteins, which is called as protein replacement therapy. As early as 1992, *in vivo* protein replacement
9
10 4 therapy was reported, in which vasopressin mRNA was injected to hypothalamus of model rats that lacks
11
12 5 vasopressin expression, to treat diabetes insipidus.²²⁴ However, over 20 years after the report, therapeutic
13
14 6 application of mRNA was focused on vaccine and immunotherapy, with very few reports addressing the
15
16
17 7 potential of mRNA for protein replacement. A major challenge for mRNA-based protein replacement is
18
19 8 the control of mRNA immunogenicity, as inflammatory responses after mRNA delivery would hamper
20
21
22 9 the therapeutic processes and pose safety concerns. This is in sharp contrast to the cases of vaccine and
23
24 10 immunotherapy, in which induction of innate immune responses is essential to obtain preventive or
25
26 11 therapeutic outcomes. To control mRNA immunogenicity, various techniques have been developed.
27
28 12 Among them, replacement of mRNA nucleosides with chemical modified species, such as m5C, t2C,
29
30
31 13 ΨU and m1ΨU, is the most common approach, which inhibits the recognition of mRNA by innate
32
33 14 immune receptors (see *Section 2.1.4* for detail).^{54, 110} High performance liquid chromatography (HPLC)
34
35 15 purification to remove dsRNA contaminants was also reported to be effective in reducing mRNA
36
37
38 16 immunogenicity.²²⁵ Along with these approaches focusing on mRNA, fine-tuned designing of mRNA
39
40 17 carriers allows for the inhibition of mRNA recognition by immune receptors. After encapsulation of
41
42 18 mRNA into PEGylated polymeric micelles (PMs), its recognition by TLR7 in endosome was suppressed,
43
44
45 19 presumably through steric repulsive effect of PEG, leading to efficient *in vivo* delivery of mRNA with
46
47 20 minimal inflammatory responses (see *Section 3.5* for detail).^{40, 174} Notably, even without mRNA
48
49 21 chemical modification and HPLC purification, mRNA PMs exhibited successful outcome in tissue
50
51
52 22 regenerative treatment to several diseases in model animals, such as osteoarthritis, intravertebral disc
53
54 23 disease and spinal cord injury.²²⁶⁻²²⁸ Such immune regulation approach without relying on mRNA
55
56 24 chemical modification is practically important, because mRNA chemical modification often leads to

1
2
3 1 impaired translational activity, compromising therapeutic potential of mRNA.^{61-63, 229}

4
5 2 These technology advances for alleviating mRNA immunogenicity opened the door for mRNA
6
7
8 3 application to protein replacement therapy. In the past decade, numerous reports demonstrated the
9
10 4 potential of mRNA for this therapeutic approach, with following 5 fields vigorously pursued: (1) Single
11
12 5 gene disorder treatment using mRNA encoding deficient genes, e.g. treatment of lung surfactant protein
13
14 6 deficiency,¹¹⁰ hemophilia,²³⁰ cystic fibrosis,^{231, 232} ornithine transcarbamylase deficiency,²³³ acute
15
16
17 7 intermittent porphyria,²³⁴ Fabry disease,²³⁵ and acute intermittent porphyria;²³⁶ (2) Production of
18
19 8 antibody, including single chain antibody (scFv),²³⁷ whole antibody,²³⁸⁻²⁴⁰ and bi-specific antibody,²⁴¹
20
21 9 targeting amyloid deposition, toxin, infectious diseases, and cancers; (3) Tissue repair and regeneration
22
23
24 10 using growth factors,^{227, 242-244} and transcriptional factors;^{226, 227} (4) Cellular reprogramming (see *Section*
25
26 11 *4.3*); (5) Cancer therapy (see *Section 4.4*).

27
28 12 While details of these applications were extensively reviewed elsewhere,^{1, 245-247} here, we
29
30
31 13 discussed therapeutic application of mRNA, by focusing on following 3 advantages of mRNA over DNA
32
33 14 in protein replacement therapy. (1) mRNA provides earlier onset of protein expression compared to DNA,
34
35 15 because mRNA does not require the processes of nuclear transport and transcription for protein
36
37 16 production (**Figure 10A**).^{40, 248} This time-dependent protein expression profile of mRNA is attractive for
38
39
40 17 targeting acute diseases. (2) Duration of protein expression from mRNA is at most one week, allowing
41
42 18 the use of mRNA to express therapeutic factors that would induce detrimental effects after prolonged
43
44
45 19 expression. (3) mRNA tends to induce protein expression in higher percentage of target cells compared
46
47 20 to DNA (**Figure 10B**), presumably because nuclear entry of DNA becomes a barrier for protein
48
49 21 expression in a large percentage of cells.^{176, 248} In the use of gene expressing secreted factors, their
50
51 22 expression in a small percentage of the target cells is sufficient for obtaining therapeutic outcome,
52
53
54 23 because untransfected cells also receives therapeutic factors secreted from transfected cells. On the
55
56 24 contrary, in the delivery of genes encoding intracellular factors, untransfected cells would obtain less

1 beneficial effect compared to transfected cells. Thus, mRNA is a more suitable option in this case,
 2 because of its capability to induce protein expression in a large percentage of cells (**Figure 10B**).



3
 4 **Figure 10. Comparison of mRNA and pDNA delivery.** A. Time dependent protein expression profile.

5 PEG-PAsp(DET)-based polyplex micelles (PMs, see *Section 3.5.*) loading luciferase mRNA or pDNA

6 were injected to cerebrospinal fluid (CSF) of rats, followed by measurement of luciferase levels in CSF.

7 The figure is adapted from [In Vivo Messenger RNA Introduction into the Central Nervous System Using](#)

8 [Polyplex Nanomicelle](#) by S. Uchida, *et al.*⁴⁰ to show pDNA and mRNA. The figure is licensed under

9 <https://creativecommons.org/licenses/by/2.0/>. B. Tissue distribution of protein expression from mRNA

1 (upper panels) and pDNA (lower panels). Left panels: GFP expression in mouse liver observed 24 h after
2 hydrodynamic injection of PMs loading GFP mRNA or pDNA. Green: GFP, Blue: cell nuclei (DAPI).
3 Scale bar: 100 μm . The figure is adapted from [Messenger RNA-based therapeutics for the treatment of](#)
4 [apoptosis-associated diseases](#) by A. Matsui *et al.*¹⁷⁶ to show the difference between mRNA and pDNA.
5 The figure is licensed under <https://creativecommons.org/licenses/by/4.0/>. Middle panels: Therapy using
6 gene encoding secreted proteins. Protein expression in a small percentage of the target cells is sufficient
7 for obtaining therapeutic outcome, because untransfected cells also receives therapeutic factors secreted
8 from transfected cells. Left panels: Therapy using gene encoding intracellular proteins. Protein
9 expression in a large percentage of the cells is required for therapy, as untransfected cells typically failed
10 to receive therapeutic effects. C. Primary hepatocytes were transfected with Bcl-2 mRNA or pDNA for
11 measuring of Bcl-2 protein expression levels (left). Bcl-2 mRNA and pDNA showed comparable levels
12 of Bcl-2 protein expression from day 1 to day 2 after the transfection (highlighted with gray). In this
13 period, cell death was induced by deprivation of oxygen and glucose. Bcl-2 mRNA showed enhanced
14 pro-survival effect compared to Bcl-2 pDNA, although total Bcl-2 expression levels were comparable
15 between these two groups. This result highlights the importance of obtaining Bcl-2 expression in a large
16 percentage of cells. Reprinted with permission from reference²⁴⁹. Copyright 2018 Elsevier. D. Treatment
17 of mouse model of fulminant hepatitis using Bcl-2 mRNA and pDNA. Liver sections 4 h post-treatment.
18 Red: apoptotic cells (TUNEL). Blue: cell nuclei (DAPI). Scale bar: 100 μm . The figure is adapted from
19 [Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases](#) by A. Matsui *et*
20 *al.*¹⁷⁶ to show the difference between mRNA and pDNA. The figure is licensed under
21 <https://creativecommons.org/licenses/by/4.0/>. E. Introduction of mRNA and pDNA to 3D cultured cells.
22 Left: An array of mesenchymal stem cell spheroids, prepared using micropatterned plate.²⁵⁰ Right:
23 Confocal microscopic images of the spheroids 24 h after introduction of GFP mRNA and pDNA.
24 Dividing cells were labeled with 5-ethynyl-2-deoxyuridine (EdU, red), a nucleic acid analogue, which is

1
2
3 1 incorporated into the genome during S phase. Green: GFP, Blue: cell nuclei (DAPI). Scale bars: 100 μ m.

4
5
6 2 The figure is reproduced from [mRNA as a Tool for Gene Transfection in 3D Cell Culture for Future](#)

7
8 3 [Regenerative Therapy](#) by S. Uchida *et al.*²⁵¹ under <https://creativecommons.org/licenses/by/4.0/>.

9
10 4
11
12 5 These three advantages of mRNA provide strong rationale for the use of mRNA in some
13
14 6 therapeutic settings. For example, the treatment of acute myocardial infarction using *vascular endothelial*
15
16 7 *growth factor (VEGF)-A* mRNA utilized the advantages (1) and (2).²⁴² While both of *VEGF-A* mRNA
17
18 8 and plasmid DNA (pDNA) were effective in reducing infarct area through their angiogenic effects, only
19
20 9 mRNA improved the survival of model animals. Surprisingly, *VEGF-A* pDNA decreased the survival
21
22 10 even when compared to control groups, due to edema caused by prolonged VEGF-A expression. Thus
23
24 11 transient protein expression profile of mRNA was advantageous in this application.

25
26
27
28 12 mRNA delivery is also a preferable method to introduce pro-survival genes, as DNA-based
29
30 13 introduction might cause prolonged expression of pro-survival factors after genomic integration of the
31
32 14 gene, which is cancer promoting. In our previous report, mRNA encoding Bcl-2, an intracellular pro-
33
34 15 survival factor, was used for the treatment of acute hepatitis in mouse model, which utilizes 3 advantages
35
36 16 of mRNA described above.¹⁷⁶ When *Bcl-2* mRNA and pDNA was introduced *in vitro* to primary
37
38 17 hepatocytes treated with cell death stimuli, mRNA provided enhanced pro-survival effects to hepatocytes
39
40 18 compared to pDNA (**Figure 10C**).²⁴⁹ The enhanced potential of *Bcl-2* mRNA is attributed to its
41
42 19 capability to provide Bcl-2 protein expression and pro-survival effects to a larger percentage of cells
43
44 20 compared to *Bcl-2* pDNA. As a result, in the treatment of acute hepatitis, mRNA showed enhanced anti-
45
46 21 apoptotic effect in the liver compared to pDNA (**Figure 10D**). Along with such *in vivo* administration,
47
48 22 *Bcl-2* mRNA is applicable for *ex vivo* administration to improve the engraftment efficiency after cell
49
50 23 transplantation therapy²⁴⁹. In hepatocyte transplantation to mouse liver, *ex vivo Bcl-2* mRNA introduction
51
52 24 provided up to 5-fold increase in the hepatocyte engraftment efficiency with improved outcome in liver

1
2
3 1 functional support to mouse model of chronic hepatitis. Together, *Bcl-2* mRNA provides a safe and
4
5 2 effective option to prevent cell death in a variety of therapeutic settings.
6
7
8 3

10 4 **4.3 Cell reprogramming**

12 5 mRNA therapeutics also provide an excellent tool for converting cell fates, *i.e.* generation of
13
14 6 induced pluripotent cells (iPSCs), differentiation of stem cells, direct reprogramming, and genome
15
16
17 7 editing, with several advantages over the other commonly used methods, such as the use of viral gene
18
19 8 transduction.^{252, 253} iPSCs were firstly generated using retrovirus gene vectors,²⁵⁴ which cause random
20
21 9 integration of the encapsulated genes into host genome. Genomic integration may result in the activation
22
23
24 10 of oncogenes near the integration sites, as reported in a clinical trial.²⁵⁵ Moreover, prolonged expression
25
26 11 of Yamanaka factors after genomic integration may hamper differentiation of iPSCs and also cause tumor
27
28 12 formation.²⁵⁶⁻²⁵⁸ Although adenovirus vectors and non-viral pDNA transfection also allowed iPSC
29
30
31 13 generation in a manner less prone to cause genomic integration,^{259, 260} thorough examination of genome
32
33 14 sequence of iPSCs would still be required before clinical usage, to check the genomic integration, which
34
35 15 occurs at certain rates after introduction of adenovirus vector and pDNA.^{261, 262} This issue of genomic
36
37
38 16 integration also poses problems in gene transfection for stem cell differentiation, direct reprogramming,
39
40 17 and genome editing. On the contrary, mRNA delivery would provide a safer option to cell
41
42 18 reprogramming. In addition, transient protein expression profile of mRNA allows precise temporal
43
44
45 19 control of protein expression, which is often needed for (trans-)differentiation of cells.

46
47 20 For iPSC generation, repeated mRNA transfection is needed due to short duration of protein
48
49 21 expression from mRNA and relatively short intracellular half-life of transcriptional factor proteins. In
50
51 22 repeated transfection, toxicity of each transfection procedure should be minimized to preserve cell
52
53
54 23 viability and obtain efficient and prolonged protein expression. Thus, in the first successful report of
55
56 24 mRNA-based iPSC generation, chemically modified mRNA with 100% substitution of C and U with
57

1
2
3 1 5mC and ΨU was used with supplementation of B18R protein, a decoy receptor for type I interferon, to
4
5 2 reduce immunogenicity of mRNA.²⁶³ Further, 5' triphosphate of uncapped mRNA contaminants, a
6
7 3 potential substrate for an innate immune receptor, RIG-I, was enzymatically removed, and low oxygen
8
9 4 culture was performed to improve iPSC generation efficiency. In subsequent researches, this protocol
10
11 5 was modified to include additional reprogramming mRNA or micro RNA (miRNA).^{264, 265} Despite these
12
13 6 advances, daily dosing of mRNA is still needed. To circumvent this troublesome procedure, self-
14
15 7 amplifying RNA (saRNA) encoding all four Yamanaka factors were employed (see *Section 2.2* for detail
16
17 8 about saRNA), which induced protein expression for more than a week.²⁶⁶ With supplementation of
18
19 9 B18R protein to reduce immune responses, single administration of saRNA successfully generated iPSCs.

20
21
22
23
24 10 mRNA also demonstrated its potential for differentiation of stem cells. In the first report of
25
26 11 mRNA-based iPSC generation described above, *MyoD* mRNA transfection to iPSCs allowed their
27
28 12 differentiation to myotube.²⁶³ Several reports succeeded in osteogenic differentiation of mesenchymal
29
30 13 stem cells (MSCs) *in vitro* using mRNA encoding *bone morphogenetic protein-2 (BMP-2)*, and also *in*
31
32 14 *vivo* bone regeneration after *BMP-2* mRNA delivery to the region of bone defect in animal models.^{243,}
33
34 15 ²⁶⁷ Alongside with such *in vivo* delivery of differentiation factor mRNA, transplantation of cells after *ex*
35
36 16 *vivo* differentiation using mRNA transfection is a promising approach of regenerative therapy. As three-
37
38 17 dimensional (3D) culturing is a wide-spread method to potential cell transplantation therapy,²⁶⁸⁻²⁷⁰ we
39
40 18 undertook *ex vivo* differentiation of 3D-cultured cells using mRNA. Interestingly, in osteogenic
41
42 19 differentiation of MSC spheroids using runt-related transcription factor 2 (*Runx2*), transfection of *Runx2*
43
44 20 mRNA exhibited improved outcomes compared to that of *Runx2* pDNA.²⁵¹ In mechanistic analysis using
45
46 21 a reporter gene, reporter protein expression efficiency from mRNA in MSC spheroids was higher than
47
48 22 that from pDNA (**Figure 10E**), while both of mRNA and pDNA induced comparable level of the protein
49
50 23 expression in MSCs in monolayer culture. This result is explained by the observation that MSCs in
51
52 24 spheroids showed lower rate of cell division compared to those in monolayer culture, and mRNA induced
53
54
55
56
57
58
59
60

1
2
3 1 more efficient protein expression in non-dividing cells compared to pDNA. This study demonstrated
4
5 2 additional advantage of mRNA over pDNA in transfection to 3D culture cells.
6
7

8 3 Various reports demonstrated the utility of mRNA for direct reprogramming, *e.g.* from
9
10 4 fibroblasts to hepatocyte-like cells,²⁷¹ endothelial progenitor cells,²⁷² neurons,²⁷³ and neural precursor
11
12 5 cells,²⁷⁴ from pancreatic exocrine cells to insulin-producing cells,²⁷⁵ and from MSCs to neural stem
13
14 6 cells.²⁷⁶ Notably, *in vivo* direct reprogramming to neurons was achieved by injection of 4 types of mRNA
15
16 7 to brain parenchyma, leading to alleviation of Parkinson's disease symptoms in mouse models.²⁷³ Other
17
18 8 exciting targets of cell programming include hematopoietic and immune cells. In CAR-T cell therapy,
19
20 9 *Foxo1* mRNA was used to increase the fraction of central memory T cells before transplantation, which
21
22 10 resulted in improved anticancer activity of CAR T cells.²⁷⁷ *Musashi-2* mRNA facilitated *ex vivo*
23
24 11 proliferation of hematopoietic stem cells (HSCs) without differentiation, which would solve the problem
25
26 12 of HSC shortage for clinical use.²⁷⁷ Because prolonged overexpression of *Musashi-2* is cancer
27
28 13 promoting,²⁷⁸ its transient expression using mRNA is desirable, as is the case in *Bcl-2* (see Section 4.2).^{176,}
29
30 14 ²⁴⁹ Regulation of macrophage polarization attracts much attention in various therapeutic fields, with M1
31
32 15 macrophages desirable for cancer treatment, and M2 macrophages for tissue regeneration. Several reports
33
34 16 succeeded in M1-to-M2 and M2-to-M1 transition *in vivo*, providing a new tool for macrophage
35
36 17 polarization.^{279, 280} Other interesting strategies of macrophage potentiation include mRNA-based
37
38 18 introduction of anti-microbial peptide in lysosome for treating bacterial infection.²⁸¹ In this strategy,
39
40 19 mRNA encodes anti-microbial peptide connected with a cathepsin B, which translocates the peptide to
41
42 20 lysosome after its translation in cytoplasm, and transplantation of the mRNA-treated macrophages was
43
44 21 effective in treatment of multidrug-resistant bacteria-induced sepsis in mice.
45
46
47
48
49
50

51 22 Genome editing is another promising strategy of cellular reprogramming. Transient protein
52
53 23 expression profile of mRNA is beneficial for genome editing, because prolonged expression increases
54
55 24 the rate of off-target genome cleavage.²⁸² In clinical trials, gene encoding *C-C chemokine receptor 5*
56
57
58
59
60

1
2
3 1 (*CCR5*), a receptor for HIV entry, was disrupted *ex vivo* using zinc finger nucleases (ZFN) mRNA, for
4
5 2 making the transplanted cells resistant to HIV infection (ClinicalTrials.gov Identifier: NCT02500849,
6
7 3 NCT02225665). Recently, research focus was shifted to RNA-based delivery of clustered regularly
8
9 4 interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein (Cas) 9. In co-delivery of
10
11 5 *Cas9* mRNA and single guide RNA (sgRNA), sgRNA was degraded in cytoplasm before translation of
12
13 6 sufficient amount of Cas9 protein, leading to reduced genome editing efficiency.²⁸³ Intracellular
14
15 7 degradation of sgRNA was effectively prevented by chemical modification of sgRNA, which provided
16
17 8 a boost in genome editing efficiency.^{115, 284} By *in vivo* co-delivery of *Cas9* mRNA and sgRNA, several
18
19 9 reports succeeded in the disruption of disease-related genes in the liver, such as *proprotein convertase*
20
21 10 *subtilisin/kexin (PCSK9)*, a target gene of familial hypercholesterolaemia,^{115, 285, 286} *transthyretin (TTR)*,
22
23 11 a target gene of TTR amyloidosis,²⁸⁷ and hepatitis B virus (HBV) DNA.²⁸⁸ Notably, up to 60% of indel
24
25 12 in the liver was achieved even after single administration of *Cas9* mRNA and sgRNA,^{115, 286} while
26
27 13 achieving such a high efficiency is difficult in pDNA delivery.²⁸⁹ This may be partially attributed to
28
29 14 mRNA capability to induce protein expression in higher percentage of cells compared to pDNA
30
31 15 transfection (see *Section 4.2*).^{176, 248, 249}

32 33 34 35 36 37 38 39 40 17 **4.4. Cancer**

41
42 18 mRNA-based vaccines were the first application to be considered for using mRNA against
43
44 19 tumors.^{116, 290-293} After the vaccination, the immune system can recognize cancer cells to elicit cell-
45
46 20 mediated antitumor responses. Thus, mRNA-based cancer vaccines can be directed to promote immunity
47
48 21 against tumor-associated antigens,²⁹⁴ or against neoepitopes due to cancer mutations.²⁹⁵ As the
49
50 22 neoepitope signature, *i.e.* mutanome, is exclusive for each patient and the mRNA molecules can encode
51
52 23 several neoantigen epitopes in their sequence, Sahin et al. proposed to use mRNA-based vaccines as
53
54 24 personalized therapeutics.^{295, 296} This concept was demonstrated in first-in-human application by
55
56
57
58
59
60

1
2
3 1 immunizing metastatic melanoma patients against 10 epitopes.²⁹⁷ This initial success has triggered
4
5 2 several clinical trials against melanoma and other tumors, as reviewed elsewhere.³
6
7

8 3 mRNA can also be used to produce therapeutic proteins with antitumor activity, such as anti-
9
10 4 angiogenic proteins or antibodies,^{41, 241} thereby, using the organs and cells in the body as temporary
11
12 5 factories. This approach could be used to promote the bioavailability of agents that otherwise are rapidly
13
14 6 cleared from the body, thereby, reducing the number of injections and decreasing the burden for patients.
15
16 7 Moreover, producing the proteins *in situ* could avoid cumbersome procedures for synthesizing and
17
18 8 purifying protein drugs in clinical grade. For example, Stadler et al. developed mRNA-loaded
19
20 9 lipopolyplexes encoding bispecific tandem single-chain variable fragments (scFv), *i.e.* bi-(scFv)₂
21
22 10 proteins, directed to simultaneously target both CD3 expressed on T cells and tumor-associated antigens,
23
24 11 *i.e.* claudin 6, claudin 18.2, and the epithelial cell adhesion molecule (EpCAM)).²⁴¹ These bi-(scFv)₂
25
26 12 work by connecting T cells to cancer cells for improving the cell killing efficiency. The mRNA-loaded
27
28 13 nanomedicines accumulated in liver to achieve effective mRNA translation and sustained release of bi-
29
30 14 (scFv)₂ for around 7-days. The nanomedicines encoding bi-(scFv)₂ directed to CD3 and claudin 6
31
32 15 eradicated large ovarian tumors, and their activity was comparable to that of the clinical recombinant
33
34 16 bispecific antibody. However, the nanomedicines required 3-fold less frequency than the antibodies to
35
36 17 exert the same antitumor effect.
37
38
39
40
41

42 18 mRNA-loaded nanomedicines can be applied to introduce specific proteins into cancer cells.
43
44 19 Such approach can be exploited to reduce cancer malignancy or sensitize cancer cells to other treatments.
45
46 20 For example, by using polymer-lipid hybrid nanoparticles comprised of PAMAM (generation 0)
47
48 21 dendrimer for complexation with mRNA, poly(lactic-co-glycolic acid) (PLGA) for increasing
49
50 22 hydrophobicity and ceramide-PEG for coating, it was possible to deliver mRNA encoding the tumor-
51
52 23 suppressor gene phosphatase and tensin homologue (*PTEN*) to tumors. The resulting expression of
53
54 24 functional PTEN in PTEN-null prostate cancer cells suppressed the phosphatidylinositol 3-kinase
55
56
57
58
59
60

1
2
3 1 (PI3K)–AKT pathway and increased apoptosis.²⁹⁸ In another report, mRNA encoding *p53*, a tumor
4
5 2 suppressor gene, was introduced to *p53*-deficient tumors using polymer-lipid hybrid nanoparticles,
6
7 3 comprised of cationic lipid-like molecules for mRNA complexation, disulfate-containing polymers for
8
9 4 mRNA release in reductive intracellular environment and PEGylated lipids.²⁹⁹ The treatment with *p53*
10
11 5 mRNA suppressed the growth of *p53*-deficient tumors, potentiated the function of a mammalian target
12
13 6 of rapamycin (mTOR) inhibitor and ultimately exhibited successful outcomes in mouse models of
14
15 7 orthotopic hepatocellular carcinoma and disseminated non-small cell lung cancer. More recently, PEI-
16
17 8 based polyplexes were used to introduce mRNA encoding vascular endothelial growth factor-C (VEGF-
18
19 9 C) into brain tumor cells to promote lymphangiogenesis and induce the infiltration of CD8 T cells into
20
21 10 the tumors.³⁰⁰ The combination of these mRNA-loaded polyplexes with immune checkpoint inhibitors
22
23 11 allowed the effective treatment of mice models of brain tumors.
24
25
26
27
28
29
30
31

32 13 **5. Future perspectives**

33 14 mRNA therapeutics are now gradually moving toward clinical applications. Vaccination
34
35 15 against cancer is one of the most advanced fields, with the first report of the clinical trials dating back to
36
37 16 2002.³⁰¹ Targeting neoantigens, which are expressed only in cancer cells, is a good approach to improve
38
39 17 the efficacy of vaccines by circumventing immune tolerance mechanisms. A recent clinical trial provided
40
41 18 a proof of concept to this approach, by preparing mRNA expressing neoantigens, which were determined
42
43 19 by deep sequencing of cancer samples from each patient.²⁹⁷ With advances in mRNA vaccine
44
45 20 technologies, including RNA design, administration routes and delivery system, further improvement of
46
47 21 therapeutic outcomes are expected. Such personalized therapy has the potential to revolutionize the
48
49 22 methodology of cancer treatment.
50
51
52

53 23 Vaccine against infectious disease is another important field. In the pandemic of COVID-19
54
55 24 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), several companies have
56
57
58
59
60

1
2
3 1 launched or planned to start clinical trials of mRNA vaccine against the viral spike protein
4
5 2 (ClinicalTrials.gov Identifier: NCT04283461, NCT04368728), based on their promising results in
6
7 3 preclinical or clinical studies of mRNA vaccine against other viruses, including Zika, influenza and
8
9 4 rabies viruses.^{197, 302-305} Importantly, mRNA vaccine against a new infectious disease can be easily
10
11 5 prepared just by changing the mRNA sequence in vaccine formulations developed for other viruses,
12
13 6 which allowed fast start of clinical trials within a few months after sequencing of SARS-CoV2 genome.
14
15 7 The utility of mRNA vaccine against pandemic will be evaluated within a year in large clinical trials.
16
17 8 Notably, competing technologies of nucleic acid vaccines, such as electroporation of pDNA and
18
19 9 adenovirus vector administration, are also being pursued for vaccination against SARS-CoV2.^{306, 307} Pros
20
21 10 and cons of each technology should be assessed from wide perspectives, including effectiveness, adverse
22
23 11 effects, production costs, quality control and large-scale production.
24
25
26
27

28 12 Clinical trials of mRNA therapeutics were conducted also for protein replacement therapy and
29
30 13 genome editing, with *VEGF-A* mRNA injection for heart regeneration (ClinicalTrials.gov Identifier:
31
32 14 NCT03370887), cystic fibrosis transmembrane conductance regulator (CFTR) supplementation for
33
34 15 cystic fibrosis (ClinicalTrials.gov Identifier: NCT03375047), and *ex vivo* ZFN-mediated disruption of
35
36 16 *CCR5* gene for HIV treatment, as extensively reviewed elsewhere.^{308, 309} However, clinical trials in these
37
38 17 fields are still much fewer than that those for mRNA vaccines, which may be partially due to the issues
39
40 18 of mRNA delivery. Protein replacement therapies and genome editing often targets larger organs
41
42 19 compared to the case of mRNA vaccine, which makes mRNA delivery difficult. While various delivery
43
44 20 systems exhibited successful outcomes in small animals, their functions should be evaluated using larger
45
46 21 animals for clinical translation. Because tremendous advances have been made in the core technologies
47
48 22 of mRNA delivery as reviewed here, combination of these technologies may provide effective systems
49
50 23 for clinical usage.
51
52
53
54

55
56 24 Target diseases and genes should be properly selected based on advantages of mRNA
57

therapeutics over competing methodologies, including viral gene therapy and protein therapeutics. As described above, mRNA provided a more proper option compared to viral gene vectors, when prolonged gene expression induces detrimental effects (see *Sections 4.2, 4.3*). Acute diseases are a promising target of mRNA therapeutics, as the onset of protein expression from mRNA is as early as a few hours after the transfection.^{40,248} A major problem of viral gene therapy is the production of neutralizing antibody, which hampers repeated systemic administration of viral vectors.³¹⁰ mRNA delivery is less prone to produce neutralizing antibody, allowing multiple systemic injection without reduction of delivery efficiency.^{233, 234} On the other hand, transient profile of protein expression from mRNA should be taken into account in selecting target diseases. Repeated injections would be required for a long term to treat chronic diseases. When compared to protein therapeutics, mRNA therapeutics are more cost-effective due to their ability to produce numerous copies of proteins from single mRNA.³¹¹ While global market of antibody therapeutics is growing,³¹² mRNA may provide an inexpensive and effective option for antibody-based treatment.²³⁷⁻²⁴¹ Moreover, mRNA delivery is an easier approach to introduce intracellular and membrane proteins compared to protein delivery, expanding the candidates of therapeutic proteins for disease treatment.

6. Conclusion

Vigorous efforts were devoted to solve the problems of mRNA therapeutics, such as immunogenicity, short duration of protein expression, rapid enzymatic degradation, and limited cellular uptake. The strategies are classified into two orthogonal approaches, mRNA designing and nanomedicines, which cooperatively function to facilitate mRNA delivery and minimize safety issues. These technological advances allowed various therapeutic applications of mRNA including vaccinations, protein replacement therapy, cancer therapy and cell reprogramming in preclinical and clinical studies. Through further development of delivery system and proper selection of target diseases, mRNA

1
2
3 1 nanomedicines will solve various medical problems, which are intractable using conventional approaches,
4
5 2 as well as promote unprecedented therapeutic strategies.
6
7
8 3
9

10 4 **Acknowledgments**

11
12 5 This work was supported by Grants-in-Aid for Challenging Research (Exploratory) (18K19901; H.C.),
13
14 6 Grants-in-Aid for Scientific Research B (20H04524 and JP16H03179; H.C.) from the Japan Society for
15
16 7 the Promotion of Science (JSPS). This work has also been supported by fellowships from the Ligue
17
18 8 Nationale Contre le Cancer (FP).
19
20
21 9
22
23
24 10
25

26 11 **References**

- 27
28 12 1. Sahin, U.; Kariko, K.; Tureci, O., mRNA-based therapeutics - developing a new class of
29
30 13 drugs. *Nat. Rev. Drug Discov.* **2014**, *13* (10), 759-80.
31
32
33 14 2. Morse, D. E.; Yanofsky, C., Polarity and the degradation of mRNA. *Nature* **1969**, *224* (5217),
34
35 15 329-31.
36
37 16 3. Pardi, N.; Hogan, M. J.; Porter, F. W.; Weissman, D., mRNA vaccines - a new era in
38
39 17 vaccinology. *Nat. Rev. Drug Discov.* **2018**, *17* (4), 261-279.
40
41
42 18 4. Naldini, L., Gene therapy returns to centre stage. *Nature* **2015**, *526* (7573), 351-60.
43
44 19 5. Bessis, N.; GarciaCozar, F. J.; Boissier, M. C., Immune responses to gene therapy vectors:
45
46 20 influence on vector function and effector mechanisms. *Gene Ther.* **2004**, *11 Suppl 1*, S10-7.
47
48
49 21 6. Hajj, K. A.; Whitehead, K. A., Tools for translation: non-viral materials for therapeutic mRNA
50
51 22 delivery. *Nature Reviews Materials* **2017**, *2* (10), 17056.
52
53
54 23 7. Zhong, Z.; Mc Cafferty, S.; Combes, F.; Huysmans, H.; De Temmerman, J.; Gitsels,
55
56 24 A.; Vanrompay, D.; Portela Catani, J.; Sanders, N. N., mRNA therapeutics deliver a hopeful message.
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Nano Today* **2018**, *23*, 16-39.

2 8. Warminski, M.; Sikorski, P. J.; Kowalska, J.; Jemielity, J., Applications of phosphate
3 modification and labeling to study (m) RNA caps. In *Phosphate Labeling and Sensing in Chemical*
4 *Biology*, Springer: 2017; pp 211-239.

5 9. Wojtczak, B. A.; Sikorski, P. J.; Fac-Dabrowska, K.; Nowicka, A.; Warminski, M.;
6 Kubacka, D.; Nowak, E.; Nowotny, M.; Kowalska, J.; Jemielity, J., 5'-Phosphorothiolate
7 dinucleotide cap analogues: reagents for messenger RNA modification and potent small-molecular
8 inhibitors of decapping enzymes. *Journal of the American Chemical Society* **2018**, *140* (18), 5987-5999.

9 10. Vallazza, B.; Petri, S.; Poleganov, M. A.; Eberle, F.; Kuhn, A. N.; Sahin, U.,
10 Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript
11 replacement therapies, pluripotent stem cell induction, and beyond. *Wiley Interdisciplinary Reviews:*
12 *RNA* **2015**, *6* (5), 471-499.

13 11. Granot, Y.; Peer, D. In *Delivering the right message: Challenges and opportunities in lipid*
14 *nanoparticles-mediated modified mRNA therapeutics—An innate immune system standpoint*, Seminars
15 in immunology, Elsevier: 2017; pp 68-77.

16 12. Asrani, K. H.; Farelli, J. D.; Stahley, M. R.; Miller, R. L.; Cheng, C. J.; Subramanian,
17 R. R.; Brown, J. M., Optimization of mRNA untranslated regions for improved expression of therapeutic
18 mRNA. *RNA biology* **2018**, *15* (6), 756-762.

19 13. Wadhwa, A.; Aljabbari, A.; Lokras, A.; Foged, C.; Thakur, A., Opportunities and
20 Challenges in the Delivery of mRNA-based Vaccines. *Pharmaceutics* **2020**, *12* (2), 102.

21 14. Rabinovich, P. M., *Synthetic messenger RNA and cell metabolism modulation: methods and*
22 *protocols*. Springer: 2013.

23 15. Langberg, S. R.; Moss, B., Post-transcriptional modifications of mRNA. Purification and
24 characterization of cap I and cap II RNA (nucleoside-2'-)-methyltransferases from HeLa cells. *Journal*

- 1
2
3 1 *of Biological Chemistry* **1981**, 256 (19), 10054-10060.
4
5 2 16. Daffis, S.; Szretter, K. J.; Schriewer, J.; Li, J.; Youn, S.; Errett, J.; Lin, T.-Y.;
6
7 3 Schneller, S.; Zust, R.; Dong, H., 2'-O methylation of the viral mRNA cap evades host restriction by
8
9 4 IFIT family members. *Nature* **2010**, 468 (7322), 452-456.
10
11 5 17. Muttach, F.; Muthmann, N.; Rentmeister, A., Synthetic mRNA capping. *Beilstein journal of*
12
13 6 *organic chemistry* **2017**, 13 (1), 2819-2832.
14
15 7 18. McCormick, C.; Khapersky, D. A., Translation inhibition and stress granules in the antiviral
16
17 8 immune response. *Nature Reviews Immunology* **2017**, 17 (10), 647.
18
19 9 19. Grudzien-Nogalska, E.; Kiledjian, M., New insights into decapping enzymes and selective
20
21 10 mRNA decay. *Wiley Interdisciplinary Reviews: RNA* **2017**, 8 (1), e1379.
22
23 11 20. Fuchs, A.-L.; Neu, A.; Sprangers, R., A general method for rapid and cost-efficient large-
24
25 12 scale production of 5' capped RNA. *RNA* **2016**, 22 (9), 1454-1466.
26
27 13 21. Pasquinelli, A.; Dahlberg, J. E.; Lund, E., Reverse 5'caps in RNAs made in vitro by phage
28
29 14 RNA polymerases. *Rna* **1995**, 1 (9), 957-967.
30
31 15 22. JEMIELITY, J.; FOWLER, T.; ZUBEREK, J.; STEPINSKI, J.; LEWDOROWICZ,
32
33 16 M.; NIEDZWIECKA, A.; STOLARSKI, R.; DARZYNKIEWICZ, E.; RHOADS, R. E., Novel
34
35 17 "anti-reverse" cap analogs with superior translational properties. *Rna* **2003**, 9 (9), 1108-1122.
36
37 18 23. STEPINSKI, J.; WADDELL, C.; STOLARSKI, R.; DARZYNKIEWICZ, E.; RHOADS,
38
39 19 R. E., Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl (3'-
40
41 20 O-methyl) GpppG and 7-methyl (3'-deoxy) GpppG. *Rna* **2001**, 7 (10), 1486-1495.
42
43 21 24. Kalek, M.; Jemielity, J.; Darzynkiewicz, Z. M.; Bojarska, E.; Stepinski, J.; Stolarski,
44
45 22 R.; Davis, R. E.; Darzynkiewicz, E., Enzymatically stable 5' mRNA cap analogs: synthesis and binding
46
47 23 studies with human DcpS decapping enzyme. *Bioorganic & medicinal chemistry* **2006**, 14 (9), 3223-
48
49 24 3230.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 25. Rydzik, A. M.; Kulis, M.; Lukaszewicz, M.; Kowalska, J.; Zuberek, J.;
4
5 2 Darzynkiewicz, Z. M.; Darzynkiewicz, E.; Jemielity, J., Synthesis and properties of mRNA cap analogs
6
7 3 containing imidodiphosphate moiety—fairly mimicking natural cap structure, yet resistant to enzymatic
8
9 4 hydrolysis. *Bioorganic & medicinal chemistry* **2012**, *20* (5), 1699-1710.
- 10
11
12 5 26. Rydzik, A. M.; Warminski, M.; Sikorski, P. J.; Baranowski, M. R.; Walczak, S.;
13
14 6 Kowalska, J.; Zuberek, J.; Lukaszewicz, M.; Nowak, E.; W. Claridge, T. D., mRNA cap analogues
15
16 7 substituted in the tetraphosphate chain with CX2: identification of O-to-CCl2 as the first bridging
17
18 8 modification that confers resistance to decapping without impairing translation. *Nucleic acids research*
19
20 9 **2017**, *45* (15), 8661-8675.
- 21
22
23 10 27. Grudzien-Nogalska, E.; Jemielity, J.; Kowalska, J.; Darzynkiewicz, E.; Rhoads, R. E.,
24
25 11 Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells.
26
27 12 *RNA* **2007**, *13* (10), 1745-1755.
- 28
29
30 13 28. Kuhn, A.; Diken, M.; Kreiter, S.; Selmi, A.; Kowalska, J.; Jemielity, J.;
31
32 14 Darzynkiewicz, E.; Huber, C.; Türeci, Ö.; Sahin, U., Phosphorothioate cap analogs increase stability
33
34 15 and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune
35
36 16 responses in vivo. *Gene therapy* **2010**, *17* (8), 961-971.
- 37
38
39 17 29. Kowalska, J.; Lewdorowicz, M.; Zuberek, J.; Grudzien-Nogalska, E.; Bojarska, E.;
40
41 18 Stepinski, J.; Rhoads, R. E.; Darzynkiewicz, E.; Davis, R. E.; Jemielity, J., Synthesis and
42
43 19 characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to
44
45 20 eIF4E and are resistant to the decapping pyrophosphatase DcpS. *Rna* **2008**, *14* (6), 1119-1131.
- 46
47
48
49 21 30. Wang, J.; Alvin Chew, B. L.; Lai, Y.; Dong, H.; Xu, L.; Balamkundu, S.; Cai, W.
50
51 22 M.; Cui, L.; Liu, C. F.; Fu, X.-Y., Quantifying the RNA cap epitranscriptome reveals novel caps in
52
53 23 cellular and viral RNA. *Nucleic acids research* **2019**, *47* (20), e130-e130.
- 54
55
56 24 31. Sikorski, P. J.; Warminski, M.; Kubacka, D.; Ratajczak, T.; Nowis, D.; Kowalska, J.;
57
58
59
60

- 1
2
3 1 Jemielity, J., The identity and methylation status of the first transcribed nucleotide in eukaryotic mRNA
4
5 2 5' cap modulates protein expression in living cells. *Nucleic acids research* **2020**, *48* (4), 1607-1626.
6
7
8 3 32. Walczak, S.; Nowicka, A.; Kubacka, D.; Fac, K.; Wanat, P.; Mroczek, S.;
9
10 4 Kowalska, J.; Jemielity, J., A novel route for preparing 5' cap mimics and capped RNAs: phosphate-
11
12 5 modified cap analogues obtained via click chemistry. *Chemical science* **2017**, *8* (1), 260-267.
13
14
15 6 33. Nagarajan, V. K.; Jones, C. I.; Newbury, S. F.; Green, P. J., XRN 5'→3' exoribonucleases:
16
17 7 structure, mechanisms and functions. *Biochimica et Biophysica Acta (BBA)-Gene Regulatory*
18
19 8 *Mechanisms* **2013**, *1829* (6-7), 590-603.
20
21
22 9 34. Proudfoot, N. J., Ending the message: poly (A) signals then and now. *Genes & development*
23
24 10 **2011**, *25* (17), 1770-1782.
25
26 11 35. Holtkamp, S.; Kreiter, S.; Selmi, A.; Simon, P.; Koslowski, M.; Huber, C.; Türeci,
27
28 12 O. z.; Sahin, U., Modification of antigen-encoding RNA increases stability, translational efficacy, and
29
30 13 T-cell stimulatory capacity of dendritic cells. *Blood* **2006**, *108* (13), 4009-4017.
31
32
33 14 36. Grier, A. E.; Burleigh, S.; Sahni, J.; Clough, C. A.; Cardot, V.; Choe, D. C.;
34
35 15 Krutein, M. C.; Rawlings, D. J.; Jensen, M. C.; Scharenberg, A. M., pEVL: A linear plasmid for
36
37 16 generating mRNA IVT templates with extended encoded poly (A) sequences. *Molecular Therapy-*
38
39 17 *Nucleic Acids* **2016**, *5*, e306.
40
41
42 18 37. Mockey, M.; Gonçalves, C.; Dupuy, F. P.; Lemoine, F. M.; Pichon, C.; Midoux, P.,
43
44 19 mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly (A) chains
45
46 20 in cis and in trans for a high protein expression level. *Biochemical and biophysical research*
47
48 21 *communications* **2006**, *340* (4), 1062-1068.
49
50
51 22 38. Mockey, M.; Bourseau, E.; Chandrashekar, V.; Chaudhuri, A.; Lafosse, S.; Le Cam,
52
53 23 E.; Quesniaux, V.; Ryffel, B.; Pichon, C.; Midoux, P., mRNA-based cancer vaccine: prevention of
54
55 24 B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated
56
57
58
59
60

- 1
2
3 1 lipopolyplexes. *Cancer gene therapy* **2007**, *14* (9), 802-814.
4
5 2 39. Perche, F.; Clemençon, R.; Schulze, K.; Ebensen, T.; Guzmán, C. A.; Pichon, C.,
6
7 Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine. *Molecular*
8 3
9 *Therapy-Nucleic Acids* **2019**, *17*, 767-775.
10 4
11
12 5 40. Uchida, S.; Itaka, K.; Uchida, H.; Hayakawa, K.; Ogata, T.; Ishii, T.; Fukushima,
13
14 S.; Osada, K.; Kataoka, K., In vivo messenger RNA introduction into the central nervous system using
15 6
16 polyplex nanomicelle. *PLoS One* **2013**, *8* (2), e56220.
17 7
18
19 8 41. Uchida, S.; Kinoh, H.; Ishii, T.; Matsui, A.; Tockary, T. A.; Takeda, K. M.; Uchida,
20
21 H.; Osada, K.; Itaka, K.; Kataoka, K., Systemic delivery of messenger RNA for the treatment of
22 9
23 pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. *Biomaterials* **2016**, *82*, 221-
24 10
25 228.
26 11
27
28 12 42. Hinnebusch, A. G.; Ivanov, I. P.; Sonenberg, N., Translational control by 5'-untranslated
29
30 regions of eukaryotic mRNAs. *Science* **2016**, *352* (6292), 1413-1416.
31 13
32
33 14 43. Peixeiro, I.; Silva, A. L.; Romão, L., Control of human β -globin mRNA stability and its
34
35 impact on beta-thalassemia phenotype. *Haematologica* **2011**, *96* (6), 905-913.
36 15
37
38 16 44. Bradley, R. D.; Hillis, D. M., Recombinant DNA sequences generated by PCR amplification.
39
40 17 *Molecular biology and evolution* **1997**, *14* (5), 592-593.
41
42 18 45. von Niessen, A. G. O.; Poleganov, M. A.; Rechner, C.; Plaschke, A.; Kranz, L. M.;
43
44 Fesser, S.; Diken, M.; Löwer, M.; Vallazza, B.; Beisert, T., Improving mRNA-based therapeutic
45 19
46 gene delivery by expression-augmenting 3' UTRs identified by cellular library screening. *Molecular*
47 20
48 *Therapy* **2019**, *27* (4), 824-836.
49 21
50
51 22 46. Verbeke, R.; Lentacker, I.; De Smedt, S. C.; Dewitte, H., Three decades of messenger RNA
52
53 vaccine development. *Nano Today* **2019**, 100766.
54 23
55
56 24 47. Chen, C.-Y.; Gherzi, R.; Ong, S.-E.; Chan, E. L.; Rajmakers, R.; Pruijn, G. J.;
57
58
59
60

- 1
2
3 1 Stoecklin, G.; Moroni, C.; Mann, M.; Karin, M., AU binding proteins recruit the exosome to degrade
4
5 2 ARE-containing mRNAs. *Cell* **2001**, *107* (4), 451-464.
6
7
8 3 48. Kudla, G.; Lipinski, L.; Caffin, F.; Helwak, A.; Zylicz, M., High guanine and cytosine
9
10 4 content increases mRNA levels in mammalian cells. *PLoS biology* **2006**, *4* (6).
11
12 5 49. Courel, M.; Clément, Y.; Bossevain, C.; Foretek, D.; Cruchez, O. V.; Yi, Z.;
13
14 6 Bénard, M.; Benassy, M.-N.; Kress, M.; Vindry, C., GC content shapes mRNA storage and decay in
15
16 7 human cells. *eLife* **2019**, *8*.
17
18
19 8 50. Petsch, B.; Schnee, M.; Vogel, A. B.; Lange, E.; Hoffmann, B.; Voss, D.; Schlake,
20
21 9 T.; Thess, A.; Kallen, K.-J.; Stitz, L., Protective efficacy of in vitro synthesized, specific mRNA
22
23 10 vaccines against influenza A virus infection. *Nature biotechnology* **2012**, *30* (12), 1210.
24
25
26 11 51. Hoerr, I.; Obst, R.; Rammensee, H. G.; Jung, G., In vivo application of RNA leads to
27
28 12 induction of specific cytotoxic T lymphocytes and antibodies. *European journal of immunology* **2000**,
29
30 13 *30* (1), 1-7.
31
32
33 14 52. Thess, A.; Grund, S.; Mui, B. L.; Hope, M. J.; Baumhof, P.; Fotin-Mleczek, M.;
34
35 15 Schlake, T., Sequence-engineered mRNA without chemical nucleoside modifications enables an
36
37 16 effective protein therapy in large animals. *Molecular Therapy* **2015**, *23* (9), 1456-1464.
38
39
40 17 53. Wang, P.; Perche, F.; Logeart-Avramoglou, D.; Pichon, C., RNA-based therapy for
41
42 18 osteogenesis. *International Journal of Pharmaceutics* **2019**, *569*, 118594.
43
44
45 19 54. Kariko, K.; Buckstein, M.; Ni, H.; Weissman, D., Suppression of RNA recognition by Toll-
46
47 20 like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity* **2005**,
48
49 21 *23* (2), 165-75.
50
51
52 22 55. Dan, M.; Zheng, D.; Field, L. L.; Bonnevie-Nielsen, V., Induction and activation of
53
54 23 antiviral enzyme 2', 5'-oligoadenylate synthetase by in vitro transcribed insulin mRNA and other cellular
55
56 24 RNAs. *Molecular biology reports* **2012**, *39* (7), 7813-7822.
57
58
59
60

- 1
2
3 1 56. Sahin, U.; Karikó, K.; Türeci, Ö., mRNA-based therapeutics—developing a new class of
4
5 2 drugs. *Nature reviews Drug discovery* **2014**, *13* (10), 759.
6
7
8 3 57. Anderson, B. R.; Muramatsu, H.; Jha, B. K.; Silverman, R. H.; Weissman, D.; Kariko,
9
10 4 K., Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase
11
12 5 resistance to cleavage by RNase L. *Nucleic acids research* **2011**, *39* (21), 9329-9338.
13
14
15 6 58. Kariko, K.; Muramatsu, H.; Welsh, F. A.; Ludwig, J.; Kato, H.; Akira, S.; Weissman,
16
17 7 D., Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased
18
19 8 translational capacity and biological stability. *Mol. Ther.* **2008**, *16* (11), 1833-40.
20
21
22 9 59. Karikó, K.; Muramatsu, H.; Keller, J. M.; Weissman, D., Increased erythropoiesis in mice
23
24 10 injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.
25
26 11 *Molecular therapy* **2012**, *20* (5), 948-953.
27
28
29 12 60. Andries, O.; Mc Cafferty, S.; De Smedt, S. C.; Weiss, R.; Sanders, N. N.; Kitada, T.,
30
31 13 N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by
32
33 14 providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice.
34
35 15 *J. Control. Release* **2015**, *217*, 337-44.
36
37
38 16 61. Uchida, S.; Kataoka, K.; Itaka, K., Screening of mRNA Chemical Modification to Maximize
39
40 17 Protein Expression with Reduced Immunogenicity. *Pharmaceutics* **2015**, *7* (3), 137-151.
41
42
43 18 62. Li, B.; Luo, X.; Dong, Y., Effects of Chemically Modified Messenger RNA on Protein
44
45 19 Expression. *Bioconjug. Chem.* **2016**, *27* (3), 849-53.
46
47 20 63. Kauffman, K. J.; Mir, F. F.; Jhunjunwala, S.; Kaczmarek, J. C.; Hurtado, J. E.; Yang,
48
49 21 J. H.; Webber, M. J.; Kowalski, P. S.; Heartlein, M. W.; DeRosa, F.; Anderson, D. G., Efficacy
50
51 22 and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with
52
53 23 lipid nanoparticles in vivo. *Biomaterials* **2016**, *109*, 78-87.
54
55
56 24 64. Lundstrom, K., Self-replicating RNA viral vectors in vaccine development and gene therapy.
57
58
59
60

- 1
2
3 1 *Future Virology* **2016**, *11* (5), 345-356.
4
5 2 65. Ying, H.; Zaks, T. Z.; Wang, R.-F.; Irvine, K. R.; Kammula, U. S.; Marincola, F. M.;
6
7 3 Leitner, W. W.; Restifo, N. P., Cancer therapy using a self-replicating RNA vaccine. *Nature medicine*
8
9 **1999**, *5* (7), 823.
10 4
11 5 66. Vogel, A. B.; Lambert, L.; Kinnear, E.; Busse, D.; Erbar, S.; Reuter, K. C.; Wicke,
12
13 6 L.; Perkovic, M.; Beissert, T.; Haas, H., Self-amplifying RNA vaccines give equivalent protection
14
15 7 against influenza to mRNA vaccines but at much lower doses. *Molecular Therapy* **2018**, *26* (2), 446-455.
16
17 8 67. Pardi, N.; Hogan, M. J.; Porter, F. W.; Weissman, D., mRNA vaccines—a new era in
18
19 9 vaccinology. *Nature Reviews Drug Discovery* **2018**, *17* (4), 261.
20
21 10 68. Blakney, A. K.; McKay, P. F.; Christensen, D.; Yus, B. I.; Aldon, Y.; Follmann, F.;
22
23 11 Shattock, R. J., Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators
24
25 12 on delivery and immunogenicity of saRNA. *Journal of Controlled Release* **2019**, *304*, 65-74.
26
27 13 69. Chahal, J. S.; Khan, O. F.; Cooper, C. L.; McPartlan, J. S.; Tsosie, J. K.; Tilley, L.
28
29 14 D.; Sidik, S. M.; Lourido, S.; Langer, R.; Bavari, S., Dendrimer-RNA nanoparticles generate
30
31 15 protective immunity against lethal Ebola, H1N1 influenza, and *Toxoplasma gondii* challenges with a
32
33 16 single dose. *Proceedings of the National Academy of Sciences* **2016**, *113* (29), E4133-E4142.
34
35 17 70. Atasheva, S.; McAuley, A. J.; Plante, J. A.; Frolova, E. I.; Beasley, D. W.; Frolov, I.,
36
37 18 Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic
38
39 19 RNAs. *Proceedings of the National Academy of Sciences* **2014**, *111* (29), 10708-10713.
40
41 20 71. Brito, L. A.; Kommareddy, S.; Maione, D.; Uematsu, Y.; Giovani, C.; Scorza, F. B.;
42
43 21 Otten, G. R.; Yu, D.; Mandl, C. W.; Mason, P. W., Self-amplifying mRNA vaccines. In *Advances in*
44
45 22 *genetics*, Elsevier: 2015; Vol. 89, pp 179-233.
46
47 23 72. Perri, S.; Greer, C. E.; Thudium, K.; Doe, B.; Legg, H.; Liu, H.; Romero, R. E.;
48
49 24 Tang, Z.; Bin, Q.; Dubensky, T. W., An alphavirus replicon particle chimera derived from venezuelan
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. *Journal of*
4
5 2 *virology* **2003**, 77 (19), 10394-10403.
6
7
8 3 73. Rupp, J. C.; Sokoloski, K. J.; Gebhart, N. N.; Hardy, R. W., Alphavirus RNA synthesis and
9
10 4 non-structural protein functions. *The Journal of general virology* **2015**, 96 (Pt 9), 2483.
11
12 5 74. Huysmans, H.; Zhong, Z.; De Temmerman, J.; Mui, B. L.; Tam, Y. K.; Mc Cafferty,
13
14 6 S.; Gitsels, A.; Vanrompay, D.; Sanders, N. N., Expression Kinetics and Innate Immune Response
15
16 7 after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin. *Molecular*
17
18 8 *Therapy-Nucleic Acids* **2019**, 17, 867-878.
19
20
21 9 75. Atkins, G. J.; Fleeton, M. N.; Sheahan, B. J., Therapeutic and prophylactic applications of
22
23 10 alphavirus vectors. *Expert reviews in molecular medicine* **2008**, 10.
24
25
26 11 76. Chen, Y. G.; Chen, R.; Ahmad, S.; Verma, R.; Kasturi, S. P.; Amaya, L.;
27
28 12 Broughton, J. P.; Kim, J.; Cadena, C.; Pulendran, B., N6-Methyladenosine Modification Controls
29
30 13 Circular RNA Immunity. *Molecular cell* **2019**.
31
32
33 14 77. Litke, J. L.; Jaffrey, S. R., Highly efficient expression of circular RNA aptamers in cells using
34
35 15 autocatalytic transcripts. *Nature biotechnology* **2019**, 37 (6), 667.
36
37
38 16 78. Wesselhoeft, R. A.; Kowalski, P. S.; Anderson, D. G., Engineering circular RNA for potent
39
40 17 and stable translation in eukaryotic cells. *Nature communications* **2018**, 9 (1), 2629.
41
42 18 79. Wesselhoeft, R. A.; Kowalski, P. S.; Parker-Hale, F. C.; Huang, Y.; Bisaria, N.;
43
44 19 Anderson, D. G., RNA Circularization Diminishes Immunogenicity and Can Extend Translation
45
46 20 Duration In Vivo. *Molecular cell* **2019**, 74 (3), 508-520. e4.
47
48
49 21 80. Kos, A.; Dijkema, R.; Arnberg, A.; Van der Meide, P.; Schellekens, H., The hepatitis
50
51 22 delta (δ) virus possesses a circular RNA. *Nature* **1986**, 323 (6088), 558.
52
53
54 23 81. Kjems, J.; Garrett, R. A., Novel splicing mechanism for the ribosomal RNA intron in the
55
56 24 archaeobacterium *Desulfurococcus mobilis*. *Cell* **1988**, 54 (5), 693-703.
57
58
59
60

- 1
2
3 1 82. Wang, P. L.; Bao, Y.; Yee, M.-C.; Barrett, S. P.; Hogan, G. J.; Olsen, M. N.;
4
5 2 Dinneny, J. R.; Brown, P. O.; Salzman, J., Circular RNA is expressed across the eukaryotic tree of life.
6
7 *PloS one* **2014**, *9* (3), e90859.
8
9
10 4 83. Salzman, J.; Gawad, C.; Wang, P. L.; Lacayo, N.; Brown, P. O., Circular RNAs are the
11
12 5 predominant transcript isoform from hundreds of human genes in diverse cell types. *PloS one* **2012**, *7*
13
14 6 (2), e30733.
15
16
17 7 84. Zhang, Y.; Zhang, X.-O.; Chen, T.; Xiang, J.-F.; Yin, Q.-F.; Xing, Y.-H.; Zhu, S.;
18
19 8 Yang, L.; Chen, L.-L., Circular intronic long noncoding RNAs. *Molecular cell* **2013**, *51* (6), 792-806.
20
21 9 85. Vicens, Q.; Westhof, E., Biogenesis of circular RNAs. *Cell* **2014**, *159* (1), 13-14.
22
23
24 10 86. Chen, L.-L., The biogenesis and emerging roles of circular RNAs. *Nature reviews Molecular*
25
26 11 *cell biology* **2016**, *17* (4), 205.
27
28
29 12 87. Wilusz, J. E., A 360 view of circular RNAs: from biogenesis to functions. *Wiley*
30
31 13 *Interdisciplinary Reviews: RNA* **2018**, *9* (4), e1478.
32
33 14 88. Cech, T. R., Self-splicing of group I introns. *Annual review of biochemistry* **1990**, *59* (1), 543-
34
35 15 568.
36
37
38 16 89. De Conti, L.; Baralle, M.; Buratti, E., Exon and intron definition in pre-mRNA splicing.
39
40 17 *Wiley Interdisciplinary Reviews: RNA* **2013**, *4* (1), 49-60.
41
42 18 90. Petkovic, S.; Müller, S., RNA circularization strategies in vivo and in vitro. *Nucleic acids*
43
44 19 *research* **2015**, *43* (4), 2454-2465.
45
46
47 20 91. Kramer, M. C.; Liang, D.; Tatomer, D. C.; Gold, B.; March, Z. M.; Cherry, S.;
48
49 21 Wilusz, J. E., Combinatorial control of Drosophila circular RNA expression by intronic repeats, hnRNPs,
50
51 22 and SR proteins. *Genes & development* **2015**, *29* (20), 2168-2182.
52
53
54 23 92. Müller, S.; Appel, B., In vitro circularization of RNA. *RNA biology* **2017**, *14* (8), 1018-1027.
55
56 24 93. Zhang, Y.; Xue, W.; Li, X.; Zhang, J.; Chen, S.; Zhang, J.-L.; Yang, L.; Chen, L.-
57
58
59
60

- 1
2
3 1 L., The biogenesis of nascent circular RNAs. *Cell reports* **2016**, *15* (3), 611-624.
4
5 2 94. Zhang, X.-O.; Wang, H.-B.; Zhang, Y.; Lu, X.; Chen, L.-L.; Yang, L., Complementary
6
7
8 3 sequence-mediated exon circularization. *Cell* **2014**, *159* (1), 134-147.
9
10 4 95. Hansen, T. B.; Jensen, T. I.; Clausen, B. H.; Bramsen, J. B.; Finsen, B.; Damgaard,
11
12 5 C. K.; Kjems, J., Natural RNA circles function as efficient microRNA sponges. *Nature* **2013**, *495* (7441),
13
14 6 384.
15
16
17 7 96. Grabowski, P. J.; Zaug, A. J.; Cech, T. R., The intervening sequence of the ribosomal RNA
18
19 8 precursor is converted to a circular RNA in isolated nuclei of Tetrahymena. *Cell* **1981**, *23* (2), 467-476.
20
21 9 97. Enuka, Y.; Lauriola, M.; Feldman, M. E.; Sas-Chen, A.; Ulitsky, I.; Yarden, Y.,
22
23
24 10 Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor.
25
26 11 *Nucleic acids research* **2015**, *44* (3), 1370-1383.
27
28 12 98. Guo, J. U.; Agarwal, V.; Guo, H.; Bartel, D. P., Expanded identification and
29
30
31 13 characterization of mammalian circular RNAs. *Genome biology* **2014**, *15* (7), 409.
32
33 14 99. Memczak, S.; Jens, M.; Elefsinioti, A.; Torti, F.; Krueger, J.; Rybak, A.; Maier, L.;
34
35 15 Mackowiak, S. D.; Gregersen, L. H.; Munschauer, M., Circular RNAs are a large class of animal RNAs
36
37
38 16 with regulatory potency. *Nature* **2013**, *495* (7441), 333.
39
40 17 100. Piwecka, M.; Glažar, P.; Hernandez-Miranda, L. R.; Memczak, S.; Wolf, S. A.;
41
42 18 Rybak-Wolf, A.; Filipchyk, A.; Klironomos, F.; Jara, C. A. C.; Fenske, P., Loss of a mammalian
43
44
45 19 circular RNA locus causes miRNA deregulation and affects brain function. *Science* **2017**, *357* (6357),
46
47 20 eaam8526.
48
49 21 101. Legnini, I.; Di Timoteo, G.; Rossi, F.; Morlando, M.; Briganti, F.; Sthandier, O.;
50
51 22 Fatica, A.; Santini, T.; Andronache, A.; Wade, M., Circ-ZNF609 is a circular RNA that can be
52
53
54 23 translated and functions in myogenesis. *Molecular cell* **2017**, *66* (1), 22-37. e9.
55
56 24 102. Pamudurti, N. R.; Bartok, O.; Jens, M.; Ashwal-Fluss, R.; Stottmeister, C.; Ruhe, L.;

- 1
2
3 1 Hanan, M.; Wyler, E.; Perez-Hernandez, D.; Ramberger, E., Translation of circRNAs. *Molecular cell*
4
5 2 **2017**, *66* (1), 9-21. e7.
6
7
8 3 103. Kowalski, P. S.; Rudra, A.; Miao, L.; Anderson, D. G., Delivering the messenger: advances
9
10 4 in technologies for therapeutic mRNA delivery. *Molecular Therapy* **2019**.
11
12 5 104. Kaczmarek, J. C.; Kowalski, P. S.; Anderson, D. G., Advances in the delivery of RNA
13
14 6 therapeutics: from concept to clinical reality. *Genome medicine* **2017**, *9* (1), 60.
15
16
17 7 105. Xiao, M.-S.; Wilusz, J. E., An improved method for circular RNA purification using RNase R
18
19 8 that efficiently removes linear RNAs containing G-quadruplexes or structured 3' ends. *Nucleic acids*
20
21 9 *research* **2019**, *47* (16), 8755-8769.
22
23
24 10 106. Ford, E.; Ares, M., Synthesis of circular RNA in bacteria and yeast using RNA cyclase
25
26 11 ribozymes derived from a group I intron of phage T4. *Proceedings of the National Academy of Sciences*
27
28 12 **1994**, *91* (8), 3117-3121.
29
30
31 13 107. Kariko, K.; Muramatsu, H.; Ludwig, J.; Weissman, D., Generating the optimal mRNA for
32
33 14 therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-
34
35 15 modified, protein-encoding mRNA. *Nucleic acids research* **2011**, *39* (21), e142-e142.
36
37
38 16 108. Abe, N.; Hiroshima, M.; Maruyama, H.; Nakashima, Y.; Nakano, Y.; Matsuda, A.;
39
40 17 Sako, Y.; Ito, Y.; Abe, H., Rolling circle amplification in a prokaryotic translation system using small
41
42 18 circular RNA. *Angew Chem Int Ed Engl* **2013**, *52* (27), 7004-8.
43
44
45 19 109. Abe, N.; Matsumoto, K.; Nishihara, M.; Nakano, Y.; Shibata, A.; Maruyama, H.;
46
47 20 Shuto, S.; Matsuda, A.; Yoshida, M.; Ito, Y.; Abe, H., Rolling Circle Translation of Circular RNA
48
49 21 in Living Human Cells. *Sci. Rep.* **2015**, *5*, 16435.
50
51
52 22 110. Kormann, M. S.; Hasenpusch, G.; Aneja, M. K.; Nica, G.; Flemmer, A. W.; Herber-
53
54 23 Jonat, S.; Huppmann, M.; Mays, L. E.; Illenyi, M.; Schams, A.; Griese, M.; Bittmann, I.;
55
56 24 Handgretinger, R.; Hartl, D.; Rosenecker, J.; Rudolph, C., Expression of therapeutic proteins after
57
58
59
60

- 1
2
3 1 delivery of chemically modified mRNA in mice. *Nature Biotechnol.* **2011**, *29* (2), 154-7.
4
5 2 111. Yoshinaga, N.; Uchida, S.; Naito, M.; Osada, K.; Cabral, H.; Kataoka, K., Induced
6
7 3 packaging of mRNA into polyplex micelles by regulated hybridization with a small number of
8
9 4 cholesteryl RNA oligonucleotides directed enhanced in vivo transfection. *Biomaterials* **2019**, *197*, 255-
10
11 267.
12
13 5 112. Kurimoto, S.; Yoshinaga, N.; Igarashi, K.; Matsumoto, Y.; Cabral, H.; Uchida, S.,
14
15 6 PEG-OligoRNA Hybridization of mRNA for Developing Sterically Stable Lipid Nanoparticles toward
16
17 7 In Vivo Administration. *Molecules* **2019**, *24* (7), 1303.
18
19 8 113. Yoshinaga, N.; Cho, E.; Koji, K.; Mochida, Y.; Naito, M.; Osada, K.; Kataoka, K.;
20
21 9 Cabral, H.; Uchida, S., Bundling mRNA Strands to Prepare Nano-Assemblies with Enhanced Stability
22
23 10 Towards RNase for In Vivo Delivery. *Angew. Chem. Int. Ed.* **2019**, *58* (33), 11360-11363.
24
25 11 114. Uchida, S.; Yoshinaga, N.; Yanagihara, K.; Yuba, E.; Kataoka, K.; Itaka, K.,
26
27 12 Designing immunostimulatory double stranded messenger RNA with maintained translational activity
28
29 13 through hybridization with poly A sequences for effective vaccination. *Biomaterials* **2018**, *150*, 162-170.
30
31 14 115. Yin, H.; Song, C. Q.; Suresh, S.; Wu, Q.; Walsh, S.; Rhym, L. H.; Mintzer, E.;
32
33 15 Bolukbasi, M. F.; Zhu, L. J.; Kauffman, K.; Mou, H.; Oberholzer, A.; Ding, J.; Kwan, S. Y.;
34
35 16 Bogorad, R. L.; Zatsepin, T.; Koteliansky, V.; Wolfe, S. A.; Xue, W.; Langer, R.; Anderson,
36
37 17 D. G., Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome
38
39 18 editing. *Nature Biotechnol.* **2017**, *35* (12), 1179-1187.
40
41 19 116. Kranz, L. M.; Diken, M.; Haas, H.; Kreiter, S.; Loquai, C.; Reuter, K. C.; Meng,
42
43 20 M.; Fritz, D.; Vascotto, F.; Hefesha, H.; Grunwitz, C.; Vormehr, M.; Husemann, Y.; Selmi,
44
45 21 A.; Kuhn, A. N.; Buck, J.; Derhovanessian, E.; Rae, R.; Attig, S.; Diekmann, J.;
46
47 22 Jabulowsky, R. A.; Heesch, S.; Hassel, J.; Langguth, P.; Grabbe, S.; Huber, C.; Tureci, O.;
48
49 23 Sahin, U., Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 *Nature* **2016**, *534* (7607), 396-401.
4
5 2 117. Cullis, P. R.; Hope, M. J., Lipid Nanoparticle Systems for Enabling Gene Therapies. *Mol. Ther.*
6
7 **2017**, *25* (7), 1467-1475.
8
9 4 118. Fenton, O. S.; Kauffman, K. J.; Kaczmarek, J. C.; McClellan, R. L.; Jhunjunwala, S.;
10
11 Tibbitt, M. W.; Zeng, M. D.; Appel, E. A.; Dorkin, J. R.; Mir, F. F.; Yang, J. H.; Oberli, M.
12
13 A.; Heartlein, M. W.; DeRosa, F.; Langer, R.; Anderson, D. G., Synthesis and Biological
14
15 6 Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes.
16
17 7 *Adv. Mater.* **2017**, *29* (33).
18
19 8 119. Kurimoto, S.; Yoshinaga, N.; Igarashi, K.; Matsumoto, Y.; Cabral, H.; Uchida, S.,
20
21 9 PEG-OligoRNA Hybridization of mRNA for Developing Sterically Stable Lipid Nanoparticles toward
22
23 10 In Vivo Administration. *Molecules (Basel, Switzerland)* **2019**, *24* (7).
24
25 11 120. Lee, J. B.; Hong, J.; Bonner, D. K.; Poon, Z.; Hammond, P. T., Self-assembled RNA
26
27 12 interference microsponges for efficient siRNA delivery. *Nature Mater.* **2012**, *11* (4), 316-22.
28
29 13 121. Hao, C.; Li, X.; Tian, C.; Jiang, W.; Wang, G.; Mao, C., Construction of RNA
30
31 14 nanocages by re-engineering the packaging RNA of Phi29 bacteriophage. *Nature Commun.* **2014**, *5*,
32
33 15 3890.
34
35 16 122. Yoshinaga, N.; Cho, E.; Koji, K.; Mochida, Y.; Naito, M.; Osada, K.; Kataoka, K.;
36
37 17 Cabral, H.; Uchida, S., Bundling mRNA Strands to Prepare Nano-Assemblies with Enhanced Stability
38
39 18 Towards RNase for In Vivo Delivery. *Angew Chem Int Ed Engl* **2019**, *58* (33), 11360-11363.
40
41 19 123. Kim, H.; Park, Y.; Lee, J. B., Self-assembled Messenger RNA Nanoparticles (mRNA-NPs)
42
43 20 for Efficient Gene Expression. *Sci. Rep.* **2015**, *5*, 12737.
44
45 21 124. Mizuguchi, H.; Xu, Z.; Ishii-Watabe, A.; Uchida, E.; Hayakawa, T., IRES-dependent
46
47 22 second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic
48
49 23 vector. *Mol. Ther.* **2000**, *1* (4), 376-82.
50
51 24
52
53
54
55
56
57
58
59
60

- 1
2
3 1 125. Poliskey, J. A.; Crowley, S. T.; Ramanathan, R.; White, C. W.; Mathew, B.; Rice, K.
4
5 2 G., Metabolically stabilized double-stranded mRNA polyplexes. *Gene Ther.* **2018**.
6
7
8 3 126. Kim, D. H.; Longo, M.; Han, Y.; Lundberg, P.; Cantin, E.; Rossi, J. J., Interferon
9
10 4 induction by siRNAs and ssRNAs synthesized by phage polymerase. *Nature Biotechnol.* **2004**, *22* (3),
11
12 5 321-5.
13
14 6 127. Barbalat, R.; Ewald, S. E.; Mouchess, M. L.; Barton, G. M., Nucleic acid recognition by
15
16 7 the innate immune system. *Annual review of immunology* **2011**, *29*, 185-214.
17
18
19 8 128. Leung, A. K.; Hafez, I. M.; Baoukina, S.; Belliveau, N. M.; Zhigaltsev, I. V.;
20
21 9 Afshinmanesh, E.; Tieleman, D. P.; Hansen, C. L.; Hope, M. J.; Cullis, P. R., Lipid nanoparticles
22
23 10 containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. *The*
24
25 11 *Journal of Physical Chemistry C* **2012**, *116* (34), 18440-18450.
26
27
28 12 129. Cheng, X.; Lee, R. J., The role of helper lipids in lipid nanoparticles (LNPs) designed for
29
30 13 oligonucleotide delivery. *Advanced drug delivery reviews* **2016**, *99*, 129-137.
31
32
33 14 130. Rietwyk, S.; Peer, D., Next-generation lipids in RNA interference therapeutics. *ACS nano* **2017**,
34
35 15 *11* (8), 7572-7586.
36
37
38 16 131. Leung, A. K.; Tam, Y. Y. C.; Chen, S.; Hafez, I. M.; Cullis, P. R., Microfluidic mixing:
39
40 17 a general method for encapsulating macromolecules in lipid nanoparticle systems. *The journal of*
41
42 18 *physical chemistry B* **2015**, *119* (28), 8698-8706.
43
44
45 19 132. Wood, H., FDA approves patisiran to treat hereditary transthyretin amyloidosis. Nature
46
47 20 Publishing Group: 2018.
48
49 21 133. Nabhan, J. F.; Wood, K. M.; Rao, V. P.; Morin, J.; Bhamidipaty, S.; LaBranche, T.
50
51 22 P.; Gooch, R. L.; Bozal, F.; Bulawa, C. E.; Guild, B. C., Intrathecal delivery of frataxin mRNA
52
53 23 encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich's ataxia.
54
55 24 *Scientific reports* **2016**, *6* (1), 1-10.
56
57
58
59
60

- 1
2
3 1 134. Sahay, G.; Querbes, W.; Alabi, C.; Eltoukhy, A.; Sarkar, S.; Zurenko, C.;
4
5 2 Karagiannis, E.; Love, K.; Chen, D.; Zoncu, R., Efficiency of siRNA delivery by lipid nanoparticles
6
7 is limited by endocytic recycling. *Nature biotechnology* **2013**, *31* (7), 653.
8
9
10 4 135. Sabnis, S.; Kumarasinghe, E. S.; Salerno, T.; Mihai, C.; Ketova, T.; Senn, J. J.;
11
12 5 Lynn, A.; Bulychev, A.; McFadyen, I.; Chan, J., A novel amino lipid series for mRNA delivery:
13
14 6 improved endosomal escape and sustained pharmacology and safety in non-human primates. *Molecular*
15
16 *Therapy* **2018**, *26* (6), 1509-1519.
17
18
19 8 136. Li, B.; Luo, X.; Deng, B.; Wang, J.; McComb, D. W.; Shi, Y.; Gaensler, K. M.;
20
21 9 Tan, X.; Dunn, A. L.; Kerlin, B. A.; Dong, Y., An Orthogonal Array Optimization of Lipid-like
22
23 10 Nanoparticles for mRNA Delivery in Vivo. *Nano Lett.* **2015**, *15* (12), 8099-107.
24
25
26 11 137. Miao, L.; Li, L.; Huang, Y.; Delcassian, D.; Chahal, J.; Han, J.; Shi, Y.; Sadtler,
27
28 12 K.; Gao, W.; Lin, J., Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy
29
30 13 by STING-mediated immune cell activation. *Nature biotechnology* **2019**, *37* (10), 1174-1185.
31
32
33 14 138. Kulkarni, J. A.; Witzigmann, D.; Leung, J.; van der Meel, R.; Zaifman, J.; Darjuan,
34
35 15 M. M.; Grisch-Chan, H. M.; Thöny, B.; Tam, Y. Y. C.; Cullis, P. R., Fusion-dependent formation
36
37 16 of lipid nanoparticles containing macromolecular payloads. *Nanoscale* **2019**, *11* (18), 9023-9031.
38
39
40 17 139. Kauffman, K. J.; Dorkin, J. R.; Yang, J. H.; Heartlein, M. W.; DeRosa, F.; Mir, F. F.;
41
42 18 Fenton, O. S.; Anderson, D. G., Optimization of lipid nanoparticle formulations for mRNA delivery in
43
44 19 vivo with fractional factorial and definitive screening designs. *Nano letters* **2015**, *15* (11), 7300-7306.
45
46
47 20 140. Oberli, M. A.; Reichmuth, A. M.; Dorkin, J. R.; Mitchell, M. J.; Fenton, O. S.;
48
49 21 Jaklenec, A.; Anderson, D. G.; Langer, R.; Blankschtein, D., Lipid nanoparticle assisted mRNA
50
51 22 delivery for potent cancer immunotherapy. *Nano letters* **2017**, *17* (3), 1326-1335.
52
53
54 23 141. Cheng, Q.; Wei, T.; Farbiak, L.; Johnson, L. T.; Dilliard, S. A.; Siegwart, D. J.,
55
56 24 Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 gene editing. *Nature Nanotechnology* **2020**, *15* (4), 313-320.
- 2 142. Eygeris, Y.; Patel, S.; Jozic, A.; Sahay, G., Deconvoluting Lipid Nanoparticle Structure for
3 Messenger RNA Delivery. *Nano Letters* **2020**.
- 4 143. Patel, S.; Ashwanikumar, N.; Robinson, E.; Xia, Y.; Mihai, C.; Griffith, J. P.; Hou,
5 S.; Esposito, A. A.; Ketova, T.; Welsher, K., Naturally-occurring cholesterol analogues in lipid
6 nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. *Nature*
7 *communications* **2020**, *11* (1), 1-13.
- 8 144. Pozzi, D.; Marchini, C.; Cardarelli, F.; Amenitsch, H.; Garulli, C.; Bifone, A.;
9 Caracciolo, G., Transfection efficiency boost of cholesterol-containing lipoplexes. *Biochimica et*
10 *Biophysica Acta (BBA)-Biomembranes* **2012**, *1818* (9), 2335-2343.
- 11 145. Ickenstein, L. M.; Arfvidsson, M. C.; Needham, D.; Mayer, L. D.; Edwards, K., Disc
12 formation in cholesterol-free liposomes during phase transition. *Biochimica et Biophysica Acta (BBA)-*
13 *Biomembranes* **2003**, *1614* (2), 135-138.
- 14 146. Imam, Z. I.; Kenyon, L. E.; Ashby, G.; Nagib, F.; Mendicino, M.; Zhao, C.; Gadok,
15 A. K.; Stachowiak, J. C., Phase-separated liposomes enhance the efficiency of macromolecular delivery
16 to the cellular cytoplasm. *Cellular and molecular bioengineering* **2017**, *10* (5), 387-403.
- 17 147. Cheng, Q.; Wei, T.; Jia, Y.; Farbiak, L.; Zhou, K.; Zhang, S.; Wei, Y.; Zhu, H.;
18 Siegwart, D. J., Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver
19 function and extend survival in a mouse model of hepatorenal tyrosinemia type I. *Advanced Materials*
20 **2018**, *30* (52), 1805308.
- 21 148. Demeneix, B.; Behr, J. P., Polyethylenimine (PEI). *Advances in genetics* **2005**, *53*, 215-230.
- 22 149. Ulkoski, D.; Bak, A.; Wilson, J. T.; Krishnamurthy, V. R., Recent advances in polymeric
23 materials for the delivery of RNA therapeutics. *Expert opinion on drug delivery* **2019**, (just-accepted).
- 24 150. Lv, H.; Zhang, S.; Wang, B.; Cui, S.; Yan, J., Toxicity of cationic lipids and cationic

- 1
2
3 1 polymers in gene delivery. *Journal of controlled release* **2006**, *114* (1), 100-109.
4
5 2 151. Masago, K.; Itaka, K.; Nishiyama, N.; Chung, U.-i.; Kataoka, K., Gene delivery with
6
7 biocompatible cationic polymer: pharmacogenomic analysis on cell bioactivity. *Biomaterials* **2007**, *28*
8
9 (34), 5169-5175.
10
11 152. Blakney, A. K.; Yilmaz, G.; McKay, P. F.; Becer, C. R.; Shattock, R. J., One size does
12
13 not fit all: The effect of chain length and charge density of poly (ethylene imine) based copolymers on
14
15 6 delivery of pDNA, mRNA, and RepRNA polyplexes. *Biomacromolecules* **2018**, *19* (7), 2870-2879.
16
17 7 153. Patel, A. K.; Kaczmarek, J. C.; Bose, S.; Kauffman, K. J.; Mir, F.; Heartlein, M. W.;
18
19 8 DeRosa, F.; Langer, R.; Anderson, D. G., Inhaled nanoformulated mRNA polyplexes for protein
20
21 9 production in lung epithelium. *Advanced Materials* **2019**, *31* (8), 1805116.
22
23
24 10 154. Zhang, F.; Parayath, N.; Ene, C.; Stephan, S.; Koehne, A.; Coon, M.; Holland, E.;
25
26 11 Stephan, M., Genetic programming of macrophages to perform anti-tumor functions using targeted
27
28 12 mRNA nanocarriers. *Nature communications* **2019**, *10* (1), 1-16.
29
30
31 13 155. Uchida, H.; Itaka, K.; Nomoto, T.; Ishii, T.; Suma, T.; Ikegami, M.; Miyata, K.;
32
33 14 Oba, M.; Nishiyama, N.; Kataoka, K., Modulated protonation of side chain aminoethylene repeats in
34
35 15 N-substituted polyaspartamides promotes mRNA transfection. *J. Am. Chem. Soc.* **2014**, *136* (35), 12396-
36
37 16 405.
38
39
40 17 156. Uchida, H.; Itaka, K.; Uchida, S.; Ishii, T.; Suma, T.; Miyata, K.; Oba, M.;
41
42 18 Nishiyama, N.; Kataoka, K., Synthetic Polyamines to Regulate mRNA Translation through the
43
44 19 Preservative Binding of Eukaryotic Initiation Factor 4E to the Cap Structure. *J. Am. Chem. Soc.* **2016**,
45
46 20 *138* (5), 1478-81.
47
48
49 21 157. Li, J.; Wang, W.; He, Y.; Li, Y.; Yan, E. Z.; Zhang, K.; Irvine, D. J.; Hammond, P.
50
51 22 T., Structurally Programmed Assembly of Translation Initiation Nanoplex for Superior mRNA Delivery.
52
53 23 *ACS Nano* **2017**, *11* (3), 2531-2544.
54
55
56 24

- 1
2
3 1 158. Perche, F.; Benvegna, T.; Berchel, M.; Lebegue, L.; Pichon, C.; Jaffrès, P.-A.;
4
5 2 Midoux, P., Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10
6
7 3 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA.
8
9 4 *Nanomedicine: Nanotechnology, Biology and Medicine* **2011**, 7 (4), 445-453.
10
11
12 5 159. Perche, F.; Gosset, D.; Mével, M.; Miramon, M.-L.; Yaouanc, J.-J.; Pichon, C.;
13
14 6 Benvegna, T.; Jaffrès, P.-A.; Midoux, P., Selective gene delivery in dendritic cells with mannosylated
15
16 7 and histidylated lipopolyplexes. *Journal of drug targeting* **2011**, 19 (5), 315-325.
17
18
19 8 160. Gao, X.; Huang, L., Potentiation of cationic liposome-mediated gene delivery by polycations.
20
21 9 *Biochemistry* **1996**, 35 (3), 1027-1036.
22
23
24 10 161. Li, S. d.; Huang, L. y., In vivo gene transfer via intravenous administration of cationic lipid-
25
26 11 protamine-DNA (LPD) complexes. *Gene therapy* **1997**, 4 (9), 891-900.
27
28
29 12 162. Pichon, C.; Midoux, P., Mannosylated and histidylated LPR technology for vaccination with
30
31 13 tumor antigen mRNA. In *Synthetic Messenger RNA and Cell Metabolism Modulation*, Springer: 2013;
32
33 14 pp 247-274.
34
35 15 163. Barbeau, J.; Lemiègre, L.; Quelen, A.; Malard, V.; Gao, H.; Gonçalves, C.;
36
37 16 Berchel, M.; Jaffrès, P.-A.; Pichon, C.; Midoux, P., Synthesis of a trimannosylated-equipped archaeal
38
39 17 diether lipid for the development of novel glycoliposomes. *Carbohydrate research* **2016**, 435, 142-148.
40
41
42 18 164. Van Der Jeught, K.; De Koker, S.; Bialkowski, L.; Heirman, C.; Tjok Joe, P.; Perche,
43
44 19 F.; Maenhout, S.; Bevers, S.; Broos, K.; Deswarte, K., Dendritic cell targeting mRNA
45
46 20 lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety. *ACS nano*
47
48 21 **2018**, 12 (10), 9815-9829.
49
50
51 22 165. Le Moignic, A.; Malard, V.; Benvegna, T.; Lemiègre, L.; Berchel, M.; Jaffrès, P.-A.;
52
53 23 Baillou, C.; Delost, M.; Macedo, R.; Rochefort, J., Preclinical evaluation of mRNA trimannosylated
54
55 24 lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells. *Journal of controlled release* **2018**,
56
57
58
59
60

- 1
2
3 1 278, 110-121.
4
5 2 166. Midoux, P.; Pichon, C., Lipid-based mRNA vaccine delivery systems. *Expert review of*
6
7
8 3 *vaccines* **2015**, *14* (2), 221-234.
9
10 4 167. Persano, S.; Guevara, M. L.; Li, Z.; Mai, J.; Ferrari, M.; Pompa, P. P.; Shen, H.,
11
12 5 Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. *Biomaterials* **2017**, *125*, 81-
13
14 6 89.
15
16
17 7 168. Kaczmarek, J. C.; Patel, A. K.; Kauffman, K. J.; Fenton, O. S.; Webber, M. J.;
18
19 8 Heartlein, M. W.; DeRosa, F.; Anderson, D. G., Polymer-Lipid Nanoparticles for Systemic Delivery
20
21 9 of mRNA to the Lungs. *Angew Chem Int Ed Engl* **2016**, *55* (44), 13808-13812.
22
23
24 10 169. Zhao, W.; Zhang, C.; Li, B.; Zhang, X.; Luo, X.; Zeng, C.; Li, W.; Gao, M.;
25
26 11 Dong, Y., Lipid Polymer Hybrid Nanomaterials for mRNA Delivery. *Cell. Mol. Bioeng.* **2018**, *11* (5),
27
28 12 397-406.
29
30
31 13 170. Lachelt, U.; Wagner, E., Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years
32
33 14 (and Beyond). *Chem. Rev.* **2015**, *115* (19), 11043-78.
34
35 15 171. Cabral, H.; Miyata, K.; Osada, K.; Kataoka, K., Block copolymer micelles in
36
37 16 nanomedicine applications. *Chem. Rev.* **2018**, *118* (14), 6844-6892.
38
39
40 17 172. Kataoka, K.; Harada, A.; Nagasaki, Y., Block copolymer micelles for drug delivery: design,
41
42 18 characterization and biological significance. *Adv. Drug. Deliv. Rev.* **2001**, *47* (1), 113-31.
43
44 19 173. Chen, Q.; Qi, R.; Chen, X.; Yang, X.; Wu, S.; Xiao, H.; Dong, W., A Targeted and
45
46 20 Stable Polymeric Nanoformulation Enhances Systemic Delivery of mRNA to Tumors. *Mol. Ther.* **2017**,
47
48 21 25 (1), 92-101.
49
50
51 22 174. Uchida, S.; Kataoka, K., Design concepts of polyplex micelles for in vivo therapeutic delivery
52
53 23 of plasmid DNA and messenger RNA. *J. Biomed. Mater. Res. A* **2019**, *107* (5), 978-990.
54
55
56 24 175. Baba, M.; Itaka, K.; Kondo, K.; Yamasoba, T.; Kataoka, K., Treatment of neurological
57
58
59
60

- 1
2
3 1 disorders by introducing mRNA in vivo using polyplex nanomicelles. *J. Control. Release* **2015**, *201*,
4 41-8.
5
6 2
7
8 3 176. Matsui, A.; Uchida, S.; Ishii, T.; Itaka, K.; Kataoka, K., Messenger RNA-based
9
10 4 therapeutics for the treatment of apoptosis-associated diseases. *Sci. Rep.* **2015**, *5*, 15810.
11
12 5 177. Zuckerman, J. E.; Choi, C. H.; Han, H.; Davis, M. E., Polycation-siRNA nanoparticles can
13 6 disassemble at the kidney glomerular basement membrane. *Proc. Natl. Acad. Sci. U. S. A.* **2012**, *109* (8),
14 3137-42.
15
16
17 7
18
19 8 178. Dirisala, A.; Uchida, S.; Tockary, T. A.; Yoshinaga, N.; Li, J.; Osawa, S.; Gorantla,
20 9 L.; Fukushima, S.; Osada, K.; Kataoka, K., Precise tuning of disulphide crosslinking in mRNA
21 10 polyplex micelles for optimising extracellular and intracellular nuclease tolerability. *J. Drug Target.*
22 11 **2019**, *27* (5-6), 670-680.
23
24
25
26
27
28 12 179. Li, J.; Chen, Q.; Zha, Z.; Li, H.; Toh, K.; Dirisala, A.; Matsumoto, Y.; Osada, K.;
29 13 Kataoka, K.; Ge, Z., Ternary polyplex micelles with PEG shells and intermediate barrier to complexed
30 14 DNA cores for efficient systemic gene delivery. *J. Control. Release* **2015**, *209*, 77-87.
31
32
33
34
35 15 180. Grasso, G.; Deriu, M. A.; Patrulea, V.; Borchard, G.; Möller, M.; Danani, A., Free
36 16 energy landscape of siRNA-polycation complexation: Elucidating the effect of molecular geometry,
37 17 polymer flexibility, and charge neutralization. *PLoS One* **2017**, *12* (10), e0186816.
38
39
40
41
42 18 181. Miyazaki, T.; Uchida, S.; Nagatoishi, S.; Koji, K.; Hong, T.; Fukushima, S.;
43 19 Tsumoto, K.; Ishihara, K.; Kataoka, K.; Cabral, H., Polymeric Nanocarriers with Controlled Chain
44 20 Flexibility Boost mRNA Delivery In Vivo through Enhanced Structural Fastening. *Advanced Healthcare*
45 21 *Materials in press*.
46
47
48
49
50
51 22 182. Elsharkasy, O. M.; Nordin, J. Z.; Hagey, D. W.; de Jong, O. G.; Schiffelers, R. M.;
52 23 Andaloussi, S. E.; Vader, P., Extracellular vesicles as drug delivery systems: Why and how? *Advanced*
53 24 *Drug Delivery Reviews* **2020**.

- 1
2
3 1 183. Markov, O.; Oshchepkova, A.; Mironova, N., Immunotherapy based on dendritic cell-
4 targeted/-derived extracellular vesicles—A novel strategy for enhancement of the anti-tumor immune
5 response. *Frontiers in pharmacology* **2019**, *10*.
6
7
8 3
9
10 4 184. Colombo, M.; Raposo, G.; Théry, C., Biogenesis, secretion, and intercellular interactions of
11 exosomes and other extracellular vesicles. *Annual review of cell and developmental biology* **2014**, *30*,
12 255-289.
13
14
15 6
16
17 7 185. Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J. J.; Lötvall, J. O., Exosome-
18 mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.
19
20
21 9
22 186. Kamerkar, S.; LeBleu, V. S.; Sugimoto, H.; Yang, S.; Ruivo, C. F.; Melo, S. A.;
23
24 10
25
26 11
27
28 12
29 187. Koh, E.; Lee, E. J.; Nam, G.-H.; Hong, Y.; Cho, E.; Yang, Y.; Kim, I.-S., Exosome-
30
31 13
32
33 14
34
35 15
36
37 16
38 188. Heusermann, W.; Hean, J.; Trojer, D.; Steib, E.; Von Bueren, S.; Graff-Meyer, A.;
39
40 17
41
42 18
43
44 19
45 189. Sun, W.; Xing, C.; Zhao, L.; Zhao, P.; Yang, G.; Yuan, L., Ultrasound Assisted
46
47 20
48
49 21
50
51 22
52 190. Pan, D.; Fujimoto, M.; Lopes, A.; Wang, Y.-X., Twist-1 is a PPAR δ -inducible, negative-
53
54 23
55
56 24
57 191. Shi, C.; Zhang, M.; Tong, M.; Yang, L.; Pang, L.; Chen, L.; Xu, G.; Chi, X.;

- 1
2
3 1 Hong, Q.; Ni, Y., miR-148a is associated with obesity and modulates adipocyte differentiation of
4
5 2 mesenchymal stem cells through Wnt signaling. *Scientific reports* **2015**, *5*, 9930.
6
7
8 3 192. Yang, Z.; Shi, J.; Xie, J.; Wang, Y.; Sun, J.; Liu, T.; Zhao, Y.; Zhao, X.; Wang,
9
10 4 X.; Ma, Y., Large-scale generation of functional mRNA-encapsulating exosomes via cellular
11
12 5 nanoporation. *Nature Biomedical Engineering* **2020**, *4* (1), 69-83.
13
14
15 6 193. Wei, X.; Zhan, C.; Shen, Q.; Fu, W.; Xie, C.; Gao, J.; Peng, C.; Zheng, P.; Lu,
16
17 7 W., A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. *Angewandte*
18
19 8 *Chemie International Edition* **2015**, *54* (10), 3023-3027.
20
21
22 9 194. Lutz, J.; Lazzaro, S.; Habbedine, M.; Schmidt, K. E.; Baumhof, P.; Mui, B. L.;
23
24 10 Tam, Y. K.; Madden, T. D.; Hope, M. J.; Heidenreich, R., Unmodified mRNA in LNPs constitutes a
25
26 11 competitive technology for prophylactic vaccines. *NPJ vaccines* **2017**, *2* (1), 1-9.
27
28
29 12 195. Kallen, K. J.; Heidenreich, R.; Schnee, M.; Petsch, B.; Schlake, T.; Thess, A.;
30
31 13 Baumhof, P.; Scheel, B.; Koch, S. D.; Fotin-Mleczek, M., A novel, disruptive vaccination
32
33 14 technology: self-adjuvanted RNAActive((R)) vaccines. *Hum. Vaccin. Immunother.* **2013**, *9* (10), 2263-76.
34
35
36 15 196. Fotin-Mleczek, M.; Duchardt, K. M.; Lorenz, C.; Pfeiffer, R.; Ojkic-Zrna, S.; Probst,
37
38 16 J.; Kallen, K. J., Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent
39
40 17 adaptive immune responses and provide antitumor activity. *J. Immunother.* **2011**, *34* (1), 1-15.
41
42
43 18 197. Alberer, M.; Gnad-Vogt, U.; Hong, H. S.; Mehr, K. T.; Backert, L.; Finak, G.;
44
45 19 Gottardo, R.; Bica, M. A.; Garofano, A.; Koch, S. D.; Fotin-Mleczek, M.; Hoerr, I.; Clemens,
46
47 20 R.; von Sonnenburg, F., Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an
48
49 21 open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. *The Lancet* **2017**, *390*
50
51 22 (10101), 1511-1520.
52
53
54 23 198. Sebastian, M.; Schröder, A.; Scheel, B.; Hong, H. S.; Muth, A.; von Boehmer, L.;
55
56 24 Zippelius, A.; Mayer, F.; Reck, M.; Atanackovic, D.; Thomas, M.; Schneller, F.;

- 1
2
3 1 Stöhlmacher, J.; Bernhard, H.; Gröschel, A.; Lander, T.; Probst, J.; Strack, T.; Wiegand, V.;
4
5 2 Gnad-Vogt, U.; Kallen, K. J.; Hoerr, I.; von der Muelbe, F.; Fotin-Mleczek, M.; Knuth, A.;
6
7 3 Koch, S. D., A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with
8
9 stage IIIB/IV non-small cell lung cancer. *Cancer Immunol. Immunother.* **2019**, *68* (5), 799-812.
10
11 4
12 5 199. Kowalczyk, A.; Doener, F.; Zanzinger, K.; Noth, J.; Baumhof, P.; Fotin-Mleczek,
13
14 6 M.; Heidenreich, R., Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to
15
16 a potent and boostable adaptive immunity. *Vaccine* **2016**, *34* (33), 3882-3893.
17
18 7
19 8 200. Selmi, A.; Vascotto, F.; Kautz-Neu, K.; Türeci, Ö.; Sahin, U.; von Stebut, E.;
20
21 9 Diken, M.; Kreiter, S., Uptake of synthetic naked RNA by skin-resident dendritic cells via
22
23 macropinocytosis allows antigen expression and induction of T-cell responses in mice. *Cancer*
24
25 *Immunology, Immunotherapy* **2016**, *65* (9), 1075-1083.
26
27 11
28 12 201. Pardi, N.; LaBranche, C. C.; Ferrari, G.; Cain, D. W.; Tombacz, I.; Parks, R. J.;
29
30 13 Muramatsu, H.; Mui, B. L.; Tam, Y. K.; Kariko, K.; Polacino, P.; Barbosa, C. J.; Madden, T.
31
32 D.; Hope, M. J.; Haynes, B. F.; Montefiori, D. C.; Hu, S. L.; Weissman, D., Characterization of
33
34 HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques. *Mol Ther Nucleic Acids*
35
36 **2019**, *15*, 36-47.
37
38 16
39 20
40 17 202. Diken, M.; Kreiter, S.; Selmi, A.; Britten, C.; Huber, C.; Türeci, Ö.; Sahin, U.,
41
42 18 Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated
43
44 upon DC maturation. *Gene therapy* **2011**, *18* (7), 702.
45
46 19
47 20 203. Joe, P. T.; Christopoulou, I.; van Hoecke, L.; Schepens, B.; Ysenbaert, T.; Heirman,
48
49 21 C.; Thielemans, K.; Saelens, X.; Aerts, J. L., Intranodal administration of mRNA encoding
50
51 22 nucleoprotein provides cross-strain immunity against influenza in mice. *Journal of translational*
52
53 *medicine* **2019**, *17* (1), 242.
54
55 23
56 24 204. Leal, L.; Guardo, A. C.; Morón-López, S.; Salgado, M.; Mothe, B.; Heirman, C.;

- 1
2
3 1 Pannus, P.; Vanham, G.; van den Ham, H. J.; Gruters, R., Phase I clinical trial of an intranodally
4
5 2 administered mRNA-based therapeutic vaccine against HIV-1 infection. *AIDS (London, England)* **2018**,
6
7 3 32 (17), 2533.
8
9
10 4 205. Kreiter, S.; Selmi, A.; Diken, M.; Koslowski, M.; Britten, C. M.; Huber, C.; Türeci,
11
12 5 Ö.; Sahin, U., Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and
13
14 6 therapeutic antitumoral immunity. *Cancer research* **2010**, 70 (22), 9031-9040.
15
16
17 7 206. Sayour, E. J.; De Leon, G.; Pham, C.; Grippin, A.; Kemeny, H.; Chua, J.; Huang,
18
19 8 J.; Sampson, J. H.; Sanchez-Perez, L.; Flores, C.; Mitchell, D. A., Systemic activation of antigen-
20
21 9 presenting cells via RNA-loaded nanoparticles. *Oncoimmunology* **2017**, 6 (1), e1256527.
22
23
24 10 207. Broos, K.; Van der Jeught, K.; Puttemans, J.; Goyvaerts, C.; Heirman, C.; Dewitte,
25
26 11 H.; Verbeke, R.; Lentacker, I.; Thielemans, K.; Breckpot, K., Particle-mediated Intravenous
27
28 12 Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction
29
30 13 of Type I Interferon. *Mol Ther Nucleic Acids* **2016**, 5 (6), e326.
31
32
33 14 208. Perche, F.; Benvegna, T.; Berchel, M.; Lebegue, L.; Pichon, C.; Jaffrès, P. A.;
34
35 15 Midoux, P., Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10
36
37 16 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA.
38
39 17 *Nanomedicine* **2011**, 7 (4), 445-53.
40
41
42 18 209. Van der Jeught, K.; De Koker, S.; Bialkowski, L.; Heirman, C.; Tjok Joe, P.; Perche,
43
44 19 F.; Maenhout, S.; Bevers, S.; Broos, K.; Deswarte, K.; Malard, V.; Hammad, H.; Baril, P.;
45
46 20 Benvegna, T.; Jaffres, P. A.; Kooijmans, S. A. A.; Schiffelers, R.; Lienenklaus, S.; Midoux, P.;
47
48 21 Pichon, C.; Breckpot, K.; Thielemans, K., Dendritic Cell Targeting mRNA Lipopolyplexes Combine
49
50 22 Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety. *ACS Nano* **2018**, 12 (10), 9815-
51
52 23 9829.
53
54
55 24 210. Verbeke, R.; Lentacker, I.; Wayteck, L.; Breckpot, K.; Van Bockstal, M.; Descamps,
56
57
58
59
60

- 1
2
3 1 B.; Vanhove, C.; De Smedt, S. C.; Dewitte, H., Co-delivery of nucleoside-modified mRNA and TLR
4
5 2 agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA. *J. Control.*
6
7 3 *Release* **2017**, *266*, 287-300.
- 9
10 4 211. Verbeke, R.; Lentacker, I.; Breckpot, K.; Janssens, J.; Van Calenbergh, S.; De Smedt,
11
12 5 S. C.; Dewitte, H., Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and alpha-
13
14 6 GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells. *ACS Nano* **2019**,
15
16 7 *13* (2), 1655-1669.
- 18
19 8 212. Pektor, S.; Hilscher, L.; Walzer, K. C.; Miederer, I.; Bausbacher, N.; Loquai, C.;
20
21 9 Schreckenberger, M.; Sahin, U.; Diken, M.; Miederer, M., In vivo imaging of the immune response
22
23 10 upon systemic RNA cancer vaccination by FDG-PET. *EJNMMI Res* **2018**, *8* (1), 80.
- 25
26 11 213. Reinhard, K.; Rengstl, B.; Oehm, P.; Michel, K.; Billmeier, A.; Hayduk, N.; Klein,
27
28 12 O.; Kuna, K.; Ouchan, Y.; Wöll, S.; Christ, E.; Weber, D.; Suchan, M.; Bukur, T.; Birtel,
29
30 13 M.; Jahndel, V.; Mroz, K.; Hobohm, K.; Kranz, L.; Diken, M.; Kühlcke, K.; Türeci, Ö.;
31
32 14 Sahin, U., An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors.
33
34 15 *Science* **2020**, *367* (6476), 446-453.
- 36
37 16 214. Liljeström, P.; Garoff, H., A new generation of animal cell expression vectors based on the
38
39 17 Semliki Forest virus replicon. *Bio/technology* **1991**, *9* (12), 1356.
- 41
42 18 215. Pushko, P.; Parker, M.; Ludwig, G. V.; Davis, N. L.; Johnston, R. E.; Smith, J. F.,
43
44 19 Replicon-helper systems from attenuated venezuelan equine encephalitis virus: Expression of
45
46 20 heterologous genes in vitro and immunization against heterologous pathogens in vivo. *Virology* **1997**, *239*
47
48 21 (2), 389-401.
- 50
51 22 216. Lundstrom, K., Replicon RNA viral vectors as vaccines. *Vaccines* **2016**, *4* (4), 39.
- 53
54 23 217. Bates, J. T.; Pickens, J. A.; Schuster, J. E.; Johnson, M.; Tollefson, S. J.; Williams, J.
55
56 24 V.; Davis, N. L.; Johnston, R. E.; Schultz-Darken, N.; Slaughter, J. C., Immunogenicity and

- 1
2
3 1 efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human
4
5 2 metapneumovirus in nonhuman primates. *Vaccine* **2016**, *34* (7), 950-956.
6
7
8 3 218. White, L. J.; Sariol, C. A.; Mattocks, M. D.; MPB, W. W.; Yingsiwaphat, V.; Collier,
9
10 4 M. L.; Whitley, J.; Mikkelsen, R.; Rodriguez, I. V.; Martinez, M. I., An alphavirus vector-based
11
12 5 tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs
13
14 6 qualitatively from immunity induced by live virus infection. *Journal of virology* **2013**, *87* (6), 3409-3424.
15
16
17 7 219. Suárez-Patiño, S. F.; Bernardino, T. C.; Núñez, E. G. F.; Astray, R. M.; Pereira, C. A.;
18
19 8 Soares, H. R.; Coroadinha, A. S.; Jorge, S. A. C., Semliki Forest Virus replicon particles production in
20
21 9 serum-free medium BHK-21 cell cultures and their use to express different proteins. *Cytotechnology*
22
23 **2019**, 1-14.
24
25
26 11 220. Scorza, F.; Pardi, N., New kids on the block: RNA-based influenza virus vaccines. *Vaccines*
27
28 12 **2018**, *6* (2), 20.
29
30
31 13 221. Moyo, N.; Vogel, A. B.; Buus, S.; Erbar, S.; Wee, E. G.; Sahin, U.; Hanke, T.,
32
33 14 Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-
34
35 15 amplifying mRNA. *Molecular Therapy-Methods & Clinical Development* **2019**, *12*, 32-46.
36
37
38 16 222. Chahal, J. S.; Fang, T.; Woodham, A. W.; Khan, O. F.; Ling, J.; Anderson, D. G.;
39
40 17 Ploegh, H. L., An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8⁺ T cell
41
42 18 responses in a mouse model. *Scientific reports* **2017**, *7* (1), 252.
43
44
45 19 223. Simmons, J. D.; White, L. J.; Morrison, T. E.; Montgomery, S. A.; Whitmore, A. C.;
46
47 20 Johnston, R. E.; Heise, M. T., Venezuelan equine encephalitis virus disrupts STAT1 signaling by distinct
48
49 21 mechanisms independent of host shutoff. *Journal of virology* **2009**, *83* (20), 10571-10581.
50
51
52 22 224. Jirikowski, G. F.; Sanna, P. P.; Maciejewski-Lenoir, D.; Bloom, F. E., Reversal of diabetes
53
54 23 insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. *Science* **1992**, *255*
55
56 24 (5047), 996-8.
57
58
59
60

- 1
2
3 1 225. Kariko, K.; Muramatsu, H.; Ludwig, J.; Weissman, D., Generating the optimal mRNA for
4
5 2 therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-
6
7 3 modified, protein-encoding mRNA. *Nucleic Acids Res.* **2011**, *39* (21), e142.
- 8
9
10 4 226. Aini, H.; Itaka, K.; Fujisawa, A.; Uchida, H.; Uchida, S.; Fukushima, S.; Kataoka,
11
12 5 K.; Saito, T.; Chung, U.-i.; Ohba, S., Messenger RNA delivery of a cartilage-anabolic transcription
13
14 6 factor as a disease-modifying strategy for osteoarthritis treatment. *Sci. Rep.* **2016**, *6*, 18743.
- 15
16
17 7 227. Crowley, S. T.; Fukushima, Y.; Uchida, S.; Kataoka, K.; Itaka, K., Enhancement of
18
19 8 Motor Function Recovery after Spinal Cord Injury in Mice by Delivery of Brain-Derived Neurotrophic
20
21 9 Factor mRNA. *Mol Ther Nucleic Acids* **2019**, *17*, 465-476.
- 22
23
24 10 228. Lin, C. Y.; Crowley, S. T.; Uchida, S.; Komaki, Y.; Kataoka, K.; Itaka, K., Treatment
25
26 11 of Intervertebral Disk Disease by the Administration of mRNA Encoding a Cartilage-Anabolic
27
28 12 Transcription Factor. *Mol Ther Nucleic Acids* **2019**, *16*, 162-171.
- 29
30
31 13 229. Thess, A.; Grund, S.; Mui, B. L.; Hope, M. J.; Baumhof, P.; Fotin-Mleczek, M.;
32
33 14 Schlake, T., Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an
34
35 15 Effective Protein Therapy in Large Animals. *Mol. Ther.* **2015**.
- 36
37
38 16 230. Ramaswamy, S.; Tonnu, N.; Tachikawa, K.; Limphong, P.; Vega, J. B.; Karmali, P.
39
40 17 P.; Chivukula, P.; Verma, I. M., Systemic delivery of factor IX messenger RNA for protein replacement
41
42 18 therapy. *Proc. Natl. Acad. Sci. U. S. A.* **2017**, *114* (10), E1941-E1950.
- 43
44
45 19 231. Haque, A.; Dewerth, A.; Antony, J. S.; Riethmuller, J.; Schweizer, G. R.; Weinmann,
46
47 20 P.; Latifi, N.; Yasar, H.; Pedemonte, N.; Sondo, E.; Weidensee, B.; Ralhan, A.; Laval, J.;
48
49 21 Schlegel, P.; Seitz, C.; Loretz, B.; Lehr, C. M.; Handgretinger, R.; Kormann, M. S. D.,
50
51 22 Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. *Sci.*
52
53 23 *Rep.* **2018**, *8* (1), 16776.
- 54
55
56 24 232. Robinson, E.; MacDonald, K. D.; Slaughter, K.; McKinney, M.; Patel, S.; Sun, C.;

- 1
2
3 1 Sahay, G., Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in
4
5 2 Cystic Fibrosis. *Mol. Ther.* **2018**, *26* (8), 2034-2046.
6
7
8 3 233. Prieve, M. G.; Harvie, P.; Monahan, S. D.; Roy, D.; Li, A. G.; Blevins, T. L.;
9
10 4 Paschal, A. E.; Waldheim, M.; Bell, E. C.; Galperin, A.; Ella-Menye, J. R.; Houston, M. E.,
11
12 5 Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency. *Mol. Ther.* **2018**, *26* (3), 801-813.
13
14
15 6 234. Jiang, L.; Berraondo, P.; Jerico, D.; Guey, L. T.; Sampedro, A.; Frassetto, A.;
16
17 7 Benenato, K. E.; Burke, K.; Santamaria, E.; Alegre, M.; Pejenaute, A.; Kalariya, M.; Butcher,
18
19 8 W.; Park, J. S.; Zhu, X.; Sabnis, S.; Kumarasinghe, E. S.; Salerno, T.; Kenney, M.; Lukacs,
20
21 9 C. M.; Avila, M. A.; Martini, P. G. V.; Fontanellas, A., Systemic messenger RNA as an etiological
22
23 10 treatment for acute intermittent porphyria. *Nat. Med.* **2018**, *24* (12), 1899-1909.
24
25
26 11 235. DeRosa, F.; Smith, L.; Shen, Y.; Huang, Y.; Pan, J.; Xie, H.; Yahalom, B.;
27
28 12 Heartlein, M. W., Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot
29
30 13 System as Compared to Enzyme Replacement Therapy. *Mol. Ther.* **2019**, *27* (4), 878-889.
31
32
33 14 236. Truong, B.; Allegri, G.; Liu, X. B.; Burke, K. E.; Zhu, X.; Cederbaum, S. D.;
34
35 15 Haberle, J.; Martini, P. G. V.; Lipshutz, G. S., Lipid nanoparticle-targeted mRNA therapy as a
36
37 16 treatment for the inherited metabolic liver disorder arginase deficiency. *Proc. Natl. Acad. Sci. U. S. A.*
38
39 **2019**.
40
41
42 18 237. Perche, F.; Uchida, S.; Akiba, H.; Lin, C. Y.; Ikegami, M.; Dirisala, A.; Nakashima,
43
44 19 T.; Itaka, K.; Tsumoto, K.; Kataoka, K., Improved Brain Expression of Anti-Amyloid beta scFv by
45
46 20 Complexation of mRNA Including a Secretion Sequence with PEG-based Block Cationomer. *Curr*
47
48 *Alzheimer Res* **2017**, *14* (3), 295-302.
49
50
51 22 238. Pardi, N.; Secreto, A. J.; Shan, X.; Debonera, F.; Glover, J.; Yi, Y.; Muramatsu, H.;
52
53 23 Ni, H.; Mui, B. L.; Tam, Y. K.; Shaheen, F.; Collman, R. G.; Kariko, K.; Danet-Desnoyers,
54
55 24 G. A.; Madden, T. D.; Hope, M. J.; Weissman, D., Administration of nucleoside-modified mRNA

- 1
2
3 1 encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. *Nature*
4
5 2 *Commun.* **2017**, *8*, 14630.
6
7
8 3 239. Thran, M.; Mukherjee, J.; Ponisch, M.; Fiedler, K.; Thess, A.; Mui, B. L.; Hope, M.
9
10 4 J.; Tam, Y. K.; Horscroft, N.; Heidenreich, R.; Fotin-Mleczek, M.; Shoemaker, C. B.; Schlake,
11
12 5 T., mRNA mediates passive vaccination against infectious agents, toxins, and tumors. *EMBO Mol. Med.*
13
14 6 **2017**.
15
16
17 7 240. Rybakova, Y.; Kowalski, P. S.; Huang, Y.; Gonzalez, J. T.; Heartlein, M. W.;
18
19 8 DeRosa, F.; Delcassian, D.; Anderson, D. G., mRNA Delivery for Therapeutic Anti-HER2 Antibody
20
21 9 Expression In Vivo. *Mol. Ther.* **2019**.
22
23
24 10 241. Stadler, C. R.; Bahr-Mahmud, H.; Celik, L.; Hebich, B.; Roth, A. S.; Roth, R. P.;
25
26 11 Kariko, K.; Tureci, O.; Sahin, U., Elimination of large tumors in mice by mRNA-encoded bispecific
27
28 12 antibodies. *Nat. Med.* **2017**, *23* (7), 815-817.
29
30
31 13 242. Zangi, L.; Lui, K. O.; von Gise, A.; Ma, Q.; Ebina, W.; Ptaszek, L. M.; Spater, D.;
32
33 14 Xu, H.; Tabebordbar, M.; Gorbatov, R.; Sena, B.; Nahrendorf, M.; Briscoe, D. M.; Li, R. A.;
34
35 15 Wagers, A. J.; Rossi, D. J.; Pu, W. T.; Chien, K. R., Modified mRNA directs the fate of heart
36
37 16 progenitor cells and induces vascular regeneration after myocardial infarction. *Nature Biotechnol.* **2013**,
38
39 17 *31* (10), 898-907.
40
41
42 18 243. Balmayor, E. R.; Geiger, J. P.; Aneja, M. K.; Berezhanskyy, T.; Utzinger, M.;
43
44 19 Mykhaylyk, O.; Rudolph, C.; Plank, C., Chemically modified RNA induces osteogenesis of stem cells
45
46 20 and human tissue explants as well as accelerates bone healing in rats. *Biomaterials* **2016**, *87*, 131-46.
47
48
49 21 244. Sun, N.; Ning, B.; Hansson, K. M.; Bruce, A. C.; Seaman, S. A.; Zhang, C.; Rikard,
50
51 22 M.; DeRosa, C. A.; Fraser, C. L.; Wagberg, M.; Fritsche-Danielson, R.; Wikstrom, J.; Chien,
52
53 23 K. R.; Lundahl, A.; Holtta, M.; Carlsson, L. G.; Peirce, S. M.; Hu, S., Modified VEGF-A mRNA
54
55 24 induces sustained multifaceted microvascular response and accelerates diabetic wound healing. *Sci. Rep.*
56
57
58
59
60

- 1
2
3 1 **2018**, 8 (1), 17509.
- 4
5 2 245. Hajj, K. A.; Whitehead, K. A., Tools for translation: non-viral materials for therapeutic mRNA
6
7 delivery. *Nature Reviews Materials* **2017**, 2 (10).
- 8
9
10 4 246. Schlake, T.; Thran, M.; Fiedler, K.; Heidenreich, R.; Petsch, B.; Fotin-Mleczek, M.,
11
12 mRNA: A Novel Avenue to Antibody Therapy? *Mol. Ther.* **2019**, 27 (4), 773-784.
- 13
14 6 247. Zhang, H. X.; Zhang, Y.; Yin, H., Genome Editing with mRNA Encoding ZFN, TALEN,
15
16 and Cas9. *Mol. Ther.* **2019**, 27 (4), 735-746.
- 17
18
19 8 248. Zou, S.; Scarfo, K.; Nantz, M. H.; Hecker, J. G., Lipid-mediated delivery of RNA is more
20
21 efficient than delivery of DNA in non-dividing cells. *Int. J. Pharm.* **2010**, 389 (1-2), 232-43.
- 22
23
24 10 249. Matsui, A.; Uchida, S.; Hayashi, A.; Kataoka, K.; Itaka, K., Prolonged engraftment of
25
26 transplanted hepatocytes in the liver by transient pro-survival factor supplementation using ex vivo
27
28 mRNA transfection. *J. Control. Release* **2018**, 285, 1-11.
- 29
30
31 13 250. Otsuka, H.; Hirano, A.; Nagasaki, Y.; Okano, T.; Horiike, Y.; Kataoka, K., Two-
32
33 dimensional multiarray formation of hepatocyte spheroids on a microfabricated PEG-brush surface.
34
35 *Chembiochem* **2004**, 5 (6), 850-5.
- 36
37
38 16 251. Uchida, S.; Yanagihara, K.; Matsui, A.; Kataoka, K.; Itaka, K., mRNA as a Tool for Gene
39
40 Transfection in 3D Cell Culture for Future Regenerative Therapy. *Micromachines* **2020**, 11 (4).
- 41
42
43 18 252. Patel, S.; Athirasala, A.; Menezes, P. P.; Ashwanikumar, N.; Zou, T.; Sahay, G.;
44
45 Bertassoni, L. E., Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine
46
47 Applications. *Tissue Eng Part A* **2019**, 25 (1-2), 91-112.
- 48
49
50 21 253. Warren, L.; Lin, C., mRNA-Based Genetic Reprogramming. *Mol. Ther.* **2019**, 27 (4), 729-734.
- 51
52 22 254. Takahashi, K.; Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and
53
54 adult fibroblast cultures by defined factors. *Cell* **2006**, 126 (4), 663-76.
- 55
56 24 255. Hacein-Bey-Abina, S.; Von Kalle, C.; Schmidt, M.; McCormack, M. P.; Wulffraat, N.;

- 1
2
3 1 Leboulch, P.; Lim, A.; Osborne, C. S.; Pawliuk, R.; Morillon, E.; Sorensen, R.; Forster, A.;
4
5 2 Fraser, P.; Cohen, J. I.; de Saint Basile, G.; Alexander, I.; Wintergerst, U.; Frebourg, T.;
6
7 3 Aurias, A.; Stoppa-Lyonnet, D.; Romana, S.; Radford-Weiss, I.; Gross, F.; Valensi, F.;
8
9 4 Delabesse, E.; Macintyre, E.; Sigaux, F.; Soulier, J.; Leiva, L. E.; Wissler, M.; Prinz, C.;
10
11 5 Rabbitts, T. H.; Le Deist, F.; Fischer, A.; Cavazzana-Calvo, M., LMO2-associated clonal T cell
12
13 6 proliferation in two patients after gene therapy for SCID-X1. *Science* **2003**, *302* (5644), 415-9.
14
15 7 256. Foster, K. W.; Liu, Z.; Nail, C. D.; Li, X.; Fitzgerald, T. J.; Bailey, S. K.; Frost, A.
16
17 8 R.; Louro, I. D.; Townes, T. M.; Paterson, A. J.; Kudlow, J. E.; Lobo-Ruppert, S. M.; Ruppert,
18
19 9 J. M., Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and
20
21 10 initiates squamous epithelial dysplasia. *Oncogene* **2005**, *24* (9), 1491-500.
22
23 11 257. Hochedlinger, K.; Yamada, Y.; Beard, C.; Jaenisch, R., Ectopic expression of Oct-4 blocks
24
25 12 progenitor-cell differentiation and causes dysplasia in epithelial tissues. *Cell* **2005**, *121* (3), 465-77.
26
27 13 258. Nakagawa, M.; Koyanagi, M.; Tanabe, K.; Takahashi, K.; Ichisaka, T.; Aoi, T.;
28
29 14 Okita, K.; Mochiduki, Y.; Takizawa, N.; Yamanaka, S., Generation of induced pluripotent stem cells
30
31 15 without Myc from mouse and human fibroblasts. *Nature Biotechnol.* **2008**, *26* (1), 101-6.
32
33 16 259. Okita, K.; Nakagawa, M.; Hyenjong, H.; Ichisaka, T.; Yamanaka, S., Generation of
34
35 17 mouse induced pluripotent stem cells without viral vectors. *Science* **2008**, *322* (5903), 949-53.
36
37 18 260. Stadtfeld, M.; Nagaya, M.; Utikal, J.; Weir, G.; Hochedlinger, K., Induced Pluripotent
38
39 19 Stem Cells Generated Without Viral Integration. *Science* **2008**, *322* (5903), 945-949.
40
41 20 261. Harui, A.; Suzuki, S.; Kochanek, S.; Mitani, K., Frequency and stability of chromosomal
42
43 21 integration of adenovirus vectors. *J. Virol.* **1999**, *73* (7), 6141-6.
44
45 22 262. Wang, Z.; Troilo, P. J.; Wang, X.; Griffiths, T. G.; Pacchione, S. J.; Barnum, A. B.;
46
47 23 Harper, L. B.; Pauley, C. J.; Niu, Z.; Denisova, L.; Follmer, T. T.; Rizzuto, G.; Ciliberto, G.;
48
49 24 Fattori, E.; Monica, N. L.; Manam, S.; Ledwith, B. J., Detection of integration of plasmid DNA into
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 host genomic DNA following intramuscular injection and electroporation. *Gene Ther.* **2004**, *11* (8), 711-
4
5 21.
6
7
8 3 263. Warren, L.; Manos, P. D.; Ahfeldt, T.; Loh, Y. H.; Li, H.; Lau, F.; Ebina, W.;
9
10 4 Mandal, P. K.; Smith, Z. D.; Meissner, A.; Daley, G. Q.; Brack, A. S.; Collins, J. J.; Cowan,
11
12 5 C.; Schlaeger, T. M.; Rossi, D. J., Highly efficient reprogramming to pluripotency and directed
13
14 6 differentiation of human cells with synthetic modified mRNA. *Cell Stem Cell* **2010**, *7* (5), 618-30.
15
16
17 7 264. Warren, L.; Ni, Y.; Wang, J.; Guo, X., Feeder-free derivation of human induced pluripotent
18
19 8 stem cells with messenger RNA. *Sci. Rep.* **2012**, *2*, 657.
20
21
22 9 265. Poleganov, M. A.; Eminli, S.; Beissert, T.; Herz, S.; Moon, J. I.; Goldmann, J.;
23
24 10 Beyer, A.; Heck, R.; Burkhart, I.; Barea Roldan, D.; Tureci, O.; Yi, K.; Hamilton, B.; Sahin,
25
26 11 U., Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells
27
28 12 Using Nonmodified RNA for Reprogramming and Immune Evasion. *Hum. Gene Ther.* **2015**, *26* (11),
29
30 13 751-66.
31
32
33 14 266. Yoshioka, N.; Gros, E.; Li, H. R.; Kumar, S.; Deacon, D. C.; Maron, C.; Muotri, A.
34
35 15 R.; Chi, N. C.; Fu, X. D.; Yu, B. D.; Dowdy, S. F., Efficient generation of human iPSCs by a
36
37 16 synthetic self-replicative RNA. *Cell Stem Cell* **2013**, *13* (2), 246-54.
38
39
40 17 267. Elangovan, S.; Khorsand, B.; Do, A. V.; Hong, L.; Dewerth, A.; Kormann, M.;
41
42 18 Ross, R. D.; Sumner, D. R.; Allamargot, C.; Salem, A. K., Chemically modified RNA activated
43
44 19 matrices enhance bone regeneration. *J. Control. Release* **2015**, *218*, 22-8.
45
46
47 20 268. Bartosh, T. J.; Ylostalo, J. H.; Mohammadipoor, A.; Bazhanov, N.; Coble, K.;
48
49 21 Claypool, K.; Lee, R. H.; Choi, H.; Prockop, D. J., Aggregation of human mesenchymal stromal cells
50
51 22 (MSCs) into 3D spheroids enhances their antiinflammatory properties. *Proc. Natl. Acad. Sci. U. S. A.*
52
53 23 **2010**, *107* (31), 13724-9.
54
55
56 24 269. Uchida, S.; Hayakawa, K.; Ogata, T.; Tanaka, S.; Kataoka, K.; Itaka, K., Treatment of
57
58
59
60

- 1
2
3 1 spinal cord injury by an advanced cell transplantation technology using brain-derived neurotrophic
4
5 2 factor-transfected mesenchymal stem cell spheroids. *Biomaterials* **2016**, *109*, 1-11.
6
7
8 3 270. Vijayavenkataraman, S.; Yan, W. C.; Lu, W. F.; Wang, C. H.; Fuh, J. Y. H., 3D
9
10 4 bioprinting of tissues and organs for regenerative medicine. *Adv. Drug. Deliv. Rev.* **2018**, *132*, 296-332.
11
12 5 271. Simeonov, K. P.; Uppal, H., Direct reprogramming of human fibroblasts to hepatocyte-like
13
14 6 cells by synthetic modified mRNAs. *PLoS One* **2014**, *9* (6), e100134.
15
16
17 7 272. Van Pham, P.; Vu, N. B.; Dao, T. T.; Le, H. T.; Phi, L. T.; Phan, N. K., Production of
18
19 8 endothelial progenitor cells from skin fibroblasts by direct reprogramming for clinical usages. *In Vitro*
20
21 9 *Cell. Dev. Biol. Anim.* **2017**, *53* (3), 207-216.
22
23
24 10 273. Baek, S.; Oh, J.; Song, J.; Choi, H.; Yoo, J.; Park, G. Y.; Han, J.; Chang, Y.;
25
26 11 Park, H.; Kim, H.; Cho, S. G.; Kim, B. S.; Kim, J., Generation of Integration-Free Induced Neurons
27
28 12 Using Graphene Oxide-Polyethylenimine. *Small* **2017**, *13* (5).
29
30
31 13 274. Connor, B.; Firmin, E.; McCaughey-Chapman, A.; Monk, R.; Lee, K.; Liot, S.;
32
33 14 Geiger, J.; Rudolph, C.; Jones, K., Conversion of adult human fibroblasts into neural precursor cells
34
35 15 using chemically modified mRNA. *Heliyon* **2018**, *4* (11), e00918.
36
37
38 16 275. Koblas, T.; Leontovyc, I.; Loukotova, S.; Kosinova, L.; Saudek, F., Reprogramming of
39
40 17 Pancreatic Exocrine Cells AR42J Into Insulin-producing Cells Using mRNAs for Pdx1, Ngn3, and MafA
41
42 18 Transcription Factors. *Mol Ther Nucleic Acids* **2016**, *5*, e320.
43
44
45 19 276. Kim, B. E.; Choi, S. W.; Shin, J. H.; Kim, J. J.; Kang, I.; Lee, B. C.; Lee, J. Y.;
46
47 20 Kook, M. G.; Kang, K. S., Single-Factor SOX2 Mediates Direct Neural Reprogramming of Human
48
49 21 Mesenchymal Stem Cells via Transfection of In Vitro Transcribed mRNA. *Cell Transplant.* **2018**, *27*
50
51 22 (7), 1154-1167.
52
53
54 23 277. Moffett, H. F.; Coon, M. E.; Radtke, S.; Stephan, S. B.; McKnight, L.; Lambert, A.;
55
56 24 Stoddard, B. L.; Kiem, H. P.; Stephan, M. T., Hit-and-run programming of therapeutic cytoreagents
57
58
59
60

- 1
2
3 1 using mRNA nanocarriers. *Nature Commun.* **2017**, *8* (1), 389.
4
5 278. Kudinov, A. E.; Karanicolas, J.; Golemis, E. A.; Bumber, Y., Musashi RNA-Binding
6 279. Xu, Y.; Huang, L.; Kirschman, J. L.; Vanover, D. A.; Tiwari, P. M.; Santangelo, P.
7 Proteins as Cancer Drivers and Novel Therapeutic Targets. *Clin. Cancer Res.* **2017**, *23* (9), 2143-2153.
8 279. Xu, Y.; Huang, L.; Kirschman, J. L.; Vanover, D. A.; Tiwari, P. M.; Santangelo, P.
9 J.; Shen, X.; Russell, D. G., Exploitation of Synthetic mRNA To Drive Immune Effector Cell
10 Recruitment and Functional Reprogramming In Vivo. *J. Immunol.* **2019**, *202* (2), 608-617.
11
12 280. Zhang, F.; Parayath, N. N.; Ene, C. I.; Stephan, S. B.; Koehne, A. L.; Coon, M. E.;
13 Holland, E. C.; Stephan, M. T., Genetic programming of macrophages to perform anti-tumor functions
14 using targeted mRNA nanocarriers. *Nature Commun.* **2019**, *10* (1), 3974.
15
16 281. Hou, X.; Zhang, X.; Zhao, W.; Zeng, C.; Deng, B.; McComb, D. W.; Du, S.;
17 Zhang, C.; Li, W.; Dong, Y., Vitamin lipid nanoparticles enable adoptive macrophage transfer for the
18 treatment of multidrug-resistant bacterial sepsis. *Nat Nanotechnol* **2020**, *15* (1), 41-46.
19
20 282. Gaj, T.; Guo, J.; Kato, Y.; Sirk, S. J.; Barbas, C. F., 3rd, Targeted gene knockout by direct
21 delivery of zinc-finger nuclease proteins. *Nat Methods* **2012**, *9* (8), 805-7.
22
23 283. Miller, J. B.; Zhang, S.; Kos, P.; Xiong, H.; Zhou, K.; Perelman, S. S.; Zhu, H.;
24 Siegwart, D. J., Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic
25 Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. *Angew Chem Int Ed Engl* **2017**, *56* (4), 1059-
26 1063.
27
28 284. Hendel, A.; Bak, R. O.; Clark, J. T.; Kennedy, A. B.; Ryan, D. E.; Roy, S.;
29 Steinfeld, I.; Lunstad, B. D.; Kaiser, R. J.; Wilkens, A. B.; Bacchetta, R.; Tsalenko, A.;
30 Dellinger, D.; Bruhn, L.; Porteus, M. H., Chemically modified guide RNAs enhance CRISPR-Cas
31 genome editing in human primary cells. *Nature Biotechnol.* **2015**, *33* (9), 985-989.
32
33 285. Liu, J.; Chang, J.; Jiang, Y.; Meng, X.; Sun, T.; Mao, L.; Xu, Q.; Wang, M., Fast
34 and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 RNA Nanoparticles. *Adv. Mater.* **2019**, *31* (33), e1902575.
- 4
5 2 286. Cheng, Q.; Wei, T.; Farbiak, L.; Johnson, L. T.; Dilliard, S. A.; Siegwart, D. J.,
6
7
8 3 Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas
9
10 4 gene editing. *Nat Nanotechnol* **2020**, *15* (4), 313-320.
- 11
12 5 287. Finn, J. D.; Smith, A. R.; Patel, M. C.; Shaw, L.; Youniss, M. R.; van Heteren, J.;
13
14
15 6 Dirstine, T.; Ciullo, C.; Lescarbeau, R.; Seitzer, J.; Shah, R. R.; Shah, A.; Ling, D.; Growe,
16
17 7 J.; Pink, M.; Rohde, E.; Wood, K. M.; Salomon, W. E.; Harrington, W. F.; Dombrowski, C.;
18
19 8 Strapps, W. R.; Chang, Y.; Morrissey, D. V., A Single Administration of CRISPR/Cas9 Lipid
20
21 9 Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. *Cell Rep.* **2018**, *22* (9), 2227-
22
23 2235.
- 24 10
25
26 11 288. Jiang, C.; Mei, M.; Li, B.; Zhu, X.; Zu, W.; Tian, Y.; Wang, Q.; Guo, Y.; Dong,
27
28 12 Y.; Tan, X., A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and
29
30 13 pcsk9 in vivo. *Cell Res.* **2017**, *27* (3), 440-443.
- 31
32
33 14 289. Yin, H.; Xue, W.; Chen, S.; Bogorad, R. L.; Benedetti, E.; Grompe, M.;
34
35 15 Koteliansky, V.; Sharp, P. A.; Jacks, T.; Anderson, D. G., Genome editing with Cas9 in adult mice
36
37 16 corrects a disease mutation and phenotype. *Nature Biotechnol.* **2014**, *32* (6), 551-3.
- 38
39
40 17 290. Van Lint, S.; Goyvaerts, C.; Maenhout, S.; Goethals, L.; Disy, A.; Benteyn, D.;
41
42 18 Pen, J.; Bonehill, A.; Heirman, C.; Breckpot, K.; Thielemans, K., Preclinical evaluation of TriMix
43
44 19 and antigen mRNA-based antitumor therapy. *Cancer Res.* **2012**, *72* (7), 1661-71.
- 45
46
47 20 291. Scheel, B.; Aulwurm, S.; Probst, J.; Stitz, L.; Hoerr, I.; Rammensee, H. G.; Weller,
48
49 21 M.; Pascolo, S., Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-
50
51 22 stranded RNA. *Eur. J. Immunol.* **2006**, *36* (10), 2807-16.
- 52
53
54 23 292. Rausch, S.; Schwentner, C.; Stenzl, A.; Bedke, J., mRNA vaccine CV9103 and CV9104
55
56 24 for the treatment of prostate cancer. *Hum. Vaccin. Immunother.* **2014**, *10* (11), 3146-52.
- 57
58
59
60

- 1
2
3 1 293. Circelli, L.; Petrizzo, A.; Tagliamonte, M.; Heidenreich, R.; Tornesello, M. L.;
4
5 2 Buonaguro, F. M.; Buonaguro, L., Immunological effects of a novel RNA-based adjuvant in liver cancer
6
7 patients. *Cancer Immunol. Immunother.* **2017**, *66* (1), 103-112.
8
9
10 4 294. Midoux, P.; Pichon, C., Lipid-based mRNA vaccine delivery systems. *Expert Rev Vaccines*
11
12 **2015**, *14* (2), 221-34.
13
14 6 295. Castle, J. C.; Kreiter, S.; Diekmann, J.; Lower, M.; van de Roemer, N.; de Graaf, J.;
15
16 Selmi, A.; Diken, M.; Boegel, S.; Paret, C.; Koslowski, M.; Kuhn, A. N.; Britten, C. M.;
17
18 Huber, C.; Tureci, O.; Sahin, U., Exploiting the mutanome for tumor vaccination. *Cancer Res.* **2012**,
19
20 *72* (5), 1081-91.
21
22 9
23
24 10 296. Kreiter, S.; Vormehr, M.; van de Roemer, N.; Diken, M.; Lower, M.; Diekmann, J.;
25
26 11 Boegel, S.; Schrors, B.; Vascotto, F.; Castle, J. C.; Tadmor, A. D.; Schoenberger, S. P.;
27
28 12 Huber, C.; Tureci, O.; Sahin, U., Mutant MHC class II epitopes drive therapeutic immune responses to
29
30 cancer. *Nature* **2015**, *520* (7549), 692-6.
31
32
33 14 297. Sahin, U.; Derhovanessian, E.; Miller, M.; Kloke, B. P.; Simon, P.; Lower, M.;
34
35 15 Bukur, V.; Tadmor, A. D.; Luxemburger, U.; Schrors, B.; Omokoko, T.; Vormehr, M.;
36
37 16 Albrecht, C.; Paruzynski, A.; Kuhn, A. N.; Buck, J.; Heesch, S.; Schreeb, K. H.; Muller, F.;
38
39 17 Ortseifer, I.; Vogler, I.; Godehardt, E.; Attig, S.; Rae, R.; Breitkreuz, A.; Tolliver, C.;
40
41 18 Suchan, M.; Martic, G.; Hohberger, A.; Sorn, P.; Diekmann, J.; Ciesla, J.; Waksman, O.;
42
43 19 Bruck, A. K.; Witt, M.; Zillgen, M.; Rothermel, A.; Kasemann, B.; Langer, D.; Bolte, S.;
44
45 20 Diken, M.; Kreiter, S.; Nemecek, R.; Gebhardt, C.; Grabbe, S.; Holler, C.; Utikal, J.; Huber,
46
47 21 C.; Loquai, C.; Tureci, O., Personalized RNA mutanome vaccines mobilize poly-specific therapeutic
48
49 22 immunity against cancer. *Nature* **2017**, *547* (7662), 222-226.
50
51
52
53 23 298. Islam, M. A.; Xu, Y.; Tao, W.; Ubellacker, J. M.; Lim, M.; Aum, D.; Lee, G. Y.;
54
55 24 Zhou, K.; Zope, H.; Yu, M.; Cao, W.; Oswald, J. T.; Dinarvand, M.; Mahmoudi, M.;
56
57
58
59
60

- 1
2
3 1 Langer, R.; Kantoff, P. W.; Farokhzad, O. C.; Zetter, B. R.; Shi, J., Restoration of tumour-growth
4
5 2 suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. *Nat Biomed Eng* **2018**,
6
7 3 2 (11), 850-864.
8
9
10 4 299. Kong, N.; Tao, W.; Ling, X.; Wang, J.; Xiao, Y.; Shi, S.; Ji, X.; Shajii, A.; Gan,
11
12 5 S. T.; Kim, N. Y.; Duda, D. G.; Xie, T.; Farokhzad, O. C.; Shi, J., Synthetic mRNA nanoparticle-
13
14 6 mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. *Sci.*
15
16 7 *Transl. Med.* **2019**, *11* (523), eaaw1565.
17
18
19 8 300. Song, E.; Mao, T.; Dong, H.; Boisserand, L. S. B.; Antila, S.; Bosenberg, M.;
20
21 9 Alitalo, K.; Thomas, J. L.; Iwasaki, A., VEGF-C-driven lymphatic drainage enables
22
23 10 immunosurveillance of brain tumours. *Nature* **2020**, *577* (7792), 689-694.
24
25
26 11 301. Heiser, A.; Coleman, D.; Dannull, J.; Yancey, D.; Maurice, M. A.; Lallas, C. D.;
27
28 12 Dahm, P.; Niedzwiecki, D.; Gilboa, E.; Vieweg, J., Autologous dendritic cells transfected with
29
30 13 prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. *J. Clin. Invest.*
31
32 14 **2002**, *109* (3), 409-17.
33
34
35 15 302. Bahl, K.; Senn, J. J.; Yuzhakov, O.; Bulychev, A.; Brito, L. A.; Hassett, K. J.;
36
37 16 Laska, M. E.; Smith, M.; Almarsson, O.; Thompson, J.; Ribeiro, A. M.; Watson, M.; Zaks,
38
39 17 T.; Ciaramella, G., Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines
40
41 18 against H10N8 and H7N9 Influenza Viruses. *Mol. Ther.* **2017**, *25* (6), 1316-1327.
42
43
44 19 303. Pardi, N.; Hogan, M. J.; Pelc, R. S.; Muramatsu, H.; Andersen, H.; DeMaso, C. R.;
45
46 20 Dowd, K. A.; Sutherland, L. L.; Scarce, R. M.; Parks, R.; Wagner, W.; Granados, A.;
47
48 21 Greenhouse, J.; Walker, M.; Willis, E.; Yu, J. S.; McGee, C. E.; Sempowski, G. D.; Mui, B.
49
50 22 L.; Tam, Y. K.; Huang, Y. J.; Vanlandingham, D.; Holmes, V. M.; Balachandran, H.; Sahu,
51
52 23 S.; Lifton, M.; Higgs, S.; Hensley, S. E.; Madden, T. D.; Hope, M. J.; Kariko, K.; Santra,
53
54 24 S.; Graham, B. S.; Lewis, M. G.; Pierson, T. C.; Haynes, B. F.; Weissman, D., Zika virus
55
56
57
58
59
60

- 1
2
3 1 protection by a single low-dose nucleoside-modified mRNA vaccination. *Nature* **2017**, *543* (7644), 248-
4
5 2 251.
6
7 304. Richner, J. M.; Himansu, S.; Dowd, K. A.; Butler, S. L.; Salazar, V.; Fox, J. M.;
8
9 Julander, J. G.; Tang, W. W.; Shresta, S.; Pierson, T. C.; Ciaramella, G.; Diamond, M. S.,
10 4 Modified mRNA Vaccines Protect against Zika Virus Infection. *Cell* **2017**, *168* (6), 1114-1125 e10.
11
12 5 305. Pardi, N.; Parkhouse, K.; Kirkpatrick, E.; McMahon, M.; Zost, S. J.; Mui, B. L.;
13
14 6 306. Tam, Y. K.; Kariko, K.; Barbosa, C. J.; Madden, T. D.; Hope, M. J.; Krammer, F.; Hensley,
15
16 7 S. E.; Weissman, D., Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin
17
18 8 stalk-specific antibodies. *Nature Commun.* **2018**, *9* (1), 3361.
19
20 9
21 306. Smith, T. R. F.; Patel, A.; Ramos, S.; Elwood, D.; Zhu, X.; Yan, J.; Gary, E. N.;
22
23 10 Walker, S. N.; Schultheis, K.; Purwar, M.; Xu, Z.; Walters, J.; Bhojnagarwala, P.; Yang, M.;
24
25 11 Chokkalingam, N.; Pezzoli, P.; Parzych, E.; Reuschel, E. L.; Doan, A.; Tursi, N.; Vasquez,
26
27 12 M.; Choi, J.; Tello-Ruiz, E.; Maricic, I.; Bah, M. A.; Wu, Y.; Amante, D.; Park, D. H.;
28
29 13 Dia, Y.; Ali, A. R.; Zaidi, F. I.; Generotti, A.; Kim, K. Y.; Herring, T. A.; Reeder, S.;
30
31 14 Andrade, V. M.; Buttigieg, K.; Zhao, G.; Wu, J. M.; Li, D.; Bao, L.; Liu, J.; Deng, W.;
32
33 15 Qin, C.; Brown, A. S.; Khoshnejad, M.; Wang, N.; Chu, J.; Wrapp, D.; McLellan, J. S.;
34
35 16 Muthumani, K.; Wang, B.; Carroll, M. W.; Kim, J. J.; Boyer, J.; Kulp, D. W.; Humeau, L.;
36
37 17 Weiner, D. B.; Broderick, K. E., Immunogenicity of a DNA vaccine candidate for COVID-19. *Nature*
38
39 18 *Commun.* **2020**, *11* (1), 2601.
40
41 19
42 307. Zhu, F.-C.; Li, Y.-H.; Guan, X.-H.; Hou, L.-H.; Wang, W.-J.; Li, J.-X.; Wu, S.-P.;
43
44 20 Wang, B.-S.; Wang, Z.; Wang, L.; Jia, S.-Y.; Jiang, H.-D.; Wang, L.; Jiang, T.; Hu, Y.;
45
46 21 Gou, J.-B.; Xu, S.-B.; Xu, J.-J.; Wang, X.-W.; Wang, W.; Chen, W., Safety, tolerability, and
47
48 22 immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,
49
50 23 open-label, non-randomised, first-in-human trial. *The Lancet* **2020**.
51
52 24
53
54
55
56
57
58
59
60

- 1
2
3 1 308. Kowalski, P. S.; Rudra, A.; Miao, L.; Anderson, D. G., Delivering the Messenger:
4
5 2 Advances in Technologies for Therapeutic mRNA Delivery. *Mol. Ther.* **2019**, *27* (4), 710-728.
6
7 309. Weng, Y.; Li, C.; Yang, T.; Hu, B.; Zhang, M.; Guo, S.; Xiao, H.; Liang, X. J.;
8 3 Huang, Y., The challenge and prospect of mRNA therapeutics landscape. *Biotechnol. Adv.* **2020**, *40*,
9 107534.
10 4
11
12 5 310. Herzog, R. W., Hepatic AAV gene transfer and the immune system: friends or foes? *Molecular*
13
14
15 6 *therapy : the journal of the American Society of Gene Therapy* **2010**, *18* (6), 1063-1066.
16
17 7
18 311. Schwanhausser, B.; Busse, D.; Li, N.; Dittmar, G.; Schuchhardt, J.; Wolf, J.; Chen,
19 8 W.; Selbach, M., Global quantification of mammalian gene expression control. *Nature* **2011**, *473* (7347),
20 9 337-42.
21
22 10
23
24 11 312. Urquhart, L., Top companies and drugs by sales in 2019. *Nat. Rev. Drug Discov.* **2020**, *19* (4),
25
26 12 228.
27
28
29
30
31
32

14 Table of Contents (TOC)

